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Abstract		
Background:	In	 recent	 decades,	 despite	 survival	 improvements	 in	 the	 majority	 of	 high	incidence	 cancers,	 survival	 rates	 for	 patients	 with	 bladder	 cancers	 have	remained	 static.	 Key	 challenges	 in	 the	 treatment	 of	 bladder	 cancer	 are	 the	acquisition	 of	 chemotherapy	 resistance,	 and	 progression	 to	 lethal	 muscle-invasive	bladder	cancer.			
Aims:	This	 thesis	 aims	 to	 explore	 methods	 of	 pharmacological	 inhibition	 of	chemotherapy	 resistance,	 mechanisms	 of	 bladder	 tumour	 invasion,	 and	 gene	expression	in	bladder	cancer.			
Rationale:	Nuclear	 factor	 (erythroid-derived	 2)-like	 2	 (NRF2)	 overexpression	 has	 been	associated	 with	 chemotherapy	 resistance	 in	 a	 number	 of	 cancers	 including	bladder.	 Therefore,	 the	 utility	 of	 the	 purported	 specific	 inhibitor	 of	 NRF2,	brusatol	 in	 the	 attenuation	 of	 cisplatin	 chemotherapy	 resistance	 was	investigated.			In	bladder	cancer,	 cluster	of	differentiation-40	 (CD40)-ligation	with	membrane	bound	 CD40-Ligand	 (CD40L)	 has	 been	 shown	 to	 induce	 marked	 cell	 death.	However,	little	is	known	about	the	role	of	CD40-ligation	in	tumour	cell	invasion.	With	 CD40	 currently	 under	 investigation	 as	 a	 putative	 target	 for	 anti-cancer	therapy,	 it	was	a	timely	goal	of	this	thesis	to	understand	more	about	 its	role	 in	tumour	cell	invasion.			Until	recently,	knowledge	of	gene	expression	profiles	in	bladder	cancer	has	been	limited.	 Understanding	 of	 gene	 expression	 patterns	 in	 cancer	 may	 allow	 for	enhanced	prognostication,	 identification	of	potential	drug	targets	and	move	the	management	of	bladder	cancer	towards	the	ideal	of	personalised	medicine.		
	 xiii	
Methods:		
In	vitro	cytotoxicity	assays	were	employed	to	determine	the	effect	of	brusatol	on	cisplatin	sensitivity.	Western	blotting	was	employed	to	determine	the	effects	of	brusatol	on	proteins	downstream	of	NRF2.			An	 organotypic	 model	 of	 bladder	 cancer	 was	 used	 to	 investigate	 the	 effect	 of	CD40-ligation	on	bladder	tumour	cell	invasion.	Non-cleavable	membrane	bound	CD40-ligand	 delivered	 by	 adenoviral	 vector	 was	 used	 in	 CD40	 expressing	 cell	lines	 of	 invasive	 and	 non-invasive	 origin.	 The	 effect	 of	 CD40-ligation	 was	investigated	downstream	by	western	analysis	and	RNA	microarray.			Whole-transcript	based	microarray	analysis	was	performed	on	bladder	biopsies	obtained	from	19	patients,	and	10	controls.	Unsupervised	hierarchical	clustering	was	used	 to	 identify	 samples	with	 similar	 expression	profiles.	Hypergeometric	analysis	 was	 used	 to	 identify	 canonical	 pathways	 and	 curated	 networks	 with	statistically	 significant	 enrichment	 of	 differentially	 expressed	 genes.	 Samples	from	a	further	6	patients	(muscle	invasive	bladder	cancer	(MIBC)	n	=	3,	normal	tissue	n	=	3)	were	tested	for	osteopontin	expression	by	immunohistochemistry.			
Results:		Brusatol	 increased	 the	 sensitivity	 of	 bladder	 cancer	 cell	 lines	 to	 cisplatin	 in	 a	dosage	and	cell	line	dependent	manner.	Furthermore,	brusatol	exhibited	marked	toxicity	 as	 a	 standalone	 treatment.	 However,	 evidence	 suggests	 that	 brusatol	does	not	act	as	a	specific	inhibitor	of	NRF2.			CD40-ligation	with	non-cleavable	membrane-bound	CD40-ligand	 led	to	marked	cell	death	 in	CD40-positive	non-muscle	 invasive	cell	 lines.	However,	 in	muscle-invasive	CD40-positive	cell	lines	marked	inhibition	of	tumour	invasion	was	also	observed.	Expression	analysis	of	 family	with	 sequence	 similarity	member	83	d	(FAM83D),	 fibronectin	 (FN1),	 matrix	 metalloproteinase	 1	 (MMP1)	 and	 anillin	(ANLN)	 revealed	downregulation	of	FN1,	FAM83D,	and	ANLN,	 and	upregulation	of	MMP1,	with	a	concurrent	upregulation	of	MMP1	and	a	paradoxical	increase	of	FN1	in	EJ	cells,	with	no	change	in	FN1	and	MMP1	expression	in	RT112	cells.		
	 xiv	
Pathways	 associated	 with	 cell	 cycle	 and	 proliferation	 were	 markedly	upregulated	 in	muscle-invasive	and	grade	3	cancers.	Genes	associated	with	 the	classical	 complement	 pathway	 were	 downregulated	 in	 non-muscle	 invasive	cancer.	 Osteopontin	 was	 significantly	 overexpressed	 in	 invasive	 cancer	compared	to	healthy	tissue.		
Conclusions:		It	 is	 unlikely	 that	 brusatol	 is	 a	 specific	 inhibitor	 of	 NRF2	 however	 its	marked	cytotoxicity	as	a	stand-alone	agent	and	potentiating	effects	in	combination	with	cisplatin	are	rationale	for	further	investigation.				CD40-ligation	attenuates	 the	 invasion	of	MIBC	cells	 in	an	organotypic	model	of	bladder	cancer.	However,	it	is	unclear	whether	the	attenuation	of	invasion	is	due	to	 the	 inhibition	 of	 invasive	 pathways,	 or	 direct	 induction	 of	 apoptosis.	Nevertheless,	with	 the	 usage	 of	 CD40-agnoistic	 antibodies	 currently	 in	 clinical	trials,	attenuation	of	tumour	invasion	is	a	promising	effect.		Gene	expression	analysis	identifies	divergent	pathways	that	may	be	useful	in	the	stratification	 of	 bladder	 cancers,	 and	 the	 identification	 of	 drug	 targets.	Furthermore,	 this	 study	 supports	 a	key	 role	 for	osteopontin	 in	bladder	 cancer,	which	warrants	further	investigation	as	a	marker	prognostic	of	muscle	invasive	disease.		
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1.1	Principles	of	cancer		The	 development	 of	 cancer	 is	 a	 progressive	 process,	 where	 cells	 evolve	 in	 a	multi-step	manner	 progressively	 into	 a	malignant	 state.	 In	 2000	Hanahan	 and	Weinberg	displayed	 that	 during	 the	process	 of	 carcinogenesis,	 cells	 acquire	 an	essential	succession	six	of	cancer-associated	hallmarks	(Fig	1.1)	[1].				More	recently,	an	increasing	body	of	work	has	begun	to	characterise	the	role	of	the	tumour-microenvironment,	and	the	ability	of	non-cancer	cells	such	as	cancer	associated	 fibroblasts	 to	 support	 malignant	 spread,	 aiding	 in	 invasion,	angiogenesis,	and	evasion	of	 immune	surveillance	 [2].	Based	on	 this	 increasing	body	 of	 research	 in	 2011	Hanahan	 and	Weinberg	 unveiled	 the	 sequel	 to	 their	seminal	 work,	 highlighting	 the	 roles	 of	 inflammation,	 genomic	 instability	 and	mutation,	 dysregulated	 cellular	 energetics	 and	 immune	 evasion	 in	 the	development	and	progression	of	cancers	(Fig	1.1)	[2].			This	thesis	focuses	on	novel	approaches	in	the	management	of	the	most	deadly	genitourinary	malignancy,	bladder	cancer	(BC)	[3].	Investigating:	methods	used	to	attenuate	 resistance	 to	 first	 line	 systemic	chemotherapy	 for	muscle-invasive	BC;	 prognostic	 biomarkers	 which	 may	 aid	 the	 early	 detection	 of	 the	 most	malignant	BC	subtypes;	and	mechanistic	work	unravelling	the	role	of	cell-surface	receptors	and	ligands	often	found	chiefly	in	the	immune	system,	and	their	role	in	tumour	cell	invasion.																	
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Figure	 1.1.	 The	 hallmarks	 of	 cancer.	 In	 the	 sequel	 to	 their	 seminal	 work,	Hanahan	and	Weinberg	identified	a	further	four	essential	hallmarks	of	cancer	in	addition	 to	 the	 six	 original	 cancer	 hallmarks:	 sustaining	 proliferative	 signals,	evasion	 of	 anti-growth	 signals,	 activation	 of	 invasion	 and	metastasis,	 limitless	replicative	potential,	 induction	of	angiogenesis	and	resistance	of	cell	death.	The	four	more	 recently	 identified	 hallmarks	 of	 cancer	 are	 the	 presence	 of	 tumour	promoting	inflammation,	genetic	instability	and	mutation,	avoidance	of	immune	surveillance	 and	 dysregulated	 cellular	 energetics.	 (adapted	 from	Hanahan	 and	Weinberg	2000,	2011)	[1,	2].						
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1.2	Bladder	cancer		This	 section	 outlines:	 physiological	 and	 anatomical	 elements	 of	 the	 urinary	bladder;	 epidemiological	 and	 aetiological	 factors	 involved	 in	 bladder	carcinogenesis;	BC	diagnosis	and	treatment.			
1.2.1	Bladder	cancer:	the	urinary	bladder			The	urinary	bladder	 (Fig	1.2)	 is	hollow	distensible	muscular	organ,	 situated	 in	the	pelvic	cavity	posterior	to	the	pubic	symphysis,	used	for	the	storage	of	urine	for	 extended	 periods	 of	 time	 [4].	 As	 such,	 the	 bladder	 has	 adapted	 in	 several	ways	 to	 protect	 the	 blood	 in	 underlying	 vessels	 and	 itself	 from	 pathologies	associated	 with	 contact	 with	 pathogenic	 microbes	 and	 toxic	 waste	 products	contained	 in	 urine.	 The	 composition	 of	 urine	 is	 vastly	 different	 to	 that	 of	 the	blood,	 with	 a	 pH	 of	 4.5	 and	 osmolality	 ranging	 from	 50-1000	 mOsmol/kg,	including	 high	 concentrations	 of	 urea	 and	 potential	 carcinogens	 [5].	 The	urothelium	 acts	 as	 the	 protective	 barrier	 between	 the	 urine,	 blood	 and	underlying	muscle.			Urothelium	consists	of	 three	stratified	 layers	of	 transitional	epithelium,	usually	no	greater	than	eight	cells	thick	(Fig	1.3)	[6].	Connected	to	the	basement	lamina	lie	small	basal	cells	(10μm),	10%	are	stem	cells,	these	have	the	highest	potential	to	 proliferate	 and	 serve	 as	 precursors	 to	 the	 cells	 above	 [6].	Upward	 from	 the	basement	layer,	with	thin	connections	to	the	basement	lamina	exists	a	region	of	larger	 (10-25μm)	 intermediate	 transit-amplifying	 cells,	 which	 will	 eventually	replace	 their	 protective	 top	 layer,	 the	 large	 (25-250μm)	 polyhedral	 umbrella	cells	 [7].	 The	 umbrella	 cells	 have	 adapted	 their	morphology	 so	 they	 are	wider	than	the	cells	beneath,	forming	a	protective	blood-urine	barrier,	and	are	able	to	adjust	 their	 diameter	 to	 adapt	 to	 the	 changing	 volume	 of	 the	 bladder	 [6].	 The	ability	of	the	transitional	epithelium	to	adapt	to	such	conditions	is	likely	due	to	a	dense	 cytokeratin	 network	 below	 the	 apical	 membrane,	 and	 urothelial	 tight	junctions.			
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Figure	 1.2.	 The	 urinary	 bladder,	 displaying	 different	 stages	 of	 urothelial	
cell	carcinoma.	Ta	refers	to	non-invasive	papillary	carcinoma	–	raised	tumours	growing	 into	 the	 bladder;	 carcinoma	 in	 situ	 (Cis),	 flat	 tumours,	 which	 do	 not	invade	past	the	mucosa.	At	stage	T1	the	tumour	has	spread	through	the	mucosa	into	the	lamina	propria,	but	does	not	invade	the	underlying	detrusor	muscle.	By	stage	T2	tumours	have	spread	into	the	muscle	of	the	bladder	wall,	T2a	tumours	are	 confined	 to	 the	 inner	 half	 of	 the	muscle,	 whereas	 T2b	 have	 spread	 to	 the	outer	half	of	the	muscle.	Tumours	at	stage	T3	have	spread	into	the	perivesicular	adipose	tissue	(fat)	–	T3a	is	microscopically	apparent,	where	at	T3b	the	invasion	is	 evident	 macroscopically	 via	 imaging	 or	 palpation.	 Stage	 T4	 tumours	 have	spread	 to	 the	 surrounding	 organs,	 with	 T4a	 accounting	 for	 spread	 into	genitourinary	organs	(prostate,	uterus	or	vagina),	where	as	T4b	denotes	spread	beyond	T4a	into	the	pelvic	or	abdominal	wall.		
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Figure	 1.3.	 Structure	 of	 the	 urothelium.	 The	 urothelium	 is	 a	 stratified	
transitional	 epithelium,	 consisting	of	 three	distinct	 layers.	The	 basal	 layer	attached	to	the	basement	lamina	consists	of	small	basal	cells	(10μm),	above	this	exists	larger	(10-25μm)	transit	amplifying	cells,	above	the	intermediate	strata	of	transit	amplifying	cells	lies	the	large	(25-250μm)	umbrella	cells.	With	a	turnover	rate	 of	 ~200	 days,	 and	 a	 tritium-thymidine	 labelling	 index	 of	 ~0.01%,	urothelium	is	one	of	the	slowest	cycling	epithelia	in	the	human	body	[8].										
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Beneath	 the	 urothelium	 lies	 a	 basal	 lamina,	 consisting	 of	 collagen,	 adhesive	glycoproteins	and	glycosaminoglycans	[4,	6,	9].	Below	this	basement	membrane	lies	the	lamina	propria	(sub-mucosa),	consisting	of	loose	connective	tissue	and	a	sparse	number	of	smooth	muscle	fibres	[4,	6].	Outside	the	lamina	propria	lies	the	muscularis	propria;	this	layer	is	formed	out	three	distinct	layers	of	muscle	(inner	longitudinal,	 outer	 circular,	 and	outermost	 longitudinal),	 this	 triad	of	muscular	layers	 are	 known	as	 the	detrusor	muscle,	when	 contracted	 their	 function	 is	 to	expel	 urine	 from	 the	 bladder	 [4,	 6].	 The	 outermost,	 and	 thickest	 layer	 of	 the	bladder	wall	is	serosa,	consisting	of	loose	connective	tissue,	and	perivesicular	fat	[4,	6].			Cancers	 of	 the	 urothelium	 are	 characterised	 by	 the	 loss	 of	 the	 mature,	differentiated	 morphology	 normal	 urothelial	 tissue,	 and	 gain	 of	 aberrant	molecular	 function	 [10].	 Changes	 in	 protective	 morphology	 of	 the	 urothelium	leave	the	underlying	tissue	and	bloodstream	susceptible	to	damage	from	urine,	through	the	leeching	of	toxins	and	carcinogens,	or	microbes,	which	may	lead	to	sepsis	 and	potentially	 increased	 localised	 inflammation,	 allowing	 for	 a	 suitable	environment	for	cancer	growth	and	progression	[4,	11].																						
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1.2.2	Bladder	cancer:	epidemiology,	aetiology	and	carcinogenesis		
	There	are	various	factors,	which	determine	the	incidence,	distribution,	possible	control	 and	 health	 implications	 of	 BC.	 The	 study	 and	 understanding	 of	 these	causative	 factors	 as	 an	 adjunct	 to	 clinical	 and	 translational	 research	 can	 aid	 in	the	 advancement	 of	 BC	 treatment	 and	 the	 understanding	 of	 bladder	carcinogenesis.		
1.2.2.1	Epidemiology	
	BC	 is	 the	7th	 commonest	malignancy	 in	 the	United	Kingdom,	where	 there	were	10,335	new	cases	of	BC	and	4,907	associated	deaths	in	2008	[12].	Although	men	have	 an	 8%	 increased	 5-year	 survival	 advantage	 over	women,	 BC	 is	 three-	 to	four-	 times	more	common	in	males	[13].	 	The	vast	majority	(90%)	of	cases	are	classified	 as	 urothelial	 cell	 carcinoma	 (UCC),	 however	 other	 cancers	 of	 the	bladder	include,	squamous	cell	carcinoma	(SCC)	(8%),	Adenocarcinoma	(1-2%)	and	the	remaining	<1%	of	cases	being	accounted	 for	by	small	cell	cancers,	and	sarcomas	 [12].	 This	 remarkably	 heterogeneous	 disease	 is	 the	 only	 top-twenty	cancer	 to	 have	 a	 significant	 decrease	 its	 relative	 survival	 between	 1990	 and	2009,	however	this	is	due	to	a	decrease	in	the	number	of	cases	in	males,	whilst	the	death	rate	remains	stable	(Fig	1.4)	[13].		Locally	 contained	 BC	 is	 stratified	 into	 muscle-invasive	 (≥T2)	 and	 non-muscle	invasive	 disease	 (≤T1);	 Non-muscle	 invasive	 BC	 (NMIBC)	 is	 associated	 with	 a	good	prognosis	with	92%	of	patients	surviving	5-years	post-diagnosis	 [10,	12].	NMIBC	 can	 be	 managed	 effectively	 through	 transurethral	 resection	 of	 the	bladder	tumour	and	Bacillus	Calmette-Guérin	(BCG)	instillation,	although	70%	of	patients	 with	 NMIBC	 have	 recurrent	 lesions,	 lending	 the	 need	 for	 regular	surveillance	using	diagnostic	cystoscopy.	The	high	potential	 for	recurrence	and	necessity	of	repeat	treatment	in	BC	makes	it	the	most	expensive	cancer	to	treat,	costing	US$3.7	Billion	 in	2001	 in	 the	USA	[14,	15].	One	 fifth	of	NMIBC	patients	will	progress	to	muscle-invasive	BC	(MIBC)	over	time,	this	number	rises	to	half	if	the	patient	presents	with	Carcinoma	in	situ	(Cis).		
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Figure	 1.4.	 Age	 standardised	 five-year	 relative	 survival	 rates	 for	 England	
and	Wales	1971-2009,	based	on	 cancer	 type.	BC	 is	 the	 only	 top	 10	 cancers	that	 has	 decreased	 in	 terms	 of	 relative	 survival	 over	 recent	 decades.	 This	 is	believed	to	be	due	to	decreasing	incidence	rates	in	males	with	the	mortality	rate	remaining	unchanged,	 combined	with	 the	 implementation	 of	 the	World	Health	Organisation	(WHO)	2004	guidelines	for	BC	risk	stratification	[12].									
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The	 5-year	 survival	 for	 patients	 with	 MIBC	 is	 under	 half	 that	 of	 a	 NMIBC	diagnosis,	with	 only	45%	surviving	 [12].	 This	 is,	 in	 part,	 believed	 to	be	due	 to	tumour	cell	 clones	undergoing	epithelial-to-mesenchymal	 transition,	entering	a	more	motile,	malignant	state	with	a	much	higher	propensity	to	form	metastatic	lesions	 [10,	 16].	 First	 line	 treatment	 options	 for	 MIBC	 include	 radical/partial	cystectomy,	 cisplatin	 based	 chemotherapy	 with	 gemcitabine,	 and	chemoradiotherapy	[17,	18].			Metastatic	 BC	 (MBC),	 is	 a	 devastating	 disease,	 leaving	 only	 6%	 of	 patients	alive	 after	 5-years	 [12,	 19].	 Treatment	 options	 will	 be	 discussed	 later,	although	 in	 the	 first	 line	 setting,	 treatment	 for	 MBC	 includes	 palliative	cisplatin-based	 chemotherapy	 with	 gemcitabine,	 radiotherapy,	chemoradiation,	neo-adjuvant	 chemotherapy,	 and	surgical	 tumour	 resection	when	possible.		
With	primary	diagnosis	of	BC	most	likely	between	the	ages	of	65	and	84,	and	a	high	 incidence	of	 co-morbidities,	 often	 related	 to	 tobacco	 smoking	 [13].	A	significant	challenge	 is	present	 in	 the	 treatment	of	MIBC,	as	 the	single	most	efficacious	 agent	 in	 the	 treatment	 of	 BC,	 cisplatin,	 is	 highly	 nephrotoxic,	leading	 to	 contraindication	 in	 patients	with	 low	 (glomerular	 filtration	 rate)	GFR	[10].			BC	 is	most	prevalent	 in	 the	Western	world,	with	 the	 incidence	rate	 in	Western	Europe	 being	 over	 4-times	 that	 of	 that	 in	 large	 parts	 of	 Africa	 [12].	 Although	North	Africa	is	an	exception,	here	there	is	a	high	rate	of	Schistosomiasis	induced	SCC	of	the	bladder,	where	90%	of	cases	are	SCC	and	only	10%	of	patients	present	with	UCC	and	other	less	common	disease	subtypes	[12].		
1.2.2.2	Aetiology			There	 are	 several	 aetiological	 factors	 which	 have	 been	 implicated	 in	 the	development	of	bladder	carcinomas,	these	are	discussed	below.			
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1.2.2.2.1	Smoking		Tobacco	 smoking	 is	 linked	 with	 a	 greater	 than	 four-fold	 increased	 chance	 of	developing	 BC,	 accounting	 for	 47%	 and	 33%	 of	 cases	 in	 American	males	 and	females,	respectively	[20,	21].	There	are	a	number	of	causative	agents	which	are	believed	to	be	secreted	into	the	urine	including	benzo(a)pyrene,	and	a	range	of	alpha-	and	beta-naphthylamines	[22,	23].			
1.2.2.2.2	Occupational			In	the	early	20th	century	the	increased	incidence	of	BC	in	people	working	in	the	textile	 industry	 led	 to	 several	 studies,	which	 revealed	 that	 oral	 ingestion	 of	 2-naphthylamine	 (a	 once	 key	 arylamine	 used	 in	 the	 production	 of	 aniline	 dyes)	induced	 BC	 in	 canines.	 It	 was	 also	 found	 that	 these	 workers	 had	 a	 20-fold	increased	chance	of	BC	development	when	compared	to	the	general	population	[24].			More	recently,	it	has	become	apparent	that	workers	from	many	different	trades	were	subject	to	the	chemical	induction	of	BC.			These	include	people	working	in	the	 chemical,	 dye,	 rubber,	 petrochemical,	 aluminium	 production,	 leather,	 and	printing	industries.	A	number	of	chemicals	have	been	implicated	in	the	increased	incidence	of	BC,	including	polycyclic	aromatic	hydrocarbons,	fluorides,	aromatic	amines,	 benzidine,	 beta-napthylamine,	 o-toluidine	 and	 4-amino-biphenyl	 [25-27].			
1.2.2.2.3	Dietary	Factors			There	 is	some	anecdotal	evidence	 that	 the	consumption	of	coffee	may	 increase	the	chance	of	BC,	as	there	is	the	number	of	coffee	drinkers	within	BC	cohorts	is	unusually	high,	however	there	is	no	established	dose-response	relationship	[28-30].			
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The	artificial	sweetener	saccharin,	 in	excess	of	normal	dietary	intake	levels	has	been	shown	 in	animal	models	 to	 increase	 the	chance	of	BC,	however	 there	has	been	no	evidence	of	this	being	the	case	in	humans[31,	32].			Conversely	consumption	of	foods	high	in	selenium,	vitamin	D	and	vitamin	E	may	shown	decrease	the	risk	of	contracting	BC	[33-35].			
1.2.2.2.4	Iatrogenic			There	 are	 a	 triad	 of	 instances	where	 the	 development	 of	 urothelial	 carcinoma	can	be	due	to	side	effects	of	medical	examination,	or	treatment.	These	are	known	as	iatrogenic	side	effects.			
Phenacetin			The	 analgesic	 phenacetin	 (acetophenetidin),	which	 has	 structural	 homology	 to	aniline	dyes,	has	been	shown	to	be	associated	with	a	two-	to	six-fold	increase	in	the	development	of	urothelial	cancers	in	the	bladder	and	urinary	tract	[36].	The	increase	 in	 BC	 incidence	 is	 most	 strongly	 associated	 with	 heavy	 usage	 of	phenacetin	 in	 young	 patients	 [36,	 37].	 The	 iatrogenic	 induction	 of	 BC	 by	phenacetin	 is	 the	key	reason	 for	 the	drugs	withdrawal,	 its	usage	has	now	been	replaced	with	safer	agents	such	as	paracetamol,	which	is	not	associated	with	an	increased	risk	of	BC	[37,	38].			
Cyclophosphamide			The	oxazophosphorine,	cyclophosphamide,	is	a	chemotherapeutic	drug	that	uses	alkylation	 as	 its	primary	mode	of	 cytotoxicity.	 Its	usage	 leads	 to	haemorrhagic	cystitis	and	is	associated	with	a	9-fold	increase	in	the	development	of	BC,	in	the	region	 of	 6-13	 years	 post-treatment	 [39].	 These	 effects	 are	 caused	 by	 a	metabolite	 of	 cyclophosphamide,	 acrolein.	 2-mercaptoethanesulfonic	 acid	(MENSA)	is	an	organosulfur	uroprotective	compound,	which	is	co-administered	with	cyclophosphamide	to	limit	the	negative	effects	on	the	bladder	[40].	MENSA	
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reacts	 with	 acrolein	 and	 other	 urotoxic	 metabolites	 leading	 the	 formation	 of	harmless	compounds	[40,	41].			
Radiotherapy			One	 of	 the	 few	 iatrogenic	 risk	 factors,	 which	 is	 not	 chemically	 induced	 is	 the	usage	of	radiotherapy	in	women	who	have	been	treated	for	cancers	of	the	ovary	or	uterine	cervix	associated	with	a	2-	to	4-fold	increased	chance	of	developing	BC	after	 a	 decade,	 in	 comparison	 to	 patients	 who	 underwent	 surgical	 tumour	management	[42,	43].			
1.2.2.2.5	Chronic	bladder	inflammation			Chronic	 inflammation,	 or	 chronic	 cystitis	 of	 the	 bladder	 is	 associated	 with	 an	increase	incidence	of	BC	[44].	Conversely	to	the	majority	of	bladder	tumours,	the	lesions	tend	to	be	SCC,	rather	than	the	more	commonly	seen	UCC	[44].			As	 a	 result	 of	 chronic	 catheter	 cystitis,	 2-10%	 of	 paraplegics	 will	 ultimately	develop	 SCC	 of	 the	 bladder,	 however	 there	 are	 reports	 of	 up	 to	 81%	of	 spinal	cord	 injury	 patients	 with	 BC	 developing	 urothelial	 cell	 carcinomas	 [45-47].	Forms	of	physical	trauma	to	the	bladder	through	infection,	calculi	formation	and	chronic	 catheter	 usage	 in	 this	 patient	 group	may	 also	 lead	 to	 the	 formation	 of	cancerous	lesions	of	the	bladder	[45,	47,	48].			Globally,	 schistosomiasis	 is	 the	most	 prevalent	 waterborne	 parasitic	 infection,	and	 after	 smoking	 it	 is	 the	 second	 leading	 cause	 of	 BC	 [49].	 The	 Schistosoma	
haematobium	 digenetic	 trematode,	 which	 effects	 at	 least	 76	 countries	 and	 is	endemic	in	Egypt	and	the	Middle	East,	infecting	200	million	people,	is	the	cause	of	schistosomiasis	associated	BC	(SABC),	which	accounts	for	>30%	of	all	cases	of	BC	in	Egypt,	for	the	most	part	leading	to	SCC	[50,	51].	In	comparison	to	smoking	associated	BCs,	the	mean	age	of	onset	of	SABC	is	much	lower	and	there	is	a	much	greater	proportion	of	males	who	suffer	from	the	disease	[51].		It	is	believed	that	an	 increased	 concentration	 of	 N-Nitroso	 compounds	 in	 the	 bladder	 of	 people	
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infected	 by	S.	haematobium	 is	 the	 cause	 of	 SCC,	 through	 deoxyribonucleic	 acid	(DNA)	damage,	leading	to	pro-malignant	point	mutations	[51].			
1.2.2.2.6	Hereditary	factors		Apart	from	radiotherapy	and	parasite	infection,	the	key	aetiological	factors	that	lead	to	BC	are	exposure	to	a	several	chemicals,	either	by	direct	action	or	after	the	metabolic	activation	of	inert	compounds	into	mutagens.		Humans	 are	 equipped	 with	 a	 range	 of	 enzymes	 that	 are	 involved	 in	 the	detoxification	 of	 compounds	 with	 biological	 activity.	 These	 enzymes	 facilitate	processes	 including	 acetylation,	 hydroxylation	 and	 conjugation	 to	 neutralise	compounds	 with	 biologically	 active	 chemical	 groups	 [4,	 52].	 This	 group	 of	enzymes	 including	 N-acetyl-transferase	 (NAT),	 cytochrome	 P450	 (CYP)	 and	glutathione	transferase	(GST)	are	subject	to	a	range	of	polymorphisms	within	the	population,	due	to	the	two	allelic	forms	derived	from	maternal	and	paternal	DNA	[4,	 52].	 A	 common	 polymorphism,	 implicated	 in	 the	 metabolism	 of	 toxic	compounds	 of	 cigarette	 smoking	 is	 the	NAT-2	 slow	 acylator	 phenotype,	which	increases	the	duration	of	arylamine	exposure	leading	to	increased	incidences	of	cancer	 formation	 [53,	 54].	 High	 expression	 of	 GSTs	 is	 linked	 to	 a	 lower	susceptibility	to	carcinogens	from	cigarette	smoke;	unsurprisingly	glutathione-s-transferase-Mu	 1	 (GSTM1)	 null	 patients	 are	 more	 likely	 to	 contract	 BC.	Furthermore,	individuals	with	Cytochrome	P450	2D6	(CYP2D6)	polymorphisms	may	have	an	increased	chance	of	developing	BC	[55-58].			There	 are	 limited	 reported	 cases	 of	 inherited	 BC,	 the	 few	 that	 do	 exist	 are	primarily	 due	 to	 the	 inheritance	 of	 hereditary	 cancer	 syndromes	 such	 as	Retinoblastoma,	 Costello	 syndrome,	 Facio-Cutaneous	 Skeletal	 syndrome,	Cowden	syndrome	and	Lynch	syndrome	[59-63].		
	
1.2.2.2.7	Other	aetiological	factors		
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There	are	a	number	of	other	aetiological	factors	which	can	result	in	an	increased	risk	of	BC,	these	include:	exposure	to	arsenic	in	well	water	and	inorganic	arsenic	compounds	 such	 as	 gallium	 arsenide	 [26,	 64,	 65];	 exposure	 to	 chlorinated	aliphatic	hydrocarbons	and	chlorination	by-products	in	treated	water	[66];	and	finally	 chronic	usage	of	Chinese	herbal	medicines	 containing	aristolochic	acids,	extracted	from	the	Aristolochia	fangchi	plant	[67,	68].	
	
1.2.3	Bladder	cancer:	diagnosis		BC	 is	 often	 identified	 due	 to	 the	 presence	 of	 visible	 blood	 in	 the	 urine	(haematuria),	 or	 blood	 detected	 upon	 urinalysis	 (microscopic	 haematuria).	Emergency	 admission	 due	 to	 BC	 related	 complications	 is	 a	 common	 mode	 of	disease	presentation	and	 is	often	associated	with	poor	prognosis.	Stage	1	BC	 is	the	 most	 frequently	 diagnosed	 (Fig	 1.5),	 however	 if	 MIBC	 is	 suspected	 at	cystoscopy,	 computed	 tomography	 (CT)	 or	magnetic	 resonance	 imaging	 (MRI)	will	be	employed	to	query	muscle	invasion.			With	 treatment	 and	 surveillance	 involving	 the	 urogenital	 tract,	 BC	 often	 has	 a	high	 psychological	 impact,	 in	 addition	 to	 the	 profound	 physical	 impact	 of	 the	disease.															
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Figure	 1.5.	 Bladder	 cancer:	 stage	 at	 diagnosis.	 Stage	 1	 (34.9%),	 stage	 II	(20.6%),	stage	III	(5.6%),	stage	IV	(13.6%)	and	stage	not	known	(25.4%)[12].													
Stage	I	Stage	II	Stage	III	Stage	IV	Stage	Not	Known	
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1.2.3.1	Histological	staging	and	grading	of	bladder	cancer			The	 tumour-node-metastasis	 (TNM)	 system	 is	 used	 to	 categorise	 the	 stage	 at	which	a	cancer	is	at	within	a	patient.	Tumour	(T)	denotes	the	size	and	location	of	the	primary	tumour,	Node	(N)	informs	as	to	whether	the	tumour	has	spread	to	the	lymph	nodes,	and	the	extent	of	lymph	involvement,	Metastasis	(M)	indicates	whether	the	tumour	has	spread	to	distant	sites	[12]	(Fig	1.2).			Tumour	(T):	In	 the	 TNM	 system,	 T	 is	 used	 plus	 a	 denomination	 to	 describe	 the	 extent	 of	tumour	invasion.		
TX:	The	tumour	is	unable	to	be	assessed.		
T0:	No	evidence	of	BC.	
Ta:	Non-invasive	papillary	BC.		
Tis:	Carcinoma	in	situ,	a	flat,	non-invasive	lesion	found	on,	or	near	the	surface	of	the	bladder.		
T1:	The	tumour	invades	up	to	an	including	the	lamina	propria.		
T2:	The	tumour	has	spread	into	the	detrusor	muscle.			 T2a:	The	tumour	spread	is	confined	to	the	inner	half	of	the	muscle.		 T2b:	The	tumour	invades	the	outer	half	of	the	muscle.		
T3:	The	tumour	invades	the	perivesicular	adipose	tissue.			 T3a:	Invasion	into	perivesicular	tissue	is	only	apparent	microscopically.			 T3b:	 Invasion	 into	 perivesicular	 tissue	 is	 apparent	 macroscopically,	through	imaging	or	palpation.		
T4:	The	tumour	has	spread	to	near-by	organs:			 T4a:	The	invasion	is	confined	to	the	prostate,	uterus	or	vagina.			 T4b:	The	tumour	infiltrates	the	pelvic	or	abdominal	diaphragm.							
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Node	(N):		Several	 lymph	 nodes	 are	 local	 to	 the	 bladder.	 These	 regional	 lymph	 nodes	include	the	hypogastric,	obturator,	 iliac,	perivesical,	pelvic,	sacral	and	presacral	lymph	nodes.			
NX:	Regional	lymph	nodes	cannot	be	assessed.		
N0:	No	cancer	is	present	in	the	regional	lymph	nodes.		
N1:	The	malignancy	has	spread	to	one	regional	lymph	node	in	the	pelvis.		
N2:	The	malignancy	has	spread	to	greater	than	one	lymph	node	in	the	pelvis.	
N3:	 The	 disease	 has	 spread	 beyond	 regional	 lymph	nodes	 of	 the	 pelvis,	 to	 the	common	iliac	lymph	nodes.			Metastasis	(M):		The	 final	 category	 in	 this	 classification	 system	 denotes	 whether	 metastasis	 is	present.	 Common	 sites	 for	 distant	 metastasis	 of	 urothelial	 cell	 carcinomas	include	 bone,	 liver	 and	 the	 lung	 [69].	 This	 classification	 does	 not	 consider	micrometastases.			
M0:	There	is	no	detectable	metastatic	disease.		
M1:	Distant	metastases	are	present.			Grade:	In	conjunction	with	the	TNM	staging	system,	the	grade	considers	the	neoplastic	potential	of	certain	cancers.	There	are	three	classifications	of	BC	cancer	grade.		
Papilloma:	 Also	 known	 as	 a	 benign	 papillary	 urothelial	 neoplasm	 of	 low	malignant	 potential	 (PUNLMP),	 there	 is	 a	 high	 chance	 this	 lesion	 will	 recur,	however	PUNLMPs	are	unlikely	to	progress	to	a	more	advanced	disease.			
Low	 Grade:	 Well	 differentiated,	 with	 a	 higher	 chance	 of	 recurrence	 and	progression	when	compared	to	a	papilloma.			
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High	Grade:	Poorly	differentiated,	there	is	the	highest	chance	of	recurrence	and	progression	to	advanced	disease.			The	1973	advice	of	the	World	Health	Organisation	(WHO),	the	system	used	prior	to	the	2004	revision	mentioned	above,	designated	grades	from	1	to	3,	with	stage	1	 showing	 the	 least	 degree	 of	 cellular	 anaplasia	 compatible	 with	 a	 cancer	diagnosis,	and	stage	3	showing	the	most	severe	degrees	of	cellular	anaplasia,	the	histological	features	of	grade	2	malignancies	lying	between	grades	1	and	3	[70].	This	 thesis	will	use	both	 the	1973,	and	2004	revision,	depending	on	 the	age	of	the	sample	used,	and/	or	the	preference	of	the	pathologist.																								
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1.2.4	Bladder	cancer:	treatment			This	section	discusses	current	approaches	in	the	treatment	of	NMIBC	and	MIBC.			
1.2.4.1	Muscle	invasive	bladder	cancer	and	non-muscle	invasive	bladder	
cancer	
	Stratification	between	aggressive	and	more	conservative	modes	of	 treatment	 is	normally	determined	by	the	presence,	or	absence	of	BC	muscle	invasion	[71].			The	 vast	majority	 of	 cases	 (90%)	 are	 histologically	 classified	 as	 urothelial	 cell	carcinomas.	 Localised	 disease	 can	 be	 stratified	 into	 NMIBC	 and	 MIBC	 [12].	NMIBC	can	be	effectively	managed	through	transurethral	resection	and	Bacillus	Calmette-Guérin	(BCG)	vaccine	bladder	instillation,	whereas	MIBC	often	requires	aggressive	 surgical	 management	 of	 surgery	 with	 radiotherapy,	 often	 with	concurrent	 neoadjuvant	 platinum	 based	 chemotherapy	 consisting	 of	 the	nucleoside	analogue	gemcitabine	and	alkylating	agent	cisplatin	[12].			Intravesical	mitomycin	C	instillation	is	often	offered	during	the	first	(diagnostic)	cystoscopy,	as	there	is	evidence	for	reduced	recurrence	[72].			
1.2.4.1.1	Treatment	of	non-muscle	invasive	bladder	cancer			With	an	80%	success	rate	the	mainstay	of	treatment	for	NMIBC	is	transurethral	resection	 of	 the	 bladder	 tumour	 (TURBT),	 with	 adjuvant	 intravesical	 therapy	[73].	BCG	is	the	most	common	and	effective	form	of	intravesical	therapy	used	in	the	 treatment	 of	 non-muscle	 invasive	 BC,	 however	 other	 agents	 such	 as	mitomycin	C	and	interferon-α	can	be	administered	in	the	same	manner	with	fair	therapeutic	efficacy	[74].					
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Trans-urethral	resection	of	the	bladder	tumour				TURBT	is	the	first-line	surgical	 treatment	for	NMIBC.	Bladder	tumours	are	first	located	 using	 a	 cystoscope,	 and	 resected	with	 an	 electrosurgical	 excision	 loop,	allowing	 for	 tumour	 resection	whilst	 sealing	underlying	blood	vessels	 [75,	76].	Tissue	is	then	histologically	staged	and	graded	by	a	pathologist.	TURBT	is	often	followed	by	intravesical	chemotherapy,	most	commonly	using	BCG	[75].	A	period	of	at	least	two	weeks	post	TURBT	is	allowed	before	BCG	instillation	to	allow	time	urothelial	 repair,	 limiting	 systemic	 exposure	 to	 the	 attenuated	Mycobacterium	
bovis	[77].		
	One	potential	drawback	of	TURBTs	is	an	increased	number	of	circulating	tumour	cells	in	peripheral	blood	post-surgery,	which	may	lead	to	dissemination	of	UCCs	to	organs	and	tissues	within	the	body	[78].	However	a	consensus	has	not	been	reached	on	this	topic	[79].		
Bacillus	Calmette-Guérin	and	other	intravesical	immunomodulators		Originally	formulated	as	a	vaccination	against	tuberculosis,	BCG	is	an	attenuated	form	of	the	bovine	tuberculosis	bacillus,	Mycobacterium	bovis	[80].	Since	the	first	reported	successful	usage	of	BCG	in	BC	by	Morales,	Eidinger	and	Bruce	in	1976,	BCG	 has	 become	 the	most	 efficacious	 agent	 used	 in	 the	 treatment	 of	 high-risk	NMIBC	[81,	82].			BCG	is	delivered	into	the	bladder	as	an	 intravesical	 treatment,	and	so	bypasses	many	 of	 the	 side	 effects	 associated	 with	 systemic	 chemotherapy,	 with	 many	patients	 reporting	mild	 to	moderate	 side	 effects.	 BCG	 treatment	 is	 superior	 to	intravesical	 treatment	 with	 conventional	 chemotherapy	 drugs	 in	 terms	 of	progression,	 specifically	 displaying	 greater	 effect	 on	 tumour	 progression	 in	comparison	 to	 the	DNA	crosslinker,	mitomycin	C	 [72,	83,	84].	 	On	average	 this	form	of	 immunotherapy	reduces	the	recurrence	rate	by	40%	and	the	chance	of	progression	 by	 20%	 in	 patients	 presenting	 with	 papillary	 lesions	 [85].	 For	
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patients	with	Cis,	more	than	40%	of	patients	respond	to	therapy,	there	is	also	a	25%	decrease	in	progression	when	Cis	patients	undergo	BCG	treatment	[85].			The	 exact	 mechanism	 behind	 the	 anti-tumour	 effects	 of	 BCG	 has	 not	 been	characterised	 although	 theories	 suggest	 that	 efficacy	 may	 be	 due	 to	 a	 local	immune	 response,	mediated	 by	 a	 concert	 of	 immune	 cells	 including	 CD4+	 and	CD8+	 lymphocytes,	 natural	 killer	 (NK)	 cells,	 granulocytes,	 macrophages	 and	dendritic	 cells	 (DCs).	 As	 a	 result	 of	 this	 immune	 response	 BC	 cells	 potentially	undergo	apoptosis	due	to	direct	cytotoxicity	possibly	mediated	through	CD40L,	secretion	 of	 soluble	 factors	 such	 as	 tumour	 necrosis	 factor-related	 apoptosis-inducing	 ligand	 (TRAIL)	 and	 direct	 action	 of	 BCG	 [86,	 87].	 BCG	 is	 the	 gold	standard	 in	 intravesical	 treatment	 for	 high-risk	 NMIBC	 although	 its	 use	 can	cause	 treatment-contraindicating	 adverse	 reactions	 and	 there	 has	 been	 a	shortage	 in	 supply	 in	 recent	 years,	 highlighting	 the	 requirement	 for	 a	 well-tolerated	efficacious	alternative	[88].			Aside	from	BCG	other	forms	of	immune	therapy	used	in	the	treatment	of	NMIBC	includes	 interferon-α	 instillation.	 Although,	 as	 a	 sole	 agent	 interferon-α	 is	 less	effective	and	more	expensive	 than	BCG,	 there	 is	no	evidence	 to	 show	 that	BCG	plus	interferon-α	exhibits	superior	efficacy	to	BCG	alone,	with	the	same	applying	for	 its	 use	 alongside	 chemotherapy	 [89-92].	 Interestingly,	 Interferon-α	 does	occasionally	 show	 efficacy	 in	 patients	 who	 are	 unresponsive	 to	 BCG	 therapy,	with	 15-20%	 completely	 responding	 [74].	 In	 addition	 to	 interferon-α,	 similar	levels	 of	 efficacy	 have	 been	 seen	 with	 Interleukins	 -2	 and	 -12	 (IL-2,	 IL-12),	tumour	 necrosis	 factor	 (TNF),	 keyhole	 limpet	 hemocyanin	 (KLH)	 and	 rubratin	[73].			
Intravesical	chemotherapy		There	 are	 a	 number	 of	 chemotherapy	 drugs,	 which	 have	 been	 used	 in	 the	intravesical	 treatment	of	BC,	 these	 include:	mitomycin	C,	doxorubicin,	 thritepa,	ethoglucid,	 valrubicin,	 epirubicin,	 cisplatin	 and	 gemcitabine	 or	 their	combinations	 [73].	 There	 is	 no	 apparent	 superior	 agent,	 the	 addition	 of	
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intravesical	 chemotherapy	 to	TURBT	yields	 a	14-17%	reduction	 in	 recurrence,	however	there	is	little	benefit	in	terms	of	disease	progression	[73].	Generally,	the	side	 effects	 of	 intravesical	 chemotherapy	 are	 less	 than	 that	 of	 BCG	 instillation,	making	 intravesical	 chemotherapy	 an	 attractive	 treatment	 in	 patients	who	 are	least	likely	to	progress.			
1.2.4.1.2	Treatment	of	muscle	invasive	bladder	cancer		Treatments	 for	 patients	 presenting	with	MIBC	 are	much	more	 radical	 than	 for	patients	 presenting	 with	 NMIBC.	 This	 is	 due	 to	 there	 being	 an	 increased	likelihood	of	progression	to	stage	3	or	4,	associated	with	poor	five-year	survival	rates	of	just	30%	and	10%	respectfully	[13].	These	treatments	vary	from	surgical	resection	of	the	whole	bladder	(cystectomy),	or	affected	portions	of	the	bladder	(partial	 cystectomy),	 with	 adjuvant	 or	 neo-adjuvant	 chemotherapy	 and	chemoradiotherapy.			
Surgery		Surgical	management	of	MIBC	 is	 limited	 to	 cystectomy,	partial	 cystectomy	and	initial	debulking	by	TURBT,	depending	on	the	amount	of	the	bladder	affected	by	the	cancer	and	patient	preference.	Surgery	is	paired	with	chemotherapy	to	target	micro-metastases.				
	
Radical	cystectomy		
	Radical	 cystectomy	 is	 the	 removal	 of	 the	 entire	 bladder,	 surrounding	 nearby	lymph	 nodes,	 the	 prostate,	 part	 of	 the	 urethra,	 surrounding	 tissue	 and	 organs	infiltrated	by	tumour	[93].			
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Partial	cystectomy		
	A	 partial	 cystectomy	 is	 an	 option	 in	 unifocal	 MIBCs.	 Part	 of	 the	 bladder	 is	removed,	 allowing	 for	 retention	 of	 bladder	 function,	 although	 with	 a	 reduced	volume	[94].		
	
Radiotherapy	and	Chemoradiotherapy		
	Radiotherapy	is	a	alternative	to	cystectomy	in	patients	with	MIBC.	It	allows	for	locoregional	control	of	the	disease	whilst	preserving	bladder	function.	Cisplatin	is	used	in	many	cancers	as	a	radio-sensitising	agent,	however	its	use	in	BC	is	not	practical	due	to	the	low	renal	function	and	performance	status	of	a	large	portion	of	patients.	Although,	the	usage	of	5-flurouracil	(5-FU)	and	Mitomycin	C	(MMC)	has	 been	 shown	 to	 significantly	 improve	 locoregional	 control	 in	 MIBC,	 when	compared	to	radiotherapy	alone,	with	no	significant	 increase	 in	adverse	events	[95].				
Chemotherapy		First	line	chemotherapy	in	BC	is	a	combination	of	cisplatin	and	gemcitabine	(GC).	Neoadjuvant	 cisplatin	based	GC	chemotherapy	 is	offered	suitable	patients	with	newly	diagnosed	MIBC,	prior	to	cystectomy	or	radiotherapy	[96].	MIBC	patients	are	 offered	 adjuvant	 cisplatin	 after	 radical	 cystectomy,	 wherever	 neoadjuvant	chemotherapy	is	not	possible.				
Cisplatin			Cis-diaminedichlorldoplatinum(II)	 is	 the	 first	member	 in	 the	 class	of	platinum-containing	 anti-cancer	 drugs,	 which	 also	 includes	 carboplatin	 and	 oxaliplatin,	and	is	the	single	most	efficacious	agent	in	the	treatment	of	MIBC	[97,	98].	Upon	entering	the	tumour	cells,	the	chloride	ions	of	cisplatin	are	subject	to	aquation	in	
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the	 cytosol	where	 the	 chloride	 content	 is	 3-20%	of	 the	 100mM	present	 in	 the	extracellular	fluid	[97].	The	resultant	activated	compound	forms	highly	reactive	platinum	complexes	and	creates	of	intra	and	inter-strand	crosslinks.	Specifically	1,2-intrastrand	 crosslinks	with	 the	N7	position	on	purine	bases,	 including	GpG	and	ApG	adducts	[97].	These	crosslinks	interfere	with	DNA	repair	mechanisms,	leading	 to	 DNA	 damage	 and	 the	 subsequent	 induction	 of	 apoptosis	 in	 tumour	cells,	 or	 indeed	 most	 quickly	 dividing	 cells,	 such	 as	 cells	 involved	 in	haematopoiesis	within	the	bone	marrow	[97].			Cisplatin	is	used	in	the	treatment	of	a	wide	variety	of	cancers	including	bladder,	head	and	neck,	lung,	ovarian,	and	most	notably	testicular	cancers	[96,	98-103].	It	shows	 efficacy	 against	 carcinomas,	 germ	 cell	 tumours,	 lymphomas,	 and	sarcomas.	 The	 renally	 excreted	 compound	 is	 intravenously	 administered	 and	binds	highly	(>95%)	to	plasma	proteins	[104].	Cisplatin	is	a	poor	penetrator	of	the	blood-brain	barrier	 and	 accumulates	most	 significantly	within	 the	kidneys,	although	accumulation	 is	 also	observed	 in	 the	 testes	and	 intestine.	 Side	effects	include	 nephrotoxicity,	 neurotoxicity,	 ototoxicity,	 electrolyte	 disturbance,	haemolytic	 anaemia,	 nausea	 and	 vomiting.	 Unfortunately,	 BCs	 often	 acquire	resistance	to	cisplatin.				
Gemcitabine		Gemcitabine	 is	 a	 hydrophilic	 nucleoside	 analogue	 pro-drug	 that	 is	intracellularally	 converted	 into	 the	 active	metabolites	 gemcitabine	 bi-	 and	 tri-	phosphate[105].	 It	 blocks	 the	 de	 novo	 synthesis	 pathway	 inhibiting	ribonucleotide	reductase	by	replacing	cytidine	during	replication,	leading	to	cell	cycle	 arrest	 and	 apoptosis	 [105].	 The	 membrane	 transport	 proteins	 human	equilibrative	 nucleoside	 transporter	 1	 (hENT1)	 and	 human	 concentrative	nucleoside	transporter	(hCNT)	are	responsible	for	the	transport	of	gemcitabine	into	the	cell,	underexpression	of	the	50KDa	transmembrane	protein	hENT1	has	been	 linked	 to	 gemcitabine	 resistance	 in	 a	 range	 of	 cancers	 as	 has	overexpression	of	the	R1	subunit	of	ribonucleotide	reductase	[105-109].		
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The	addition	of	gemcitabine	to	cisplatin	allowed	for	a	similar	survival	advantage	to	 the	 previous	 gold-standard	 first	 line	 therapy	 for	 BC	 -	 methotrexate,	vinblastine,	doxorubicin,	and	cisplatin	(MVAC)	-	but	GC	is	better	tolerated	with	a	lower	incidence	of	adverse	events,	and	as	such	is	the	current	standard	of	care	for	patients	with	MIBC	and	MBC	[99].			
Chemotherapy	Resistance			Most	 patients	 initially	 respond	well	 to	 cisplatin-based	 chemotherapy,	 however	90%	 of	 patients	 will	 acquire	 resistance	 to	 cisplatin.	 Interestingly,	 a	 small	proportion	of	patients	will	present	with	intrinsically	cisplatin	resistant	BC.		
	Modes	 of	 cisplatin	 resistance	 are	 facilitated	 by	 decreased	 intracellular	concentrations	 of	 cisplatin,	 increased	 DNA	 repair,	 and	 decreased	 mitotic	checkpoint	surveillance.			Decreased	 intracellular	 concentrations	 of	 cisplatin	 are	 achieved	 through:	increased	 efflux	 –	 multidrug	 resistance-associated	 protein	 2	 (MRP2),	 with	 an	antioxidant	response	element	(ARE)	in	its	promoter	region,	has	been	implicated	in	cisplatin	accumulation,	and	cisplatin	resistance	[110];	increased	detoxification	–	glutathione	(GSH)	overexpression,	also	containing	an	ARE	in	its	promoter,	has	been	 linked	 to	 cisplatin	 resistance,	 furthermore	 GSH-cisplatin	 conjugates	 are	substrates	 for	MRP2	 efflux	 [111-113].	 DNA	 excision	 repair	 protein	 1	 (ERCC1),	which	 functions	 within	 the	 nucleotide	 excision	 repair	 pathway,	 has	 been	implicated	in	cisplatin	resistance	in	several	cancers,	where	increased	expression	leads	 to	 the	 repair	 of	 platinum	 adducts	 formed	 by	 cisplatin,	 attenuating	 its	cytotoxic	effects	[114-118].	Interestingly,	dysregulation	of	checkpoint	proteins	at	the	G2/M	phase	mitotic	 checkpoint	has	been	 implicated	 in	 cisplatin	 resistance,	mediated	by	overexpression	of	cyclin-dependent	kinase	1	(CDK1),	and	M-phase	inducer	phosphatase	3	(CDC25C)	in	lung	cancer	cells	[119].			There	is	much	to	be	understood	about	the	modes	of	cisplatin	resistance,	however	it	is	likely	that	resistance	is	due	to	a	combination	of	the	above	factors.	Finding	a	
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target	that	governs	a	range	of	proteins	implicated	in	cisplatin	detoxification	may	be	useful	in	mitigating	cisplatin	resistance	in	BC.																																
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1.3	The	NRF2-KEAP1	axis			Nuclear	 factor	 (erythroid-derived	 2)-like	 2	 (NRF2)	 is	 a	 basic	 leucine	 zipper	transcription	factor	encoded	by	the	NFE2L2	gene,	and	the	master	regulator	of	a	battery	 of	 proteins	 involved	 in	 intracellular	 redox	 homeostasis	 [120].	 NRF2	expression	is	ubiquitous	throughout	the	body,	with	the	highest	levels	of	activity	being	 observed	 in	 tissues	 exposed	 to	 high	 concentrations	 of	 environmental	toxicants,	reactive	oxygen	species	(ROS),	and	carcinogens	such	as	the	kidney	and	liver	[121].			In	 normally	 functioning	 cells	 NRF2	 pathway	 activation	 elicits	 strong	 anti-inflammatory	 and	 anti-apoptotic	 effects,	 limiting	 macromolecular	 damage	 by	intracellular	 chemical	 and	 oxidative	 stress	 [122,	 123].	 Under	 basal	 conditions	NRF2	 is	 kept	 transcriptionally	 inactive	 by	 kelch-like	 ECH-associated	 protein	 1	(KEAP1)	 binding	 [124].	 Subsequent	 ubiquitination	 facilitated	 by	 cullin	 3	ubiquitin	 ligase	 (CUL3),	 promoting	 proteasomal	 degradation	 (Fig	 1.6)	 [124].	When	the	cell	is	subject	to	oxidative	or	electrophilic	stress,	it	is	hypothesised	that	cysteine	 thiol	 groups	 are	 modified	 on	 KEAP1	 and	 NRF2	 undergo	phosphorylation,	inhibiting	ubiquitination,	leading	to	KEAP1	saturation,	allowing	newly	 synthesised	 NRF2	 to	 accumulate	 in	 the	 nucleus	 and	 transactivate	 a	plethora	of	cytoprotective	genes	[124].				KEAP1	 is	 the	chief	regulator	of	NRF2	activation,	although	NRF2	activation	may	be	 mediated	 in	 a	 KEAP1-independent	 manner	 such	 as	 phosphorylation	 by	 a	number	of	kinases	 including	protein	kinase	C	 (PKC),	mitogen-activated	protein	kinase	 (MAPK)/	 extracellular	 signal-regulated	 kinase	 (ERK)/	 c-Jun	 N-terminal	kinase	(JNK),	and	phosphatidylinositide	3-kinase	(PI3K)	[125].		Furthermore,	 NRF2	 expression	 is	 also	 dependent	 on	 autoregulation.	 For	example,	 an	 autoregulatory	 loop	 is	 formed	with	 CUL3	 and	RING-box	protein	 1	(RBX1),	whereby	NRF2	expression	triggers	the	transcription	of	CUL3	and	RBX1	[126].	 Interestingly,	 NRF2	 can	 autoregulate	 its	 expression	 through	 an	 ARE	
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located	in	the	proximal	region	of	its	promoter,	allowing	for	NRF2	replenishment	in	times	of	cellular	stress,	upon	NRF2	nuclear	translocation	[127].			Studies	 in	 transgenic	 NRF2	 knockout	 mice	 have	 highlighted	 the	 physiological	significance	 of	 NRF2	 mediated	 cytoprotective	 effects,	 where	 these	 mice	 have	demonstrated	 increased	 susceptibility	 to	 drug	 induced	 toxicities	 [128].	Unsurprisingly,	 the	 NRF2-KEAP1	 axis	 has	 been	 implicated	 in	 many	 disease	processes	including	cancer.	
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Figure	1.6.	The	NRF2-KEAP1	axis.	Under	 basal	 conditions	 KEAP1	 sequesters	NRF2	 in	 a	 complex	 with	 CUL3	 and	 RBX1	 that	 facilitates	 ubiquitin	 ligation.	Polyubiquitinylation	 of	 NRF2	 results	 in	 proteasomal	 degradation.	 Under	conditions	of	cellular	stress	cysteine	residues	on	KEAP1	are	disrupted,	leading	to	decreased	NRF2	binding,	resulting	in	NRF2	release,	followed	by	translocation	to	the	 nucleus,	 ARE	 binding	 and	 heterodimerisation	 with	 small	 MAF	 (SMAF)	facilitating	the	upregulation	of	a	battery	of	cytoprotective	genes.							
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1.3.1	NRF2	in	cancer				Since	 the	 discovery	 of	 NRF2,	 there	 has	 been	 an	 increasing	 body	 of	 evidence	indicating	a	positive	role	of	NRF2	in	cancer.		In	healthy	cells	NRF2	transcription	factor	binding	mediates	 cellular	detoxification,	 furthermore	NRF2	 induction	by	compounds	such	as	sulforaphane,	found	in	broccoli,	has	been	hypothesised	as	a	mechanism	 of	 chemoprevention	 [129,	 130].	 The	 chemopreventitive	 nature	 of	such	 compounds	 is	 due	 to	 induction	 of	 the	NRF2-mediated	 adaptive	 response,	leading	 to	 increased	 expression	 of	 phase	 II	 detoxifying	 enzymes,	 antioxidants,	and	transporters	responsible	for	cytoprotection	from	mutagens.	Interestingly,	in	NRF2-null	mice	 an	 increased	 incidence	 of	 cancer	was	 noted	 compared	 to	wild	type,	further	highlighting	the	tumour	suppressor	protein	(TSP)	role	of	NRF2,	as	a	result	 for	 many	 years	 NRF2	 has	 been	 viewed	 as	 a	 positive	 factor	 in	 terms	 of	cancer	prevention[131,	132].			However,	 the	 NRF2-mediated	 response	 is	 a	 double-edged	 sword,	 beneficial	 in	the	context	of	protecting	cells	 from	damaging	oxidative	stress,	whilst	 in	cancer	overexpression	of	NRF2	can	lead	to	chemotherapy	resistance	through	increased	cellular	efflux	and	detoxification,	and	the	promotion	of	proliferation,	and	a	more	aggressive	cancer	phenotype	[133].		Increased	 levels	 of	NRF2	 are	 associated	with	 cisplatin	 resistance	 in	 a	 range	 of	cancers	 including	 pancreatic	 cancer,	 ovarian	 cancer,	 and	 BC	 [134-139].	 The	result	of	high	NRF2	levels	in	cancer	is	the	upregulation	of	a	battery	of	genes	with	an	 ARE	 in	 their	 promoter	 region.	 Upregulated	 genes	 that	 result	 in	 decreased	sensitivity	 to	 cisplatin	 are	 those	 involved	 in	 efflux,	 and	 intracellular	detoxification.	 MRP2,	 regulated	 by	 NRF2,	may	 be	 responsible	 for	 the	 efflux	 of	cisplatin	 [140].	 Interestingly,	 in	 oesophageal	 SCC	 MRP2	 expression	 strongly	positively	 correlates	with	patients’	 sensitivity	 to	 cisplatin-based	 therapy	 [141].	The	 multidrug	 resistance	 protein	 1	 (MDR1)	 transport	 protein,	 moderated	 by	NRF2,	has	also	been	 implicated	 in	cisplatin	resistance,	where	 in	ovarian	cancer	MDR1	 expression	 was	 associated	 with	 reduced	 sensitivity	 to	 cisplatin	 [142].	High	 resistance	 to	 cisplatin	 in	 ovarian	 cancer	 cell	 lines	 is	 associated	with	 high	
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levels	of	 glutathione	 synthesis	 [143].	 Furthermore,	 glutathione	 s-transferase	pi	(GSTπ)	amplification	has	been	linked	with	cisplatin	resistance	in	head	and	neck	cancers,	 further	 implicating	 genes	 downstream	 of	 NRF2	 in	 cisplatin	 resistance	[144].	 	 Notably,	 cisplatin	 treatment	 has	 been	 shown	 to	 increase	 the	 level	 of	cellular	oxidative	stress	[145].	This	effect	has	potential	to	lead	an	increase	in	the	expression	 of	 NRF2	 and	 downstream	 proteins	 that	 may	 render	 cisplatin	chemotherapy	 treatment	 ineffective,	 whilst	 still	 inflicting	 marked	 systemic	adverse	toxicity	on	the	patient.			Some	 cancers	 have	 activating	 mutations	 in	 NRF2,	 which	 may	 alter	 its	 KEAP1	binding	 affinity,	 whilst	 inactivating	 mutations	 in	 KEAP1	 have	 been	 associated	with	 increased	NRF2	expression,	as	has	KEAP1	epigenetic	suppression	through	promoter	 hypermethylation,	 and	KEAP1	mutation	 in	NRF2	 binding	 sites	 [146-148].	Without	KEAP1-mediated	regulation,	NRF2	levels	can	greatly	increase	due	to	 its	 positive	 autoregulatory	 action	 [127].	 Furthermore,	 disruption	 of	 the	KEAP1-RBX1-CUL3	complex	has	been	associated	with	highly	malignant	invasive	UCCs	[149].			Aside	 from	 its	 role	 in	 the	 regulation	 of	 drug	 efflux	 and	 metabolism,	 there	 is	evidence	for	an	oncogenic	role	of	NRF2	in	a	number	of	cancers,	associated	with	a	more	 aggressive,	 proliferative	 phenotype	 [133,	 150-153].	 	 Interestingly,	hyperactivation	of	NRF2	has	 also	been	 implicated	 in	 the	onset	 of	 the	Warburg	effect,	 a	 phenomenon	 where	 the	 majority	 of	 cancer	 cells	 produce	 energy	primarily	 through	glycolysis,	rather	than	mitochondrial	pyruvate	oxidisation	as	in	 normal	 cells	 under	 aerobic	 conditions	 [154].	 The	 Warburg	 effect	 is	hypothesised	 to	 be	 associated	 with	 a	 tumour	 promoting	 microenvironment,	defined	 by	 lactate	 acidosis,	 where	 H+	 ions	 secreted	 by	 cancer	 cells	 cause	breakdown	 surrounding	 parenchyma,	 enhancing	 invasiveness	 [155,	 156].	Furthermore,	 increased	 glucose	 demand	 by	 tumour	 cells	 can	 lead	 to	 glucose	starvation	 in	 the	 surrounding	 environment,	 giving	 tumour	 cells	 a	 selective	advantage	 [157].	 Interestingly,	 NRF2-null	 mice	 produce	 tumours	 that	 are	significantly	less	malignant	than	tumours	in	wild-type	mice,	further	indicating	a	multifaceted	role	of	NRF2	in	cancer	[158].	Indeed,	when	comparing	NRF2	wild-
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type	with	NRF2-null	mice	in	a	urethane	induced	multistep	model	of	lung	cancer	
Satoh	et	al,	demonstrated	an	initial	chemoprotective	role	of	NRF2,	where	tumour	onset	time	was	longer	in	wild-type	mice	[158].								
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1.3.1.1	NRF2	in	bladder	cancer			Several	proteins	regulated	by	the	NRF2	pathway	are	directly	linked	to	cisplatin	resistance	 or	 clinical	 parameters,	 including	 the	 negative	 correlation	 of	 pre-treatment	 GSH	 levels	 with	 response	 to	 cisplatin-based	 chemotherapy	 [159].	Furthermore,	 several	 proteins	 involved	 in	 GSH	 synthesis	 (including	 GSH	reductase	 and	 γ-glytamylcysteine	 synthetase),	 and	 other	 mediators	 of	 the	antioxidant	 response	 	 (such	 as	GSH	peroxidase	 and	 superoxide	dismutase)	 are	overexpressed	 in	 BC	 samples	 compared	 to	 normal	 urothelium,	 aberrant	expression	 of	 these	 factors	 correlates	 with	 tumour	 stage	 and	 grade	 [160].	Compellingly,	a	cisplatin	resistant	variant	of	the	T24	UCC	cell	line	with	increased	levels	 of	 GSH	 or	 GST	 presented	 a	 less	 sensitive	 phenotype,	 whilst	 chemical	depletion	 of	 GSH	 and	 GST	 block	 led	 to	 increased	 cisplatin	 cytotoxicity	 [161].	Moreover,	 expression	 of	 metallothionein,	 proteins	 central	 to	 heavy	 metal	metabolism,	 correlates	 with	 cisplatin	 resistance	 in	 BC	 cell	 lines,	 and	 a	 poor	prognosis	 clinically	 [162,	 163].	Additionally,	 expression	of	 the	 inducible	heme-degradation	 enzyme,	 heme	 oxygenase-1	 (HO-1),	 involved	 in	 the	 response	 to	heavy	metals	and	oxidative	stress,	correlates	with	chemotherapy	resistance	and	increased	 tumour	 grade	 [164].	 The	 involvement	 of	 HO-1	 in	 BC	 is	 further	exemplified	 by	 increased	 chemosensitivity	 in	 cell	 line	 models	 of	 BC,	 resulting	from	HO-1	 inhibition	[164,	165].	 Interestingly,	overexpression	of	 the	multidrug	resistance-associated	 proteins	 (e.g.	 MRP1/2,	 which	 have	 been	 directly	implicated	 in	 cisplatin	 efflux),	 and	 MDR1	 are	 predictive	 of	 chemotherapy	resistance	and	a	poor	prognosis	[166,	167].	Conversely,	an	oncoprotective	role	of	NRF2	has	been	demonstrated	a	murine	N-butyl-N-(4-hydroxybutyl)	nitrosamine	(BBN)-induced	model	of	BC,	highlighting	the	context-dependent	effects	of	NRF2-ARE	signalling	[168].			Further	 rationale	 for	 pharmacological	 targeting	 of	 NRF2	 in	 BC	 has	 been	demonstrated	 using	 in	 vitro	 expression	 silencing	 techniques.	 An	 interesting	investigation	by	Hayden	et	al,	using	RT112	and	RT112-CP	UCC	cells	in	an	in	vitro	model	 of	 cisplatin	 resistance,	 demonstrated	 a	 marked	 increase	 in	 NRF2	expression,	 with	 a	 concurrent	 decrease	 in	 KEAP1	 expression	 in	 the	 cisplatin	
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resistant	 RT112-CP	 cell	 line	 [134].	 Furthermore,	 siRNA	 knockdown	 of	 NRF2	markedly	 increased	 the	 cisplatin-sensitivity	 of	 RT112-CP	 cells,	 although	sensitivity	 to	 cisplatin	 was	 not	 fully	 restored	 to	 that	 of	 the	 parent	 cell	 line,	RT112,	indicating	a	multifaceted	mechanism	of	cisplatin	resistance	in	these	cells	[134].	Interestingly,	Hayden	et	al	reported	unfavourable	overall,	BC-specific,	and	recurrence	 free	 survival	 in	 neoadjuvant	 cisplatin	 treated	 patients	 treated	with	cystectomy,	 but	 not	 in	 patients	 treated	 with	 cystectomy	 alone	 [134].	 With	evidence	of	NRF2	 implication	 in	cisplatin	resistance	 in	a	 range	of	cancers,	now	including	 a	 mechanistic	 rationale	 in	 UCC,	 the	 usage	 of	 a	 selective	 inhibitor	 of	NRF2	 may	 be	 clinically	 useful	 management	 of	 cisplatin	 resistance	 in	 patients	with	advanced	BC.																									
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1.3.1.2	Targeting	NRF2		There	 are	 many	 specific	 inducers	 of	 NRF2	 activity,	 including	 CDDO-Me	 and	numerous	 phytochemicals,	 implicated	 in	 the	 management	 of	 a	 number	 of	diseases	 including	 neurodegenerative	 disorders	 and	 cancer	 prevention	 [169].	Unfortunately,	 there	 has	 been	 little	 success	 in	 the	 development	 of	 specific	inhibitors	of	the	NRF2	pathway.	Amongst	the	limited	number	of	identified	NRF2	inhibitors	include:	trigonelline,	a	coffee	alkaloid	which	has	been	shown	to	inhibit	NRF2	 in	 chemotherapy	 resistant	 pancreatic	 cancer	 cells	with	 high	 basal	 NRF2	activity,	 increased	 sensitivity	 to	 chemotherapy	 drugs	 was	 noticed	 in	 Panc1,	Colo357	 and	 MiaPaca2	 cells,	 resulting	 in	 TRAIL-induced	 apoptosis	 [170];	ascorbic	 acid	 is	 a	 key	 antioxidant,	 and	 has	 been	 shown	 to	 suppress	 NRF2	expression,	 leading	 to	 decreased	NRF2-DNA	 binding	 and	 partial	 restoration	 of	imatinib	sensitivity	in	a	myelogenous	leukaemia	cell	 line	[171];	brusatol,	which	is	discussed	in	more	detail	below	has	been	shown	to	reduce	NRF2	protein	level	without	 affecting	 KEAP1	 status,	 sensitises	 to	 chemotherapy	 drugs	 including	carboplatin,	5-fluorouracil,	etoposide	and	paclitaxel	 in	HeLa,	MDA-MB-231,	and	A549	 cells.	 Furthermore,	murine	 xenograft	models	 have	 highlighted	 a	marked	anticancer	effect,	indicating	brusatol	may	be	clinically	useful	in	the	management	of	chemotherapy	resistant	cancers	[172].															
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1.3.1.3	Brusatol		
	Brusatol	 is	 a	 quassinoid	 extracted	 from	 the	 South	 East	 Asian	 plant,	 Brucea	
Javanica.	Brusatol	displays	promise	as	a	specific	inhibitor	of	NRF2	protein	levels,	with	associated	inhibitory	affects	downstream,	increasing	sensitivity	to	chemical	stresses	 [173,	174].	Furthermore,	robust	effects	have	been	displayed	 in	cancer,	where	in	a	murine	xenograft	model	of	lung	adenocarcinoma	brusatol	treatment	initiated	 potent	 and	 transient	 inhibition	 of	 the	 NRF2	 pathway,	 causing	 a	reduction	in	tumour	size	when	combined	with	cisplatin	compared	to	the	single	use	of	either	agent,	providing	rationale	for	the	usage	of	brusatol	in	combination	with	cisplatin	in	BC	[172].		
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1.4	Cluster	of	differentiation	40		
	Cluster	of	differentiation	40	(CD40)	is	a	48	kDa	glycoprotein	member	of	the	TNF-receptor	 super-family.	 Originally	 identified	 in	 BC,	 since	 its	 role	 in	 immune	biology	 has	 been	 well	 characterised,	 where	 CD40	 plays	 a	 central	 role	 in	 the	regulation	of	the	immune	response	[175-179].	Mediation	of	humoral	and	cellular	immune	responses	is	 facilitated	by	binding	of	CD40	with	CD40-Ligand	(CD40L)	which	 acts	 between	 T-cells	 and	 antigen	 presenting	 cells	 in	 a	 bi-directional	manner	[176,	177].					The	expression	of	CD40	is	not	only	confined	to	the	immune	system,		but	also	to	a	plethora	 of	 cells	 including,	 endothelial	 cells,	 fibroblasts,	 and	 epithelial	 cancer	cells	 –	 where	 it	 regulates	 processes	 such	 as	 cell	 proliferation,	 growth	suppression	and	cell	death	[178,	180,	181].		CD40	 cytoplasmic	 domain	 lacks	 any	 intrinsic	 kinase	 activity,	 therefore,	 signal	transduction	is	reliant	on	recruitment	of		a	number	of	adaptor	proteins	known	as	TNFR-associated	factors	(TRAFs)	(Fig	1.7)	[180].	Two	domains	critical	for	TRAF	association	 and	 signal	 transduction,	 reside	 in	 the	 cytoplasmic	 tail	 of	 CD40:	 a	region	 proximal	 to	 the	membrane,	 where	 amino	 acids	 Gln234	and	Glu235	reside,	responsible	for	TRAF6	binding,	a	Pro250	XGlu252	and	XThr254	motif	which	directly	binds	 TRAF2	 and	 TRAF3	 and	 indirectly	 binds	 TRAF5	 [180].	 Depending	 on	 the	nature	 of	 CD40-ligation,	 recruitment	 of	 the	 TRAFs	 triggers	 the	 activation	 of	 a	number	of	signalling	pathways,	including	JNK,	ERK,	p38,	MAPK,	the	transcription	factors	 nuclear	 factor	 kappa-light-chain-enhancer	 of	 activated	 B	 cells	 (NF-κB)	and	 signal	 transducer	 and	 activator	 of	 transcription	 (STAT),	 and	 the	 PI3K	signalling	module,	which	acts	 collaboratively	 to	modulate	 the	many	pleiotropic	effects	of	CD40	dependent	on	cell	type	and	context	[180].			
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Figure	1.7.	Mechanism	of	CD40L	induced	cell	death.	CD40-ligation	results	 in	pro-	 and	 anti-apoptotic	 signals,	 the	 balance	 between	 which	 decides	 cell	 fate.	When	 CD40L	 is	 not	 present,	 the	 conformation	 of	 CD40	 facilitates	 binding	 of	TRAF6,	 promoting	 cell	 survival	 via	 Akt	 signalling.	 This	 conformation	 does	 not	allow	 for	 TRAF3	 binding,	 leading	 to	 its	 degradation.	 CD40	 ligation	 causes	receptor	 trimerisation,	 which	 leads	 to	 TRAF6	 dissociation	 and	 degradation	leading	 to	 the	 loss	 of	 Akt-dependent	 pro-survival	 signals,	 and	 TRAF3	 binding,	leading	 to	 TRAF3	 mediated	 phosphorylation	 of	 JNK,	 which	 leads	 to	 caspase	induction	and	apoptotic	cell	death	[180].				
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1.4.1	CD40	expression	in	bladder	cancer				CD40	 is	highly	expressed	 in	a	number	of	epithelial	 cancers,	 including	BC,	with	undetectable	expression	of	CD40	in	normal	epithelial	tissue	at	the	site	of	tumour	origin	[182,	183].				In	BC	expression	of	CD40	is	associated	with	lower	stage	and	lower	grade	UCCs,	with	89%	of	Ta	and	T1	tumours	expressing	CD40,	and	62%	of	tumours	at	T2	or	higher	 expressing	 CD40,	 compared	 to	 predominately	 negative	 normal	urothelium	[178].	Although,	expression	of	CD40	is	not	an	independent	marker	of	prognosis,	 nor	 does	 it	 link	 with	 other	 clinicopathological	 factors	 such	 as	 the	expression	 of	 P53	 or	 BCL2	 [178].	 Interestingly,	 the	 high	 incidence	 of	 CD40	expression	in	non-muscle	 invasive	BCs	 is	 likely	a	significant	contributing	factor	in	the	excellent	response	to	BCG	therapy	[178].			With	 CD40	 being	 expressed	 in	 the	 majority	 of	 BCs,	 but	 not	 surrounding	urothelium	 it	 is	 attractive	 target	 for	 potential	 therapies.	 The	 consequences	 of	ligation	with	the	membrane	bound	derivative	of	its	ligand,	CD40L	add	further	to	its	therapeutic	potential.	The	consequences	of	CD40-ligation	in	BC	are	discussed	next.			
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1.4.2	CD40-ligand	
	CD40L	is	a	member	of	the	TNF	superfamily	of	molecules	and	is	most	commonly	expressed	on	activated	T	cells	[184,	185].	The	32	kDa	plasma	membrane-bound	protein	 (mCD40L)	 is	 subject	 to	 cleavage	 by	 MMPs,	 forming	 soluble	 CD40L	(sCD40L).			In	cancer	cells,	research	into	the	effect	of	CD40L	binding	in	epithelial	cells	shows	outcome	 of	 CD40	 ligation	 is	 multifaceted,	 with	 the	 type	 of	 ligand	 and	 cellular	context	 influencing	 the	 physiological	 consequence	 [180].	 Sustained	 CD40	engagement	 induces	 growth	 arrest	 and	 apoptosis,	 whereas	 transient	 CD40	ligation	 promotes	 proliferation	 and	 cell	 survival	 signalling	 [180].	 The	 most	profound	 effects	 are	 elicited	 by	mCD40L,	with	 sCD40L	 only	 inducing	 transient	survival	 signalling.	 This	 disparity	 in	 effect	 is	 believed	 to	 be	 due	 to	 differential	recruitment	of	TRAFs	–	however	there	is	much	to	be	learned	about	the	results	of	CD40	ligation	by	both	forms	of	CD40L	[180].			In	 epithelial	 cells	 there	 is	 no	 detectable	 expression	 of	 CD40,	 however	 in	 a	number	 of	 epithelial	 cancers,	 including	 bladder,	 CD40	 expression	 is	 present	[178].	In	order	to	determine	more	about	the	consequences	of	CD40-ligation	with	mCD40L	 and	 sCD40L,	 a	 cleavage	 resistant	 CD40L	 construct,	 delivered	 via	conditionally	 replicating	 adenoviral	 vector	 (AdNclCD40L),	 and	 recombinant	soluble	CD40L	(rsCD40L)	have	been	utilised.			
In	vitro	work	 into	 the	 comparative	 effects	 of	 rsCD40L	 and	AdNclCD40L	on	 the	CD40-positive	EJ	urothelial	cell	carcinoma	cell	line	exhibited	contrasting	effects,	with	 AdNclCD40L	 displaying	 the	 most	 potent	 response	 through	 sustained	signalling	inducing	cell	death,	whereas	sCD40L	induced	signalling	was	transient	[180,	 186].	 Additionally,	 stimulation	 of	 CD40	 with	 rsCD40L	 in	 carcinoma	 cell	lines	induces	PI3K	and	ERK/MAPK	mediated	survival	signals,	with	the	induction	of	apoptosis	only	occurring	in	the	presence	of	cytotoxic	drugs,	PI3K/	mammalian	target	of	rapamycin	(mTOR)	and/or	ERK	pathway	inhibitors,	or	in	the	presence	of	 the	 protein	 synthesis	 inhibitor	 cycloheximide	 (CHX)	 [180].	 This	 is	 a	 stark	
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contrast	to	the	effects	of	AdNclCD40L,	when	delivered	through	co-culture	of	the	CD40-positive	UCC	 cell	 line	 EJ	with	 AdNclCD40L	 expressing	 fibroblasts,	where	marked	 apoptosis	 is	 observed	 without	 the	 addition	 of	 other	 agents	 [180].	Similarly,	high	levels	of	cell	death	are	reported	when	EJ	cells	are	directly	infected	with	AdNclCD40L	[180].																																									
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1.4.3	TRAFs	facilitate	CD40	signal	transduction	
		CD40	 lacks	 intrinsic	 kinase	 ability	 on	 its	 cytoplasmic	 tail	 therefore	 a	 group	 of	TRAFs	are	essential	 for	 the	propagation	of	 ligation-dependent	 signalling	 [187].	Interestingly,	the	nature	of	ligation	affects	the	level	of	TRAFs	recruitment	leading	to	divergent	outcomes	discussed	below.			CD40	ligation	with	AdNclCD40L	leads	to	an	increase	in	the	expression	of	TRAF1	and	 TRAF3	 with	 a	 concurrent	 decrease	 in	 the	 expression	 of	 TRAF6,	 the	 two	former	projecting	pro-apoptotic	signals,	whilst	the	latter	is	responsible	for	pro-survival	 signalling	 [180].	 This	 contrasts	 with	 rsCD40L,	 which	 induces	 only	 a	modest	 increase	 in	 the	expression	of	TRAF1	 [180].	 Intriguingly,	 changes	 in	 the	expression	 of	 TRAF3	 and	 TRAF6	 as	 a	 result	 of	 CD40-ligation	 are	 due	 to	 post-translational	modifications,	 as	mRNA	 levels	 are	 not	 affected	 [180].	 Conversely,	TRAF1	mRNA	 increases	 as	 a	 result	 of	 CD40	 ligation,	 indicating	 transcriptional	regulation	 [180].	 Interestingly,	 ligation	with	AdNclCD40L	 but	 not	 rsCD40L	 has	been	 shown	 in	 a	 number	 of	 cases	 to	 increase	 the	 expression	 of	 TRAF3	 in	UCC	cells,	but	not	in	normal	urothelial	cells,	further	indicating	the	potential	of	CD40-ligation	as	a	specific	therapy	for	the	management	of	BC	[180,	188,	189].			Evidence	 suggests	 that	 TRAF3	 induces	 apoptosis	 through	 sustained	phosphorylation	of	JNK	post	ligation	with	AdNclCD40L	[180].	Two	key	pieces	of	evidence	implicate	JNK	pathway	in	CD40-ligaiton	induced	cell	death	in	UCC	cells.	These	 are	 a	 decrease	 in	 cell	 death	 when	 a	 JNK	 inhibitor	 is	 introduced;	 whilst	cytochrome	 c	 is	 released	 from	 the	 mitochondria	 –	 JNK	 dependent	 process	mediated	by	the	phosphorylation	of	c-JUN,	B-cell	lymphoma	2	(BCL2)	and	B-cell	lymphoma-extra-large	 (BCLxL)	[180].	 Interestingly,	 the	 transient	 nature	 of	 the	signal	resulting	from	CD40	ligation	with	rsCD40L	is	believed	to	explain	the	lack	of	 JNK	 mediated	 apoptosis,	 as	 sustained	 activation	 of	 JNK	 is	 required	 for	 cell	death	induction	[180,	190].				TRAF6	is	key	in	the	propagation	of	survival	signals	through	the	PI3K/Akt-	
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pathway.	Interestingly,	TRAF6	has	been	shown	to	be	downregulated	upon	CD40	ligation	with	mCD40L,	and	subsequent	TRAF3	stabilisation	[180].	Notably,	whilst	siRNA	 knockdown	 of	 TRAF3	 maintained	 TRAF6	 expression,	 artificial	overexpression	 of	 TRAF6	 could	 not	 divert	 the	 cells	 from	 an	 apoptotic	 fate,	indicating	that	TRAF3	binding	may	inhibit	TRAF6	localisation	to	the	cytoplasmic	tail	of	CD40	[180].																														
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1.4.4	Clinical	application	of	CD40	targeted	therapies	in	bladder	cancer		
	CD40	is	an	attractive	target	in	BC	due	to	its	direct	cell	death	inducing	effects	on	BC	cells	and	 its	activating	effects	on	 the	 immune	system	may	also	 increase	 the	response	 to	 therapy.	 Recent	 investigations	 in	 BC	 have	 unveiled	 local	immunotherapy	as	a	potential	method	of	treatment	for	 localised	and	MBC	with	more	limited	toxic	effects	when	compared	to	traditional	chemotherapy.			The	usage	of	intravesical	instillation	of	CD40L-expressing	adenoviruses	has	been	demonstrated	 to	mediate	 antitumor	 effects	 in	 NMIBC,	with	 a	 low	 incidence	 of	adverse	 events	 [191].	 Furthermore,	 agonistic	 CD40	 antibodies	 have	 shown	promise	in	the	treatment	of	solid	tumours	[191,	192].	However,	this	thesis	aims	to	understand	more	about	the	role	of	CD40-ligation	in	BC	invasion.																					
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1.5	Matrix	metalloproteinase-1			Controlled	 remodelling	 of	 the	 ECM	 is	 key	 for	 tumour	 progression	 and	dissemination	 [193].	 The	 matrix	 metalloproteinases	 (MMPs)	 are	 a	 family	 of	calcium-dependent	 zinc-containing	 endopeptidases	 that	 are	 capable	 of	degrading	 many	 different	 kinds	 of	 extracellular	 matrix	 (ECM)	 proteins	 [194].	Further	 to	 their	role	 in	ECM	remodelling,	MMPs	are	 involved	 in	 the	proteolytic	activation	of	proproteins.			The	interstitial	collagenase,	MMP1,	has	substrates	that	include	collagens	(I,	II,	III,	VII,	and	X),	proteoglycans,	entactin,	ovostatin,	MMP2	and	MMP9	[195].	In	normal	physiology	MMP1	 is	 involved	 in	a	number	of	processes	 including	development,	angiogenesis,	reproduction	and	tissue	morphogenesis	 [194,	196].	As	a	result	of	their	 proteolytic	 activity,	 MMPs	 can	 release	 growth	 factors	 from	 the	 ECM,	facilitating	receptor	binding	[196].	Pathologically	MMP1	is	known	to	be	involved	in	rheumatoid	arthritis	and	cancer	metastasis	[197].			MMPs	 have	 been	 implicated	 in	 the	 progression	 of	 several	 cancers.	 In	 a	 breast	cancer	 cell	 line	 murine	 xenograft	 model	 elevated	 MMP1	 expression	 has	 been	implicated	in	local	growth	and	brain	tumour	metastases	in	[198].	Furthermore,	MMP1	 has	 also	 been	 suggested	 as	 a	 predictive	 marker	 of	 breast	 cancer	 and	metastatic	 colorectal	 cancer	 [199,	 200].	 In	BC,	 increased	urinary	 expression	 of	MMP1	 is	 associated	 with	 advanced	 disease	 [201].	 Finally,	 MMP1	 single	nucleotide	 polymorphisms	 (SNPs)	 have	 been	 associated	 with	 an	 increased	susceptibility	to	BC	[202-204].			Despite	 a	 lack	 of	 success	 in	 early-stage	 clinical	 trials	 for	 broad-range	 MMP	inhibitors,	 MMPs	 remain	 a	 potential	 target	 for	 cancer	 therapeutics	 [196,	 205-211].	Early	drugs	were	designed	at	a	time	where	only	three	out	of	24	MMPs	had	been	 identified,	 prior	 to	 knowledge	 of	 the	 roles	 of	 MMPs	 in	 cancer.	 With	hindsight,	the	poor	trial	performance	of	MMP	inhibitors	can	be	reasoned	to	lack	of	 knowledge	 of	 the	 roles	 of	MMPs	 in	 cancer.	 Furthermore,	 the	 importance	 of	context	must	be	addressed	as	MMPs	clearly	have	multifaceted	roles	in	the	human	
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body,	especially	with	evidence	of	MMP	inhibition	linked	with	a	worse	prognosis.	Two	 tansomastat	 trials	 in	 small-cell	 lung	 cancer	 and	 pancreatic	 cancer	 were	halted	early	after	patients	taking	the	inhibitor	had	a	significantly	poorer	survival	than	 those	 receiving	 placebo	 [212,	 213].	 New	 efforts	 in	 targeting	 MMPs	must	focus	using	molecular	data	to	develop	targeted	agents,	with	high	accumulation	in	cancerous	 tissues	 and	 low	 systemic	 adverse	 effects.	 Moreover,	 compared	 to	previous	 approaches	 where	 MMP	 inhibitors	 were	 unsuccessfully	 trailed	 in	advanced	stage	cancers,	where	marked	invasion	and	dissemination	had	already	occurred,	 a	 novel	 approach	 where	 MMP	 inhibitors	 are	 administered	 prior	 to	disease	advancement	to	mitigate	the	effects	of	MMPs	in	invasion	and	metastasis.		
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1.6	Fibronectin			Fibronectin	(FN1)	 is	a	ubiquitous	ECM	glycoprotein,	which	exists	as	a	dimer	of	two	 ~250kDa	 subunits,	 that	 binds	 to	 receptors	 in	 the	 integrin	 family	 [214].	Integrins	are	heterodimeric	cell-surface	receptors	that	connect	the	ECM	with	the	intracellular	 cytoskeleton;	 they	 sense	 the	 cell	microenvironment	 and	modulate	numerous	 signalling	 pathways	 [214].	 Similarly	 to	 integrins,	 FN1	 binds	 ECM	constituents	 including	 collagen,	 fibrin,	 and	 syndecans.	 FN1	 mediates	 a	 large	array	 of	 cellular	 interactions	 within	 the	 ECM	 including	 roles	 in	 cell	 cycle	regulation,	 cell	 adhesion,	 differentiation,	 growth,	 and	 migration	 [214-219].	Under	 normal	 physiological	 conditions	 FN1	 is	 expressed	 predominantly	 by	fibroblasts	 and	 hepatocytes,	 and	 is	 essential	 for	 cell-cell	 crosstalk,	 interaction	with	the	cellular	microenvironment,	and	development	and	wound	healing	[214].			The	FN1	gene	is	subject	to	alternative	splicing	creating	different	truncated	copies	of	 full	 length	 FN1	 [214].	 Resultantly,	 FN1	 exists	 in	 both	 insoluble	 and	 soluble	(plasma)	 forms	 [214].	 Under	 normal	 conditions	 insoluble	 FN1	 is	 primarily	produced	by	fibroblasts	where	it	is	produced	as	a	major	component	of	the	ECM,	whilst	plasma	FN1	is	produced	by	hepatocytes	and	is	involved	in	blood	clotting	[215].	Plasma	FN1	has	been	suggested	as	a	prognostic	marker	in	several	cancers	[220-222].	 Notably,	 Yiätupa	 et	 al	 demonstrated	 that	 86%	 of	 patients	 with	digestive	 tract	 malignancies	 had	 elevated	 blood	 FN1	 levels	 compared	 to	 the	healthy	group,	potentially	indicating	merit	as	a	blood	biomarker	[220].			In	 the	 tumour	microenvironment,	 endocrine	 growth	 factors	 from	 the	 primary	tumour	facilitate	the	upregulation	of	FN1	secretion	by	fibroblasts	preparing	sites	for	 distant	metastasis	 known	 as	 premetastatic	 niches	 [223-225].	 Furthermore,	the	 co-injection	 of	 FN1	with	 tumour-cells	 increased	 tumour	 cell	 adhesion	 and	metastasis,	 whilst	 mesothelial	 cell	 secreted	 FN1	 has	 been	 implicated	 in	 the	promotion	of	early	metastasis	 in	an	organotypic	model	of	ovarian	cancer	 [226]	[227].			
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Interestingly,	 integrin	 α5β1,	 a	 FN1	 receptor	 involved	 in	 development	 and	neoangiogenesis,	 has	 been	 suggested	 as	 a	 therapeutic	 target	 in	 a	 number	 of	advanced	cancers	including	those	of	the	colon,	breast,	ovary	and	brain	[228].		
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1.7	Family	with	sequence	similarity	83,	member	D			The	family	with	sequence	similarity	83,	member	D	(FAM83D),	gene	is	located	on	chromosome	20q,	where	amplifications	are	present	in	cancers	including	bladder,	breast,	colorectal,	ovarian,	pancreatic	and	prostate	[229-234].	First	identified	as	a	mitotic	 spindle	 associated	 protein,	 FAM83D	 interacts	with	 the	 chromkinesin	KID22	 to	 allow	 for	 proper	 chromosome	 congression	 in	metaphase	 [235,	 236].	During	mitosis,	 the	mitotic	spindle	 is	essential	 for	precise	distribution	of	 sister	chromatids;	functional	alterations	to	components	of	the	mitotic	spindle	may	be	a	source	 of	 the	 chromosomal	 aberrations,	 and	 aneuploidy	 observed	 in	 advanced	cancer.	 Interestingly,	 microarray	 studies	 have	 identified	 overexpression	 in	hepatocellular	 carcinoma,	ovarian	cancer	and	 lung	adenocarcinoma	metastases	however	 there	 are	 few	mechanistic	 studies	 into	 the	 role	 of	 FAM83D	 in	 cancer	[231,	237,	238].		An	 in	vitro	 study	 in	 breast	 cancer	 by	Wang	 et	 al	 suggests	 FAM83D	 as	 a	 novel	oncogene	that	inhibits	the	expression	of	the	tumour	suppressor	protein	(TSP)	F-box/WD	 repeat-containing	 protein	 7	 (FBXW7),	 leading	 to	 hyperactive	 mTOR-signalling	and	a	resultant	 increase	 in	cell	proliferation	and	motility	 [239].	With	the	 addition	 of	 the	mTOR	 inhibitor,	 rapamycin,	mTOR	dependent	 oncogenicity	was	 markedly	 depleted,	 indicating	 a	 possible	 therapeutic	 option	 in	 FAM83D	overexpressing	malignancies	[239].	Furthermore,	the	TSP	FBXW7	is	reported	to	be	 downregulated	 in	 a	 large	 number	 of	 malignancies,	 including	 BC	 [240].	 In	concert	with	Skp-Cullin-F-box	(SCF)	E3	ubiquitin	 ligase,	FBXW7	 is	essential	 for	the	ubiquitin-mediated	degradation	of	an	array	of	oncoproteins	including,	c-JUN,	c-MYC,	Cyclin	E,	NOTCH,	and	mTOR	[241-246].									
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1.8	Anillin			Anillin	(ANLN)	is	a	ubiquitously	expressed	124	kDa	protein	centrally	involved	in	formation	of	the	contractile	ring	and	cleavage	furrow,	acting	as	a	scaffold	linking	ras	 homolog	 gene	 family,	 member	 A	 (RHOA),	 actin	 and	 myosin	 during	cytokinesis	 [247].	 In	 healthy	 neurones,	 ANLN	 is	 associated	 with	 neuronal	migration	 and	 neurite	 growth	 through	 linkage	 of	 ras	 homolog	 gene	 family,	member	 A	 (RHOG)	 and	 the	 actin	 cytoskeleton	 [248].	 Furthermore,	 ANLN	 is	implicated	 in	 the	 regulation	of	 tight	 junctions	 (TJ)	 and	adherens	 junctions	 (AJ)	[249].	The	referenced	study	reports	AJ	and	TJ	disassembly,	without	change	to	the	expression	 of	 junction	 proteins,	 as	 a	 result	 of	 downregulation	 of	 ANLN	expression,	 indicating	a	key	regulatory	role	[249].	Overexpression	of	ANLN	has	been	linked	with	poor	survival	in	a	number	of	cancers	including	colorectal	[250,	251].		Further	 examples	 of	 the	 involvement	 of	 ANLN	 in	 tumour	 invasion	 and	progression	 are	 presented	 by	 Liang	 et	 al	 who	 reported	 a	 significant	 positive	correlation	between	nuclear	ANLN	levels	and	tumour	stage,	grade,	and	invasion	patterns	 in	 upper	 urinary	 tract	 UCCs	 [252].	 Furthermore,	 they	 reported	 a	significant	 association	 between	 nuclear	 ANLN	 levels	 and	 poor	 disease-specific	survival	and	metastasis	free	survival.	Whereas	overexpression	of	cytosolic	ANLN	was	negatively	correlated	with	tumour	grade	and	vascular	 invasion,	whilst	 low	total	ANLN	 levels	were	 strongly	 associated	with	poor	disease-specific	 survival,	and	metastasis	free	survival	[252].	Furthermore,	ANLN	has	been	identified	as	a	marker	 of	 poor	 survival	 in	 hepatocellular	 carcinoma	 [253].	 Additionally,	 high	ANLN	is	one	of	three	markers	in	a	signature	of	poor	prognosis	in	breast	cancer	[254].	 Moreover,	 ANLN	 levels	 were	 19.8-fold	 higher	 in	 pancreatic	 cancer	patients,	 than	 in	 normal	 pancreas	 [255].	 Conversely	 ANLN	 expression	 is	 a	marker	of	a	favourable	prognosis	in	patients	with	renal	cell	carcinoma	[256].			Interestingly,	 in	 vitro	 studies	 have	 reported	 lentiviral	 knockdown	 of	 ANLN	leading	to	the	inhibition	of	cell	growth	and	migration	in	a	model	of	breast	cancer,	suggesting	usefulness	as	a	therapeutic	target	[257].	Furthermore,	the	referenced	study	 reported	 increased	 accumulation	 at	 G2/M	 phase	 as	 a	 result	 of	 CDK1	
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phosphorylation	and	Cyclin	D1	suppression,	suggesting	inhibition	of	cytokinesis	as	a	mechanism	of	action	[257].																																							
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1.9	Biomarkers	in	bladder	cancer	
	MBC	 and	 MIBC	 are	 the	 deadliest	 variants	 of	 BC,	 associated	 with	 meagre	outcomes.	 Patients	 who	 can	 be	 treated	 at	 an	 earlier	 stage	 are	 more	 likely	 to	survive	for	a	longer	period.	However,	beyond	TNM	staging	and	grading	there	are	little	tools	to	predict	the	chance	of	a	BC	developing	into	muscle	invasive	disease.	A	marker	or	signature	indicative	of	MIBC,	which	can	be	obtained	in	a	minimally	invasive	 manner	 could	 allow	 for	 more	 accurate	 and	 timely	 treatment	stratification.					 	
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1.9.1	Biomarkers			Biomarkers	are	molecules,	genes	or	characteristics	associated	with	an	increased	risk	of	a	certain	disease	event,	for	example	progression	to	MIBC.	Alterations	may	include	 germline	 or	 somatic	 mutations,	 transcriptional	 changes	 and	 post-translational	modifications	[258].			A	‘molecular	signature’	is	are	a	collection	of	alterations	indicative	of	a	particular	physiological	state,	altered	components	making	up	molecular	signatures	may	be,	genetic	 (gene	 expression	 and/or	 mutation),	 proteomic,	 and/or	 metabolomic	[258].	 Such	 panels	 of	 biomarkers	 can	 offer	 increased	 specificity	 than	 single	biomarkers.	 Biomarkers	 can	 be	 detected	 by	 non-invasive	 means,	 in	 the	 blood	(whole	blood,	serum	or	plasma),	or	 in	secretions	or	excretions	(sputum,	nipple	discharge,	 faeces	 or	 urine),	 these	 can	 be	 assessed	 regularly	 in	 comparison	 to	tissue-derived	 biomarkers,	which	 require	 a	 biopsy	 such	 as	 those	 taken	 during	TURBTs	 [258].	 Biomarkers	 are	 used	 by	 three	 principal	 means:	 as	 diagnostic	markers,	e.g.	identification	of	early	stage	cancers,	prognostic	i.e.	to	forecast	how	aggressive	a	cancer	is	and	predictive,	for	example	to	predict	how	well	a	patient	will	respond	to	treatment.	A	small	number	of	biomarkers	are	currently	used	in	different	 cancers,	 giving	 the	 medical	 oncologist	 more	 insight	 into	 the	 tumour	biology,	 aiding	 in	 the	 determination	 of	 treatment	 regimens.	 These	 include	prostate-specific	antigen	(PSA)	a	prostate	cancer	related	marker,	and	the	breast	cancer	 susceptibility	 genes	 breast	 cancer	 related	 genes	 -1	 and	 -2	 (BRCA1)	and	(BRCA2)	[259].			In	BC,	 there	 is	a	dire	need	 for	a	non-invasive	marker	of	MIBC,	as	patients	with	aggressive	 BC	 who	 are	 treated	 more	 radically	 from	 the	 outset,	 have	 the	 best	chance	of	 long-term	survival	 in	comparison	to	 those	patients	whose	aggressive	disease	has	progressed.	An	early	marker	of	muscle	invasive	BC	could	inform	the	medical	 oncologist	 whether	 the	 patient	 can	 have	 their	 disease	 managed	 by	minimally	 invasive	 methods	 such	 as	 TURBT	 and	 BCG	 instillation,	 rather	 than	cystectomy	and	systemic	chemotherapy,	potentially	enhancing	patient	outcomes,	whilst	reducing	treatment	costs.			
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1.9.1.1	Osteopontin		
	Osteopontin	 (OPN)	 is	 a	 highly	negatively	 charged	phosphorylated	 glycoprotein	secreted	by	activated	T	 lymphocytes,	 activated	macrophages,	 leukocytes	and	 is	present	 at	 sites	 of	 inflammation	 in	 the	 interstitial	 fluid,	 and	 at	 the	 matrix	 of	mineralized	 tissues	 such	 as	 bone	 [259].	 There	 are	 a	 number	 of	 physiological	functions	where	OPN	has	been	shown	to	be	involved,	it	has	roles	in	inflammation	and	immune	function,	in	mineralized	tissues,	in	vascular	tissue	as	well	as	in	the	kidney	[259].	OPN	elicits	its	physiological	effects	through	binding	with	a	diverse	range	 of	 cell	 surface	 receptors	 including	 several	 integrins	 and	 CD44	 [259].	Receptor	binding	mediates	specific	signalling	 functions	 leading	to	cell	adhesion	and	 migration	 [259].	 More	 recently	 it	 has	 been	 discovered	 that	 OPN	 is	overexpressed	 in	 a	 number	 of	 cancers	 including	 BC,	 breast	 cancer,	 colorectal	cancer,	 lung	 cancer,	 ovarian	 cancer	 and	melanoma	where	 it	 promotes	 tumour	proliferation,	 differentiation,	 invasion	 and	metastasis,	 and	 is	 associated	with	 a	poor	 prognosis	 [259-261].	 Interestingly	 it	 has	 been	 observed	 that	 OPN	 is	 also	elevated	in	the	blood	of	patients	with	metastatic	cancers	[259].			In	 a	 model	 of	 invasive	 BC	 using	 the	 T24	 cell	 line	 RNAi	 inhibition	 of	 OPN	significantly	inhibited	proliferation	and	invasion,	whilst	study	examining	the	role	of	 OPN	 in	 BC,	 which	 enrolled	 225	 patients	 with	 UCC,	 and	 230	 age-	 and	 sex-	matched	 healthy	 volunteers	 as	 control	 subjects,	 demonstrated	 significantly	higher	plasma	OPN	levels	 in	patients	with	UCC	compared	to	healthy	volunteers	[260,	261].	It	was	also	found	that	high	levels	of	OPN	correlated	significantly	with	high-grade	UCCs	when	compared	to	low	grade	UCC	[261].	Patients	with	disease	confined	to	the	bladder	had	the	lowest	levels	of	OPN,	whereas	those	with	lymph	node	positive	UCC	showed	higher	expression,	with	the	highest	level	of	OPN	being	present	 in	 metastatic	 disease	 [261].	 Intriguingly,	 the	 overall	 survival	 rate	 in	MIBC	 patients	 expressing	 high	 levels	 OPN	 was	 significantly	 lower	 than	 those	with	 lower	 expression	 of	 OPN	 [261].	 Further	 studies	 in	 hepatocellular	carcinoma,	 head	 and	 neck	 squamous	 cell	 carcinoma,	 lung	 and	 prostate	 cancer	have	shown	that	OPN	level	is	highly	associated	with	prognosis	[261-267].		
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The	 mechanism	 whereby	 OPN	 increases	 tumour	 invasion	 and	 metastasis	 is	essentially	 unclassified.	 Although,	 in	vitro	 data	 suggests	 OPN	mediates	 tumour	invasiveness.	For	example,	breast	cancer	cell	lines	lacking	OPN	expression	form	tumours	 in	 nude	 mice	 much	 more	 slowly	 than	 wild	 type	 [268].	 Also,	 as	previously	mentioned,	inhibition	of	OPN	expression	in	T24	BC	cells	significantly	limits	 their	 invasive	 capacity	 [260].	 Conversely,	 some	 data	 suggests	 that	 OPN	may	indirectly	contribute	to	the	survival	of	cancer	cells	through	the	upregulation	of	hyaluronic	acid	synthase,	another	prominent	feature	in	metastatic	cancer	cells	[269].			
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1.10	Thesis	hypotheses			
	
Chapter	3:	Brusatol,	via	 inhibition	of	NRF2	will	 increase	 the	sensitivity	of	UCC	cell	lines	to	cisplatin.		
Chapter	 4:	 CD40-ligation	 will	 modulate	 UCC	 cell	 invasion	 in	 An	 organotypic	model	of	BC.			
Chapter	5:	Gene	expression	analysis	will	 identify	molecularly	distinct	subtypes	of	BC.		
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Unless	 stated	 otherwise,	 all	 reagents	 and	materials	were	 sourced	 from	 Sigma-Aldrich,	Poole,	UK		
2.1	Tissue	culture	techniques		
2.1.1	Maintenance	of	cell	lines		The	 human	 urothelial	 cell	 carcinoma	 cell	 lines,	 EJ,	 253-J,	 MGH-U3,	 RT112,	RT112-CP	 and	 the	 human	 colorectal,	 carcinoma	 cell	 line	 HCT116	 were	maintained	 in	 either	 Roswell	 Park	 Memorial	 Institute	 medium	 (RPMI),	Dulbecco’s	modified	Eagles	medium	(DMEM)	or	modified	Eagles	medium	MEM	supplemented	 with	 2mM	 glutamine,	 10%	 foetal	 calf	 serum	 and	 1%	 antibiotic	antimycotic	 solution	 (final	 concentrations	 100U/ml	 penicillin,	 0.1mg/ml	streptomycin	 and	 0.25μg/ml).	 RT112-CP	 cells	 were	 supplemented	 with	 an	additional	5μM	of	freshly	prepared	cisplatin	in	dimethylformamide	(DMF).	Cells	were	 grown	 in	 vented	 75cm2	 flasks	 (Corning,	 USA)	 at	 37°C	 in	 5%	 CO2,	 and	routinely	passaged	when	90%	confluent.	The	media	was	discarded,	cells	washed	once	 with	 phosphate	 buffered	 saline	 (PBS),	 and	 trypsin-ethylenediaminetetracetic	 acid	 (EDTA)	 (0.5%	 w/v	 trypsin,	 0.02%	 w/v	 EDTA)	added	 to	cover	 the	cells.	Cells	were	 transferred	 to	complete	culture	media	and	pelleted	 through	 centrifugation	 at	 1300rpm	 for	 5min.	 The	 supernatant	 was	discarded	 and	 the	 cell	 pellet	 was	 resuspended	 in	 fresh	 complete	 media	 and	plated	into	a	75cm2	flask.												
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Table	2.1.	Cell	lines	and	their	tissue	origins.	
Cell	Line	
Tumour	
Description	 Stage	 Grade	 Sex	 Established	 Ref	
EJ	 Bladder	Primary	 ≥T3	 G3	 M	 1972	 [270]	
253-J	
Retroperitoneal	lymph	node	metastasis	 T4	 G4	 M	 1972	 [271]	
MGH-U3	 Papillary	UCC	 ≤T1	 G1	 M	 1977	 [270]	
RT112	
Well	differentiated	UCC	 ≤T1	 G1	 F	 1973	 [272]	
RT112-
CP	
Cisplatin	resistant	RT112	 ≤T1	 G1	 F	 1990	 [273]												
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2.1.2	Cryopreservation	and	thawing	of	cell	stocks		Approximately	2x106	pelleted	 cells	were	 resuspended	 in	1ml	of	 freezing	down	media	(DMEM	supplemented	with	20%	FBS,	and	10%	DMSO)	and	transferred	to	a	 1ml	 cryovial	 (Nunc,	 Fisher	 Scientific	 UK	 Ltd,	 Loughborough,	 UK).	 The	 vials	were	 placed	 at	 -70°C	 overnight	 in	 a	 freezing	 container	 immersed	 in	 isopropyl	alcohol,	before	being	transferred	into	liquid	nitrogen	for	long-term	storage.	Cells	were	recovered	by	 thawing	 the	cryovials	quickly	at	37°C	and	 transferring	cells	into	10ml	warm	complete	media.	Cells	were	pelleted,	resuspended	 in	complete	media	and	transferred	to	a	75cm2	flask.			
2.1.3	Cell	counting	and	cell	seeding			Cells	were	counted	using	a	haemocytometer.	Briefly,	cells	were	dissociated	from	the	 culture	 flasks	 and	 resuspended	 as	 described	 above.	 10μl	 of	 the	 cell	suspension	was	pipetted	onto	a	haemocytometer.	Cells	 in	the	central	grid	were	visualised	using	a	Zeiss	Axiovert	40	C	inverted	microscope	and	counted.		
2.1.4	Cell	viability	assay		The	 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium	 bromide;	 thiazolyl	blue	 (MTT)	 assay	 was	 used	 to	 determine	 cell	 viability	 in	 response	 to	 various	treatments.	Leaving	4	wells	blank,	cells	were	plated	 into	each	well	of	a	96-well	microtiter	plate	at	a	density	of	3x103	cells	per	well,	and	incubated	overnight	at	37°C	5%	CO2.	Cells	were	 treated	with	appropriate	 titre	of	 compound,	with	 four	wells	 reserved	 for	 an	untreated	 control,	 a	 vehicle	 control	 and	only	 cell	 culture	media	 in	 the	 4	wells	with	 no	 cells.	 After	 48-hours	MTT	 reagent	was	 added	 to	each	 well	 at	 a	 final	 concentration	 of	 0.5mg/ml	 in	 cell	 culture	 media,	 and	 is	incubated	 at	 37°C	 5%	CO2	 for	 3-hours.	 The	MTT	 reagent	 is	 then	 removed,	 the	plates	are	dried	and	the	insoluble	formazan	is	solubilised	in	DMSO	prior	to	being	read	by	a	microtiter	plate	reader	(Turner	Biosystems)	at	570nM	and	a	reference	wavelength	of	650nM.			
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2.1.5	Short	tandem	repeat	profiling			To	determine	the	provenance	of	 the	cell	 lines	used	 in	 this	 thesis,	 short	 tandem	repeat	(STR)	profiling	was	undertaken.	One	million	cells	were	plated	in	a	60	mm	dish,	 incubated	 overnight	 at	 37°C	 5%	CO2.	DNA	was	 prepared	 as	 follows:	 Cells	were	detached	with	trypsin	and	centrifuged	for	5	minutes	at	500g,	4°C	prior	to	washing	with	 ice	cold	PBS	and	re-suspension	in	digestion	buffer	(100mM	NaCl,	10mM	Tris-HCl	(pH	8),	25mM	EDTA	(pH	8),	0.5%	SDS,	0.1mg/ml	proteinase	K).	Lysates	 were	 then	 incubated	 overnight	 at	 50°C	 with	 agitation.	 One	 volume	 of	phenol/chloroform/isoamyl	alcohol	was	added	prior	to	centrifugation	at	1700g	for	10	minutes.	The	aqueous	layer	was	then	transferred	to	a	fresh	tube,	with	0.5	volumes	 of	 7.5M	 ammonium	 acetate,	 and	 2	 volumes	 of	 absolute	 ethanol,	 and	centrifuged	for	2	minutes	at	1700g.	The	DNA	pellet	was	then	washed	with	70%	ethanol,	 prior	 to	 air-drying	 and	 re-suspension	 at	 1μg/μl	 in	 TE	 buffer.	 	 STR	profiling	was	performed	by	departmental	technical	laboratory	staff.	
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Table	2.2.	Results	of	STR-profiling	of	human	bladder	carcinoma	cell	 lines.		Where	data	was	available,	provenance	of	cell	lines	was	confirmed	to	be	a	100%	match	to	published	data.	However,	there	is	no	published	STR	data	(NR)	for	two	cell	 lines,	MGH-U3	 and	RT112-CP.	 As	RT112	 and	RT112-CP	 almost	 completely	match,	 loss	of	TPOX	11	 in	RT112-CP	could	be	a	result	of	 selective	pressures	 in	the	cisplatin	resistant	RT112	clone,	due	to	cisplatin-induced	genomic	instability.	
								
Marker	 EJ	 253-J	 MGH-U3	 RT112	 RT112-CP	
THO1	 6	 6,	9.3	 8,	9	 7	 7	
D21S11	 29	 28,	29	 28,	31	 27,	30	 27,	30	
D5S818	 10,	12	 10,	12	 10,	11	 10,	13	 10,	13	
D135317	 12	 9	 8,	11	 13,	14	 13,	14	
D7S820	 10,	11	 9	 8,	9	 11,	12	 11,	12	
D165539	 9	 9,	12	 9,	11	 11,	13	 11,	13	
CSF1PO	 10,	12	 10,	12	 10,	12	 10,	11	 10,	11	
AMEL	 X	 X	 XY	 X	 X	
vWA	 17	 17,	18	 17,	19	 14,	17	 14,	17	
TPOX	 8,	11	 8,	11	 8,	11	 8,	11	 8	
Match		 100%	 100%	 NR	 100%	 NR	
Reference	 [274]	 [275,	276]	 -	 [277,	278]	 -	
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2.1.6	Treatment	of	cells	with	compounds		For	 cell	 viability	 assays,	UCC	 cells	were	 seeded	 at	 a	 density	 of	 3000	 cells/well	prior	to	overnight	incubation	at	37°C,	5%	CO2.			For	protein	and	nucleic	acid	extraction	cells	were	plated	in	60mm	petri	dishes	at	a	density	of	600,000	cells/dish,	and	incubated	overnight	prior	to	treatment.			Samples	were	treated	with	the	required	concentration,	for	the	required	time	as	follows.	Cisplatin	was	dissolved	in	DMF	at	1000x	the	final	concentration	(FC)	for	FCs	at	≤50μM.		For	FCs	>50μM	cisplatin	was	dissolved	in	DMEM.	The	FC	of	DMF	in	all	samples	was	0.1%.	Brusatol,	CDDO-Me,	CHX	and	MG132	were	dissolved	in	DMSO,	 to	 1000x	 the	 FC,	with	 a	 final	 dimethyl	 sulfoxide	 (DMSO)	 concentration	across	 all	 samples	of	0.1%.	Once	 appropriately	 treated	 cells	were	 incubated	at	37°C,	5%	CO2,	for	 the	required	 time.	Following	 incubation	cells	were	processed	as	 required	 and	 where	 appropriate	 data	 was	 normalised	 to	 a	 1/1000	 vehicle	control.		
2.1.7	Transfection	with	NRF2	targeting	short	interfering	RNA		Cells	were	plated	 to	20%	confluence,	 and	 incubated	overnight	at	37°C	and	5%	CO2.	Transfection	 solutions	were	prepared.	 Solution	1	 (S1)	 comprises	 of	 200μl	optimem	and	2μl	Lipofectamine	2000	per	well,	S1	is	mixed	and	allowed	to	rest	for	 5	 minutes.	 Meanwhile	 solution	 2	 (S2)	 was	 prepared	 by	 combining	 200μl	optimem	 media,	 and	 either	 1.5μl	 NRF2	 short	 interfering	 RNA	 (siRNA)	 20μM	(Dharmacon	 siGenome	 Smart	 Pool	 NRF2),	 or	 1.5μl	 20μM	 non-targeting	 siRNA	(Dharmacon	Control	Pool	Non-Targeting	#1)	per	well.	Equal	volumes	of	S1	and	S2	were	 then	 combined	 and	 allowed	 to	 stand	 for	 20	minutes	 (S3).	 Cells	 were	then	 treated	 in	 a	6-plate,	 in	2.6ml	 culture	medium;	0.4ml	S3	was	added	 to	 the	appropriate	wells	drop	wise.	Cells	were	cultured	for	72-hours	prior	to	lysis	and	subsequent	 western	 blotting,	 where	 NRF2	 siRNA	 data	 was	 compared	 to	 non-targeting	siRNA.		
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2.1.8	Organotypic	model	of	invasion			Organotypic	 cultures	 of	 UCCs	were	 assembled	 as	 described	 by	 and	 detailed	 in	Figure	2.1.	 [279].	Concisely,	1x106	human	foreskin	fibroblast	(HFF1)	cells	were	suspended	 in	a	matrigel	 and	collagen,	 rat	 tail	 type	1	matrix	 (1:1),	 incubated	at	37°C	5%	CO2	overnight.	Prior	to	being	overlaid	with	5x105	UCC	cells	(EJ,	MGH-U3	or	RT112)	untreated,	treated	with	AdMock	or	treated	with	AdNclCD40L.	After	a	further	24	hours	at	37°C	5%	CO2,	the	gels	were	raised	onto	steel	gauzes	with	a	collagen	membrane	acting	as	an	air-media	interface.	After	10-days,	the	gels	were	formalin	fixed	and	paraffin	embedded	before	staining	by	haematoxylin	and	eosin	(H&E)	 or	 immunohistochemistry	 (IHC)	 for	 further	 analysis.	 All	 cultures	 were	conducted	in	triplicate.																							
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Figure	2.1.	An	organotypic	model	of	bladder	cancer.	This	organotypic	forms	
an	 air-liquid	 interface	 to	 emulate	 growth	 conditions	 in	 the	 bladder.	 A	pseudostroma	consisting	of	collagen,	matrigel	(1:1)	and	HFF1	cells	 lies	under	a	colony	 of	 urothelial	 cell	 carcinoma	 cell	 lines.	 	 Beneath	 the	 gel	 lies	 a	 collagen-coated	membrane	acting	as	an	interface	between	the	culture	medium	below,	and	the	 gel	 above.	 Suspending	 the	 gel	 above	 the	 culture	 medium	 is	 a	 steel	 gauze	platform,	performed	in	a	6-well	plate.	
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2.1.8.1	Infection	of	cells	with	AdNclCD40L		EJ,	 RT112	 &	 MGH-U3	 cells	 were	 incubated	 at	 37°C	 5%	 CO2	 for	 2	 hours,	 with	constant	agitation,	 in	cell	culture	medium	with	1	multiplicity	of	 infection	(MOI)	of	AdNclCD40L	in	parallel	with	a	1	MOI	AdMock	virus	control,	both	replications	deficient	viruses.	The	cells	were	then	centrifuged	at	1,000	RPM	for	5	minutes,	the	supernatant	was	 discarded,	 the	 pellet	was	 re-suspended	 in	 PBS,	 and	 the	 prior	centrifugation	step	was	 then	repeated,	 and	 the	 supernatant	discarded.	The	cell	pellet	 was	 then	 re-suspended	 in	 cell	 culture	 medium,	 prior	 to	 addition	 to	organotypic	experiments,	with	1x106	of	cells	being	cultured	for	24h	before	lysis	and	western	blotting	to	confirm	infection.		
Taha	Elmitwalli,	performed	this	work	under	the	instruction	of	myself,	as	I	did	not	have	approval	to	undertake	class	II	work	with	adenoviral	vectors.	I	set	up	the	experiment	up	until	the	infection	of	cells.	Once	fixed	in	formalin	I	continued	my	work	with	the	samples.		
2.1.8.2	Fixation			Complete	organotypic	assays	were	 transferred	 to	neutral	buffered	 formalin	 for	24	hours	at	4°C,	prior	to	being	transferred	to	70%	ethanol	in	dH2O	for	a	further	24	hours	at	4°C.												
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2.2	Protein	biochemistry	techniques			
2.2.1	Preparation	of	protein	extracts			To	extract	protein	from	BC	cells,	cells	were	washed	three	times	with	ice	cold	PBS.	Once	 the	 PBS	wash	was	 removed,	 cells	were	 lysed	 in	situ	with	 an	 appropriate	volume	of	radioimmunoprecipitation	assay	(RIPA)	lysis	buffer,	and	crude	lysate	collected	into	pre-chilled	microfuge	tubes.	Cells	were	left	on	ice	for	30	minutes	to	allow	for	complete	lysis.	Debris	was	removed	from	the	lysis	by	centrifugation	at	13,000	 rpm	 for	 5	 minutes	 at	 4°C,	 the	 supernatant	 transferred	 to	 a	 fresh	 pre-chilled	microfuge	tube	and	stored	at	-20°C.			
2.2.1.1	Determination	of	protein	concentration			Protein	 concentration	 was	 determined	 using	 the	 Bradford	 Protein	 assay	 kit	(BioRad	Lab	Ltd.,	Hemel	Hempstead,	UK)	by	thoroughly	mixing	by	vortex	2.5μl	of	clarified	 lysates	 with	 1.2ml	 dH2O	 and	 300μl	 Bradford	 reagent	 (BioRad).	Absorbance	 at	 λ595	 was	 measured	 by	 a	 spectrophotometer,	 and	 protein	concentrations	were	calculated	in	reference	to	the	bovine	serum	albumin	(BSA)	standard	curve.			
2.2.2	Western	Immunoblotting	techniques			
2.2.2.1	SDS-PAGE	electrophoresis			Western	blotting	was	performed	using	a	mini-PROTEAN	Tetra	cell	tank	(BioRad)	using	 the	method	of	Laemmli.	Glass	plates	were	cleaned	using	ethanol	and	 the	apparatus	 was	 assembled	 according	 to	 the	 manufactures	 instructions.	 10ml	resolving	gel	(375mM	Tris-HCl	(pH	8.8),	0.1%	SDS,	0.1%	ammonium	persulfate,	30%	 w/v	 acrylamide/	 0.8%	 w/v	 bis	 mix	 (National	 Diagnostics,	 Geneflow,	Frandley,	 UK)	 and	 tetramethylethylenediamine	 (TEMED)	 depending	 on	 the	
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desired	acrylamide	of	 the	gel)	was	poured.	Methanol	was	 layered	on	top	of	 the	resolving	gel	to	remove	air	bubbles.	Gels	were	set	at	room	temperature	until	the	hydrogel	 had	 solidified.	 Methanol	 was	 discarded	 and	 the	 gel	 was	 rinsed	 with	dH2O.	 4ml	 of	 stacking	 gel	was	 then	prepared	 (125mM	Tris-HCl	 (pH	6.8),	 0.1%	SDS,	 0.1%	 ammonium	 persulfate,	 0.01%	 TEMED	 and	 670μl	 30%	 (w/v)	acrylamide/0.8%	 (w/v)	 bis	mix)	 and	 poured	 on	 top	 of	 the	 set	 resolving	 gel,	 a	comb	was	 inserted	and	 the	gel	was	 set	 at	 room	 temperature.	Where	 increased	separation	was	appropriate,	4-20%	pre-cast	mini-PROTEAN	gels	(BioRad)	were	used.	Prior	to	gel	 loading,	the	comb	was	removed	whilst	submerged	in	running	buffer;	 the	 wells	 were	 washed	 extensively	 with	 x1	 sodium	 dodecyl	 sulfate-polyacrylamide	 gel	 electrophoresis	 (SDS-PAGE)	 running	 buffer	 (x10	 stock	solution;	 0.25M	 Tris-HCl	 pH	 8.3,	 1.92M	 glycine,	 and	 1%	 (w/v)	 SDS).	 Samples	containing	15-100ug	of	total	protein	were	denatured	by	incubating	at	95°C	with	3x	 concentrated	 protein	 sample	 buffer	 (PSB:	 187.5mM,	 Tris-HCL	 pH	 6.8,	 6%	(w/v)	 SDS,	 30%	 glycerol,	 0.03%	 (w/v)	 bromophenol	 blue,	 10%	 (v/v)	 2-Mercaptoethanol)	 for	 5	 minutes.	 Denatured	 samples	 were	 cooled	 on	 ice,	centrifuged	to	remove	condensation	and	loaded	into	the	appropriate	wells	of	the	assembled	PAGE	gel.	Gels	were	electrophoresed	at	150-175V	(constant	volts)	for	60-120	minutes.		
2.2.2.2	Western	Immunoblotting			After	 SDS-electrophoresis,	 the	 proteins	 are	 transferred	 onto	 nitrocellulose	transfer	 membranes,	 methanol	 soaked	 0.45μM	 PDVF	 membranes	 using	 the	BioRad	 Trans-Blot	 Turbo	 system.	Where	 pre-assembled	 BioRad	 transfer	 packs	were	not	used,	 the	 filter	paper	and	membranes	were	 soaked	 in	 transfer	buffer	(50mM	Tris-HCl,	 190mM	glycine,	 20%	 (v/v)	methanol)	 prior	 to	 assembly.	 The	proteins	were	 then	 transferred	 for	10	min	at	25V/1.5A.	Membranes	were	 then	washed	 in	 TBST	 (1x	 TBS;	 20mM	Tris-HCl	 pH	 7.6,	 136mM	NaCl,	 supplemented	with	0.1%	Tween-20)	for	5	minutes,	followed	by	blocking	in	10%	skimmed	milk	or	 10%	BSA	 (phospho-proteins)	 for	 1	 hour	 at	RT	or	 overnight	 at	 4°C.	Blocked	membranes	were	washed	in	TBST	for	5	minutes,	and	incubated	overnight	in	the	
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appropriate	 primary	 antibody	 diluted	 in	 TBST	 with	 2%	 milk	 (Table	 2.3.).	Membranes	were	washed	6	times	for	10	minutes	each	in	TBST,	incubated	for	1	hour	at	RT	in	the	relevant	peroxidase	conjugated	secondary	antibody	(Table	2.2.)	diluted	in	TBST	with	2%	milk.	The	membrane	is	washed	a	further	6	times	for	10	minutes	each	in	TBST,	before	being	visualised	by	enhanced	chemiluminescence	(Amersham).			
2.2.2.3	Reprobing	membranes			Membranes	 were	 thoroughly	 washed	 in	 TBST,	 and	 horseradish	 peroxidase	(HRP)	was	inactivated	through	incubation	with	15ml	PBS	supplemented	with	3	drops	H2O2	 and	3	drops	Chromagen	 (Vector	Labs)	 for	20	min	 in	 a	 light	 sealed	box.	Blots	were	then	incubated	with	another	primary	antibody,	overnight	at	4°C.		
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Table	0.3.	Western	blot	antibody	conditions.	
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2.2.3	Immunohistochemistry			Antigen	retrieval	was	performed	using	PT	Link	antigen	retrieval	machine	(Dako)	at	 pH	9.	 Prior	 to	 blocking,	where	TBST	was	 removed,	 the	 slide	was	dried,	 and	each	 section	 was	 incubated	 in	 peroxidase	 blocker	 (Envision,	 Dako)	 for	 10-minutes,	 before	 three	 1-minute	 washes	 in	 TBST.	 Primary	 antibody	 solutions	were	 prepared	 to	 the	 appropriate	 concentration	 in	 Chemomate,	 and	 added	 to	each	 slide	 for	 1-hour	 at	 room	 temperature,	 prior	 to	 three	 1-minute	washes	 in	TBST.	The	slides	are	then	dried	and	secondary	antibody	(Envision,	Dako)	is	then	applied	 at	 room	 temperature,	 for	 60	minutes,	 prior	 to	 a	 triplicate	 of	 1-minute	washes	in	TBST.	DAB/Chromagen	(Dako)	were	then	made	as	per	manufacturers	instructions	and	was	applied	to	each	dried	slide	for	10-minutes,	before	washing	in	 TBST	 three	 times	 for	 1-minute.	 The	 slides	 were	 then	 counterstained	 in	haematoxylin	 for	 30	 seconds,	 before	 being	 washed	 in	 distilled	 water	 for	 5-seconds,	then	washed	in	acid	water	for	5	seconds,	prior	to	a	5	second	wash	in	2%	ammonium	 hydroxide.	 The	 slides	 were	 then	 incubated	 in	 90%	 ethanol	 for	 1	minute,	 before	 transferring	 to	 two	 separate	 1-minute	 washes	 in	 absolute	ethanol,	 prior	 to	 two	 subsequent	 1-minute	 washes	 in	 xylene	 and	 cover-slip	mounting	using	DPX	mountant.																
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Table	2.4.	Primary	antibody	concentrations	for	IHC.	
Primary	
Antibody	
Primary	Antibody	
Concentration		
Secondary	Antibody	
Concentration	
Osteopontin	
(R&D	AF1433)	 1:50	 1/100	
CD40-Ligand	(SC-
978)	 1:1000	 Stock	
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2.2.3.1	Histological	processing			
2.2.3.1.1	Paraffin	embedding		Paraffin	infiltration	was	performed	overnight	using	a	tissue	processor.			
2.2.3.1.2	Sectioning	and	slide	preparation		Sections	 for	 IHC	 and	 H&E	 staining	 were	 prepared	 using	 a	 microtome,	 at	 a	thickness	 of	 4μm,	 on	 SuperFrost	 Plus	 slides	 (ThermoFisher	 Scientific).	 Slides	were	dried	at	30°C	overnight	prior	to	staining,	or	storage	in	an	anoxic	cabinet.			
2.2.3.1.3	Haematoxylin	and	eosin	Staining			In	the	appropriate	rack,	slides	were	placed	in	xylene	for	5	minutes,	prior	to	two	30-second	washes	in	fresh	xylene.	The	slides	were	then	washed	in	100%	ethanol	three	 times	 for	 thirty	 seconds	 each,	 the	 previous	 step	was	 then	 repeated	with	95%	ethanol,	70%	ethanol	and	30%	ethanol	respectively,	before	being	agitated	in	 water	 for	 30-seconds.	 The	 slides	 were	 then	 placed	 in	 haematoxylin	 (30-seconds	 for	 cell	 pellets	 and	 organotypic	 assays,	 1	 minute	 for	 tissue	 sections),	prior	 to	being	washed	 in	 running	water	until	 the	 solution	 ran	clear.	The	 slides	were	then	agitated	in	acid	water	for	30-seconds,	rinsed	in	running	tap	water	for	a	further	30-seconds,	then	agitated	in	Scott’s	tap	water	for	30	seconds.	Once	the	sections	were	 clearly	 stained	 blue/	 purple,	 the	 slides	were	washed	 in	 running	tap	water,	 followed	 by	 30-seconds	 of	 agitation	 in	 100%	 ethanol,	 prior	 to	 a	 2-minute	incubation	in	eosin.	The	slides	were	then	transferred	into	100%	ethanol	for	50	seconds,	before	being	transferred	into	fresh	absolute	ethanol	twice	for	30-seconds,	then	xylene	three-times	for	30-seconds.	Coverslips	were	mounted	using	DPX.			
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2.2.3.2	Scoring	of	immunohistochemical	staining	intensity			Staining	intensity	was	scored	by,	consultant	pathologist,	Dr	Vijay	Aachi.	Briefly,	staining	 intensity	 was	 graded	 as	 0	 (negative),	 +	 (weak),	 ++	 (moderate),	 +++	(strong).	
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2.3	Nucleic	acid	techniques		
2.3.1	Reverse	transcription	polymerase	chain	reaction		
2.3.1.1	RNA	isolation			Following	 treatment,	 the	 media	 was	 discarded	 before	 washing	 the	 cells	 twice	with	 ice-cold	 PBS,	 discarding	 each	 time.	 The	 cells	 were	 then	 subjected	 to	digestion	with	RLT	 lysis	buffer,	and	transferred	to	RNase-free	microfuge-tubes.	Lysates	 were	 centrifuged	 at	 8,000g	 for	 3	 minutes;	 the	 supernatant	 was	 then	transferred	into	fresh	microfuge	tubes	(RNase	free).	420μl	absolute	ethanol	/	1	volume	70%	ethanol	was	 added	 to	 the	 supernatant	prior	 to	mixing	by	 flicking	the	tube.	<700μl	of	the	supernatant	including	precipitate	was	transferred	into	a	RNeasy	 mini	 column,	 and	 2ml	 collection	 tube,	 before	 15	 seconds	 of	centrifugation	at	8,000g,	discarding	the	flow-through.	350μl	of	buffer	RW1	was	added	to	 the	spin	column	prior	 to	15	seconds	centrifugation	at	8,000g.	 In	each	sample	10μl	 of	DNAse	 I	 stock	 solution	was	 added	 to	70μl	RDD	buffer,	 prior	 to	mixing	 by	 inverting,	 then	 adding	 directly	 to	 the	 RNase	 silica-gel	 in	 the	 mini-column.	The	columns	were	then	incubated	at	room	temperature	for	15	minutes,	before	the	addition	of	350μl	of	RW1	buffer,	and	a	subsequent	centrifugation	for	15	seconds.	The	flow-through	was	then	discarded.	500μl	RPE	buffer	was	added	to	the	RNeasy	mini	spin	column,	prior	2	minutes’	centrifugation	at	8,000g,	then	discarding	the	flow-through.	The	column	was	then	transferred	into	a	fresh	RNase	free	collection	tube,	prior	to	centrifugation	at	8,000g	for	1	minute	to	dehydrate	the	 column.	RNA	was	 then	 solubilised	 in	30-50μl	of	RNase	 free	water,	prior	 to	adding	 to	 the	 column,	 which	 in	 a	 fresh	 RNase-free	 collection	 tube	 was	centrifuged	at	8,000g,	for	1	minute.			
2.3.1.2	RNA	quality	control			The	 concentration	 and	 quality	 of	 RNA	 was	 assessed	 using	 the	 NanoDrop	 ND-1000	 spectrophotometer.	 Here	 1μl	 nuclease-free	 water	 was	 added	 to	 the	
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nanodrop,	to	calibrate	a	blank	reading.	After-which	1μl	of	each	RNA	sample	was	added	to	the	sensor.	The	nanodrop	measures	the	concentration	using	Beer’s	Law.	Whereby,	 nucleic	 acid	 concentration	 (ng/μL)	 equals,	 absorbance	 (in	 AU)	multiplied	 by	wavelength-dependent	 extinction	 coefficient	 (ng-cm/μL)	 divided	by	the	path	length	(cm).	The	calculated	concentration	is	used	to	standardise	RNA	loading	amount	during	cDNA	synthesis.			The	RNA	quality	is	then	assessed	based	on	purity	in	relation	to	protein	content	(260/280nM)	 –	 where	 a	 value	 >	 1.8	 is	 acceptable,	 values	 below	 this	 are	considered	 as	 contaminated	 with	 protein	 and	 discarded;	 or	 in	 relation	 to	 the	solvent	 content	 (260/230nM)	 –	where	 a	 value	 of	 >1.8	 is	 accepted,	 any	 values	below	this	are	considered	as	contaminated	with	solvents	and	are	discarded.		
	
2.3.1.3	cDNA	synthesis			Complementary	 DNA	 (cDNA)	 was	 prepared	 following	 the	 manufacturer’s	instructions	(RETROscript®	Kit,	AMBION).	Briefly,	2μg	RNA	and	2μl	of	Oligo(dT)	were	 added	 12μl	 (final	 volume)	 nuclease	 free	 water.	 Samples	 were	 heated	 at	85°C	 for	 3	minutes,	 before	 adding	 reverse	 transcription	 (RT)	 components	 (2μl	10X	 RT	 Buffer,	 4μl	 dNTP	 mix,	 1μl	 RNase	 inhibitor	 and	 1μl	 MMLV-RT)	immediately	at	44°C.	Prior	to	1	hour	incubation	at	44°C.	Samples	were	heated	at	92°C	for	10	minutes	to	deactivate	MMLV-RT.		
2.3.1.4	PCR	amplification	
	Amplification	of	MMP1,	FAM83D,	ANLN,	FN1	and	GAPDH	cDNA	 fragments	was	performed	 by	 PCR.	 Reaction	 mixes	 were	 performed	 in	 a	 final	 volume	 of	 25μl	consisting	 of	 1	 volume	 of	DreamTaq	Green	PCR	Master	Mix	 2x	 (ThermoFisher	Scientific,	K1081),	 and	1	 volume	 containing	dH2O,	 2	pM	 forward	primer,	 2	pM	reverse	primer,	and	1.5μl	cDNA	from	the	above	cDNA	synthesis.	dH2O	replaces	cDNA	 in	no-cDNA	control.	The	amplification	was	performed	on	a	 thermocycler	(MJ	Research	PTC-200)	as	follows:	1)	93°C	for	5	minutes,	2)	93°C	for	30	seconds,	
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3)	60.3°C	for	30	seconds,	4)	72°C	for	1.5	minutes,	repeat	2-4	29	times,	to	a	total	of	30	cycles.		
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Table	2.5.	PCR	primers	targeting	MMP1,	FAM83D,	ANLN	and	FN1.	
Gene	 Direction	 Sequence	5’-3’	
MMP1	 FWD		 aaggtctctgagggtcaagc	
MMP1	 REV	 tgagctcaacttccgggtag	
FAM83D	 FWD		 ggtaattctgtctggccaagtg	
FAM83D	 REV	 gtttgagagcttgctatcctgg	
ANLN	 FWD	 acgtccatcaataaagcaggtg	
ANLN	 REV	 aagtacttgctaatggtgtggc	
FN1	 FWD	 caggatcacttacggagagaca	
FN1	 REV	 cagtgaatgccagtcctttagg	
GAPDH	 FWD	 cctccaaaatcaagtggggcg	
GAPDH	 REV	 accaccaggtgctcagtgtag		
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2.3.1.5	Agarose	gel	electrophoresis			A	1.2%	suspension	of	agarose	was	prepared	in	Tris	base,	acetic	acid,	and	EDTA	(TAE)	buffer,	prior	to	heating	with	a	domestic	microwave	until	all	agarose	was	in	solution	with	the	buffer.	The	solution	was	cooled	to	50°C	before	adding	SYBR®	safe	 DNA	 gel	 stain	 according	 to	 manufacturer’s	 instructions,	 gently	 mixing	 to	avoid	 bubbles,	 then	 pouring	 into	 a	midi-gel	 cassette	 to	 cast	 the	 gel.	 Once	 cast,	samples	were	loaded	to	a	final	volume	of	10μl.	Electrophoresis	was	performed	at	140V	until	sufficient	separation	of	had	occurred.	The	gel	was	visualised	by	UV-light	detection	using	the	ChemiDoc™	Touch	Imaging	System	(BioRad).		
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2.4	Gene	expression	analysis	methods		Unless	marked	with	 an	 asterisk	 (*)	 the	 following	methods	were	 performed	 by	authors	 of	 the	 2017	 paper	 published	 in	 The	 International	 Journal	 of	 Oncology	(IJO)	 “Gene	 expression	 profiling	 in	 bladder	 cancer	 identifies	 potential	therapeutic	targets”	excluding	I,	Richard	Greensmith.			
2.4.1	Patients	and	tissue	samples			Tissue	biopsies,	collected	by	cystoscope	were	collected	between	May	2004	and	November	 2005.	 Before	 cystoscopy,	 all	 participants	 gave	 written	 informed	consent	for	additional	samples	to	be	taken	for	this	study	during	their	procedure.	Eligible	 patients	 were	 aged	 18	 to	 80	 years,	 with	 a	 diagnosis	 of	 histologically	confirmed	NMIBC	(n	=	14)	or	MIBC	(n	=	5)	urothelial	cell	carcinoma,	who	had	not	undergone	 any	 previous	 therapy.	 Control	 samples	 (n=11)	 were	 from	histologically	confirmed	normal	bladder	tissue	obtained	from	uninvolved	tissues.		Ten	 of	 the	 control	 samples	 were	 paired	 with	 corresponding	 UCC	 biopsies	 (4	NMIBC,	 5	 MIBC),	 the	 remaining	 sample	 was	 obtained	 from	 a	 patient	 with	 no	diagnosis	of	BC.			Patient	demographic	data	is	presented	in	table	2.6.			
2.4.2	Study	ethical	considerations		Study	approval	was	obtained	from	the	South	Birmingham	Local	Research	Ethics	Committee.	All	participants	gave	written	informed	consent	for	the	usage	of	their	respective	biopsies	in	this	study.			*Approval	for	further	analysis	was	granted	by	the	Liverpool	Tissue	Bank	Ethics	Committee	 (application	number	12-09).	All	 participants	 gave	written	 informed	consent	for	their	respective	biopsies	to	be	used	in	biomedical	analysis.			
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Table	 2.6.	 Patient	 demographics	 for	 gene	 expression	 analysis.	 N/A:	 not	
applicable	
		 Controls	
(n=11)	 NMIBC	(n=14)	 MIBC	(n=5)	
Age	 in	 years	 {median	
(range)}	 79.2	 (64-85.8)	 70.8	 (47.0	 -	81.9)	 80.14	(65.3-85.8)	
Gender	 Male	 8	(72.2)	 11	(78.6)	 3	(60.0)	
		 Female	 3	(27.2)	 3	(21.4)	 2	(40.0)	
Grade	 G1	 N/A	 6	(42.8)	 0	(0)	
		 G2	 N/A	 1	(7.1)	 0	(0)	
	 G3	 N/A	 7	(50.0)	 5	(100)	
T	stage	 PT1	 N/A	 5	(35.7)	 0	(0)	
		 PT1B	 N/A	 1	(7.1)	 0	(0)	
		 PTa	 N/A	 8	(57.1)	 0	(0)	
		 PT2	 N/A	 0	(0)	 5(100)	
Recurrence	No	 N/A	 12	(92.3)	 0	(0)	
				 Yes	 N/A	 1	(7.7)	 5	(100)	
Survival	 in	 Months	
(95%	CI)	 N/A	 81.2	 (73.3-not	estimatable)	12.26	 (0	 -	35.6)		
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Table	 2.7.	 Tumour	 information	 for	 immunohistochemical	 analysis.	 N/A:	
not	applicable.	*			 Controls	(n=3)	 MIBC	(n=3)	
Grade	 G2	 N/A	 1	G3	 N/A	 2	
T	Stage	
pT2	 N/A	 1	pT3	 N/A	 1	pT4	 N/A	 1	Survival	in	Months	 		 N/A	 66.3	(20-120)		
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2.4.3	Tissue	biopsy	sample	preparation			Tissue	 samples	 were	 snap	 frozen	 and	 stored	 in	 liquid	 nitrogen	 prior	 to	 RNA	isolation.		
	
2.4.3.1	RNA	extraction			Total	RNA	was	extracted	from	each	biopsy	with	TRIzol	(Invitrogen),	before	silica	purification	 (RNAeasy	Mini	 columns,	QIAGEN)	 according	 to	 the	manufacturer’s	instructions.	RNA	integrity	was	confirmed	using	the	Agilent	Bioanalyser,	samples	with	a	RIN	of	6.0	were	included	in	this	study.		
2.4.3.2	cDNA	probe	synthesis		200ng	 of	 total	 RNA	was	 processed	 in	 to	 cDNA	 including	 targeted	 depletion	 of	rRNA	 transcripts	 using	 the	 WT	 Expression	 kit	 (Ambion)	 according	 to	 the	manufacturer’s	 instructions.	 The	 cDNA	 was	 then	 fragmented	 and	 biotin	 end	labelled	with	the	WT	Terminal	Labelling	Kit	(Affymetrix).		
	
2.4.4	Human	Gene	1.0	ST	Microarray	hybridisation	analysis		The	 resulting	 labelled	 cDNA	 was	 hybridised	 to	 Human	 Gene	 1.0	 ST	 whole	transcript-based	arrays	(Affymetrix)	prior	to	washing	and	staining	on	the	FS450	fluidics	 station	 (Affymetrix).	 The	 Human	 Gene	 1.0	 ST	 Array	 (Affymetrix)	 was	made	up	of	764.885	distinct	25nt	probes,	probing	28,869	annotated	genes	based	on	 the	 March	 2006	 (UCSC	 hg18,	 NCBI	 Build	 36)	 human	 genome	 sequence	assembly	with	widespread	coverage	of	RefSeq,	Ensembl	and	putative	whole	CDS	GeneBank	transcripts.		
	
2.4.4.1	Signal	collection	and	analysis		
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A	 Scanner	 3000	 7G	 (Affymetrix)	was	 used	 to	 scan	 the	 arrays	 and	 a	 Command	Console	 (Affymetrix)	 was	 implemented	 in	 instrument	 control.	 Standard	Affymetrix	 protocols	 were	 adhered	 to	 throughout.	 Raw	 microarray	 data	 was	submitted	to	ArrayExpress	(Accession:	E-MTAB-1560).			
2.4.5	Statistical	analysis	of	microarray	data		
2.4.5.1	Data	transformation		Robust	 multi-array	 averaging,	 adjustments	 for	 non-specific	 binding,	Bioconductor	GCRMA	was	used	for	data	normalisation	and	summarisation	of	the	probe	intensity	signals	as	described	in	the	following	referenced	literature	[280,	281].	 RMA	 background	 correction	 and	 quantile	 normalisation	 across	 all	 chips	was	applied	to	the	data	as	to	ensure	comparable	mean,	and	standard	deviation	of	probe	 intensities,	 Log2	 transformation	 and	 median	 polish	 probe	 set	summarisation	was	then	undertaken.			
2.4.5.2	Quality	estimation	of	array	data		The	 NUSE	 of	 each	 array	 was	 calculated	 in	 order	 to	 compare	 inter-	 and	 intra-array	data	variability	as	described	in	the	referenced	paper	[282].	The	upper	limit	for	acceptable	quality	was	a	NUSE	value	of	1.05.		
2.4.5.3	Data	analysis		Principal	 Components	 Analysis	 applying	 a	 covariance	 dispersion	 matric	 was	undertaken	 to	map	multidimensional	 data	 of	 each	 sample	 to	 three	dimensions	for	clustering	according	to	classification,	and	identification	of	outliers.			ANOVA	 including	 methods	 of	 moments	 estimation	 was	 applied	 to	 locate	differential	 expression	 between	 normal	 bladder	 tissue,	 NMIBCs	 and	 MIBCs.	Batch	effects	were	accounted	for	within	the	model.	When	conducting	ANOVA	the	
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patient	 was	 designated	 as	 a	 factor,	 paired	 samples	 were	 taken	 into	consideration.	 The	 t-test	 was	 applied	 to	 assess	 differences	 in	 gene	 expression	between	 BCs	 of	 different	 grade	 and	 between	 samples.	 To	 adjust	 for	 multiple	testing,	genes	were	deliberated	to	be	differentially	expressed	if	a	FDR	adjusted	p	value	of	p<0.05	was	attained.	FDR	was	calculated	as	described	here	[283].		Genes	selected	 for	 further	 analysis	 were	 those	 with	 a	 significant	 fold	 change	 in	expression	above	2-fold.			Unsupervised	 hierarchical	 agglomerative	 clustering	 (Euclidean	 distance	 with	average	 linking	 clustering)	 was	 implemented	 to	 identify	 samples	 with	 similar	expression	profiles.			MetaCore	version	6.7	(GenGo	Unc,	St.	 Joseph,	MI,	USA),	 IPA	(Ingenuity	systems,	Redwood	City,	CA,	USA)	and	DAVID	Bioinformatics	resource	v6.7	were	applied	in	the	 identification	 of	 canonical	 pathways	 and	 curated	 networks	 which	 had	statistically	 significant	 levels	 of	 amplification	 of	 differentially	 expressed	 genes	[284].	 Unless	 otherwise	 stated,	 all	 pathways	 from	 metacore	 analysis	 in	 the	results	section	are	filtered	with	a	FDR	of	<0.05.	The	association	between	disease	progression	and	differential	gene	expression	was	analysed	using	univariate	Cox	proportional	hazards	regression	analysis.				
2.4.6	Meta-analysis		A	meta-analysis	was	performed	utilising	publicly	available	gene	expression	data	from	 NCBI	 Gene	 Expression	 Omnibus	 [285].	 Out	 of	 12	 potential	 datasets,	 two	datasets,	which	used	the	same	microarray	platform	(Affymetrix	Human	Genome	U133A	 array	 GSE3167,	 GSE5287),	 were	 used	 for	 further	 investigation,	 with	 a	large	 sample	 number	 for	 further	 investigation.	 Raw	 CEL	 files	 from	 GSE3167	consisting	 of	 60	 samples,	 and	 from	 GSE5287	 consisting	 of	 30	 samples,	 were	imported	 into	 Partek	 Genomic	 Suite	 (Partek	 Inc.),	 data	 was	 processed	 and	differential	genes	were	identified	following	the	same	protocol	applied	to	the	in-
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house	 microarray	 data	 [19,	 286].	 	 The	 authors	 kindly	 provided	 clinic-pathological	 data	 for	 each	 dataset.	 The	 GSE3167	 data	 set	 consisted	 of	 NMIBC	with	surrounding	Cis	(n	=	13),	NMIBC	without	surrounding	Cis	(n	=	15),	MIBC	(n	=	13),	Cis	alone	(n	=	5)	and	normal	bladder	tissue	(n	=	14).	The	GSE2587	dataset	consisted	entirely	of	MIBC	cases	(n	=	30).				
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3.1	Introduction		
	The	platinum	containing	anti-cancer	drug,	cisplatin,	is	the	single	most	efficacious	agent	 in	 the	 treatment	 of	 MIBC,	 although	 90%	 of	 patients	 acquire	 resistance	associated	with	disease	progression	and	a	very	poor	prognosis.	In	recent	years,	there	 has	 been	 an	 increased	 focus	 on	 NRF2	 and	 its	 role	 in	 chemotherapy	resistance	in	several	cancers,	including	those	of	the	bladder.			The	Basic	Leucine	Zipper	transcription	factor,	NRF2,	is	the	chief	mediator	of	the	antioxidant	 response,	 and	 is	 responsible	 for	 cytoprotection	 and	 redox	homeostasis	 in	normally	 functioning	cells.	However,	 in	many	cancers	 increased	levels	 of	 NRF2	 are	 associated	 with	 chemoresistance	 and	 a	 more	 aggressive	phenotype.	The	hypothesised	mechanism	of	NRF2	mediated	chemoresistance	is	through	 increased	transactivation	of	NRF2	mediated	genes,	which	 include	GSH,	MDR1/2	and	metallothionein,	together	it	is	believed	that	these	proteins	facilitate	increased	metabolism	and	efflux	of	chemotherapeutic	agents,	including	cisplatin,	lowering	 intracellular	 drug	 concentrations	 into	 a	 sub-toxic	 range,	 whilst	 still	exerting	 considerable	 toxicities	 on	 the	 body.	 In	 this	 context,	 it	 may	 be	therapeutically	useful	to	inhibit	NRF2	activity	to	potentiate	the	cytotoxic	effects	of	cisplatin-based	chemotherapy.		
	In	this	chapter	brusatol,	a	quassinoid	extracted	from	the	South	East	Asian	plant	
Brucea	Javancia,	which	has	shown	to	cause	a	marked	reduction	in	NRF2	levels	in	several	 cell	 line	models,	 is	 investigated	with	 respect	to	 its	 capacity	 to	 increase	the	 sensitivity	 of	 BC	 cell	 lines	 to	 cisplatin.	 A	 panel	 of	 cell	 lines	 (Table	 2.1.)	originating	from	a	range	of	stages	and	grades	of	bladder	cancer,	and	a	model	of	cisplatin	resistant	UCC	were	selected	to	test	the	hypothesis	stated	below.			
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3.1.2	Chapter	aims	
	
• To	determine	whether	brusatol	enhances	the	sensitivity	of	urothelial	cell	carcinoma	cells	to	cisplatin.			
• Define	the	response	in	terms	of	inhibition	of	NRF2	levels	and	downstream	effects.		
	
Hypothesis:	Brusatol,	via	 inhibition	of	NRF2	 levels	will	 increase	the	sensitivity	of	UCC	cell	lines	to	cisplatin.	
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3.2	Results	
	
3.2.1	Evaluation	of	the	sensitivity	of	a	panel	of	5	UCC	cell	lines	to	the	
cytotoxic	effects	cisplatin	
	A	titre	of	10	cisplatin	concentrations	ranging	from	10nM	to	1mM	was	employed	to	decipher	 its	concentration-dependent	cytotoxic	effects	on	EJ,	253-J,	MGH-U3,	RT112	 and	RT112-CP	 cells	 (Fig	 3.1).	 Cells	were	 treated	 for	 48	hours,	with	 the	cytotoxicity	 being	 determined	 using	 the	 MTT	 assay	 and	 displayed	 as	 a	percentage	 of	 viable	 cells	 when	 normalised	 to	 the	 vehicle	 control.	 The	 mean	IC50s	range	from	17.08μM	for	EJ	cells	to	136.7μM	for	cisplatin	resistant	RT112-CP,	5.9-fold	higher	than	the	23.11μM	IC50	observed	in	its	parent	cell	line,	RT12,	significantly	 higher	 than	 all	 cisplatin	 sensitive	 cell	 lines	 (RT112	 p=0.0007,	 EJ	p=0.0005,	 253-J	 p=0.0006,	 MGH-U3	 p=0.0006).	 There	 was	 no	 significant	difference	between	the	IC50	values	of	all	cisplatin-sensitive	cell	 lines*,	with	the	most	and	least	sensitive	cell	lines	being	separated	by	only	6.03μM.				*Cisplatin-sensitive	cell	 lines	are	defined	as	EJ,	253-J,	MGH-U3	and	RT112	cells.	RT112-CP	cells	are	considered	cisplatin	resistant.	
	 92	
	
Figure	 3.1.	 Cisplatin	 exerts	 its	 cytotoxicity	 in	 a	 concentration	 dependent	
manner	 on	 5	 UCC	 cell	 lines.	 After	 48-hours	 exposed	 to	 cisplatin,	 the	 cell	viability	was	determined	in	EJ	(A),	253-J	(B),	MGH-U3	(C),	RT112	(D),	RT112-CP	(E),	cells	using	the	MTT	assay.	(F)	A	comparison	of	cisplatins	cytotoxic	effects	on	RT112	 cells	 when	 compared	 to	 the	 cisplatin	 resistant	 RT112-CP	 sub-line.	 (G)	Mean	 IC50	 values	 +	 standard	deviation	 (SD)	 (μM).	All	 dose-response	data	was	normalised	 to	 vehicle	 control,	 data	 shown	 is	 mean	 of	 three	 independent	experiments	 +	 SD.	 The	 average	 IC50	 values	 are	 plotted	 with	 SD.	 Statistical	
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analysis	was	performed	using	a	one-way	ANOVA	(***p<0.001	vs	EJ,	253-J,	MGH-U3,	and	RT112	cells).			
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3.2.2	Determination	of	the	sensitivity	of	5	UCC	cell	lines	to	the	cytotoxic	
effects	of	brusatol	
	To	understand	more	about	the	effects	of	brusatol	on	UCC	cell	 lines	the	effect	of	brusatol	on	UCC	cell	viability	was	investigated	on	the	same	panel	of	5	cell	 lines	(Fig	3.2).	Here	the	UCC	cell	lines	were	cultured	for	48	hours	in	a	titre	of	brusatol	concentrations	ranging	from	10pM	to	1μM,	before	the	MTT	assay	was	employed	to	determine	the	effect	on	cell	viability	as	a	percentage	of	the	mean.	IC50	values	range	from	78.11nM	in	253-J	cells,	to	282nM	(p=0.0324)	in	the	slowest	dividing	cell	line	in	the	panel,	MGH-U3.					
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Figure	 3.2.	 Brusatol	 exerts	 concentration-dependent	 cytotoxic	 effects	 in	
UCC	cells.	5	UCC	cell	lines	(A)	EJ,	(B)	253-J,	(C)	MGH-U3,	(D)	RT112,	(E)	RT112-CP)	were	treated	with	a	range	of	concentrations	of	brusatol	from	1pM	to	1μM	for	48-hours.	The	effect	on	cell	viability	was	determined	using	the	MTT	assay,	with	all	dose	response	data	being	represented	as	a	percentage	of	the	vehicle	control,	and	 is	mean	 of	 three	 independent	 experiments	 +	 SD.	 (F)	 Average	 IC50	 values	(with	SD).		
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3.2.3	DMSO	at	a	concentration	of	1:1000	does	not	alter	the	sensitivity	of	
UCC	cell	lines	to	cisplatin	
	It	has	been	reported	 that	DMSO	binds	with	cisplatin	 in	a	manner	 that	 severely	attenuates	its	efficacy	as	a	cytotoxic	agent	[287].	However,	brusatol	used	in	this	investigation	 was	 only	 available	 in	 solution	 with	 DMSO,	 so	 the	 effect	 of	 the	maximum	concentration	of	DMSO	(1:1000)	was	assessed	in	terms	of	its	effect	on	cisplatin	toxicity.	In	all	UCC	cell	lines	tested	there	was	no	negative	effect,	in	terms	of	 attenuated	 cytotoxicity,	 of	 adding	 1:1000	 DMSO	 to	 cisplatin	 dose	 response	experiments	(Fig	3.3).			
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 97	
	
	
Figure	3.3.	The	comparative	cytotoxicity	of	cisplatin	alone	and	cisplatin	in	
combination	with	1:1000	DMSO.	After	48-hours	exposed	 to	cisplatin,	 the	cell	viability	was	determined	in	(A)	EJ,	(B)	253-J,	(C)	MGH-U3,	(D)	RT112,	(E)	RT112-CP	cells	using	the	MTT	assay.	(F)	Mean	IC50	values	(μM).	All	dose-response	data	was	 normalised	 to	 vehicle	 control,	 data	 shown	 is	 mean	 of	 three	 independent	experiments.		The	average	IC50	values	are	plotted	with	SD.			
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3.2.4	Investigation	into	the	effects	of	2-hour	pre-treatment	with	a	range	of	
concentrations	of	brusatol	with	respect	to	the	sensitivity	to	cisplatin	
	To	 determine	 whether	 brusatol	 increases	 the	 sensitivity	 of	 urothelial	 cell	carcinoma	cell	 lines	 to	cisplatin,	 the	 full	panel	of	5	cell	 lines	were	employed	 to	allow	for	a	pathologically	diverse	cross-section	of	BC	disease	grades	and	stages.	Based	on	prior	observations	a	2-hour	brusatol	pre-treatment	time	was	selected	as	 it	has	been	noted	 in	 the	 literature	 that	maximum	depletion	of	NRF2	protein	expression	 occurs	 at	 this	 time-point	 [172].	 There	 are	 reports	 of	 brusatol	concentrations	 as	 low	 as	 40nM	 and	 as	 high	 as	 300nM	 inhibiting	 NRF2,	 thus	 a	range	 of	 concentrations	 of	 brusatol	 were	 selected	 from	 5nM,	 which	 over	 48	hours	 exhibits	 negligible	 toxicity	 on	 UCC	 cell	 lines,	 up-to	 a	 concentration	 of	400nM	 where	 marked	 toxicity	 was	 observed.	 After	 the	 2-hour	 pre-treatment	with	brusatol,	a	titre	of	cisplatin	was	added	to	the	plate	from	1nM	to	1mM.	The	MTT	assay	was	use	for	read	out,	and	each	treatment	was	normalised	to	a	vehicle	control.		Statistical	analysis	was	performed	using	a	one-way	ANOVA.			In	EJ	cells	(Fig	3.4),	the	addition	of	brusatol	to	cisplatin	allowed	for	a	significant	increase	 in	 sensitivity	 to	 cisplatin	 at	 the	 400nM	 brusatol	 concentration	 point	(p=0.0125).			The	 response	 to	 2-hour	 brusatol	 pre-treatment	 in	 253-J	 cells	 (Fig	 3.5)	 was	similar	 to	 that	 in	 EJ	 cells.	 Here	 a	 small	 shift	 to	 the	 left	was	 observed	with	 the	addition	 of	 200nM	 and	 a	 significant	 change	 in	 the	 IC50	 is	 observed	 at	 400nM	(p=0.0494).			2-hour	pre-treatment	with	5-400nM	brusatol	does	not	significantly	increase	the	sensitivity	of	MGH-U3	cell	lines	to	the	cytotoxic	effects	of	cisplatin	(Fig	3.6).			In	 the	NMIBC	 cell	 line,	 RT112	 (Fig	 3.7),	 a	 significant	 decrease	 in	 the	 IC50	was	observed	 when	 compared	 to	 cisplatin	 plus	 vehicle	 at	 brusatol	 concentrations	greater	than	100nM	(100nM	p=0.0003,	200nM	p=0.0118,	400nM	p=0.0111).			
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Interestingly,	in	the	cisplatin	resistant	RT112-CP	cell	line	(Fig	3.8),	an	increase	in	sensitivity	 to	 cisplatin	 was	 noted	 to	 be	 significant	 at	 concentrations	 above	200nM	of	brusatol	 (200nM	0.0326,	 400nM	0.0373).	Although	a	non-significant	shift	to	the	left	was	evident	at	100nM	of	brusatol.			The	most	 profound	 effects	were	 displayed	 in	 the	 NMIBC	 cell	 lines	 RT112	 and	RT112-CP,	where	 cisplatin	 is	 unlikely	 to	 be	 used	 as	 a	 treatment	 option	 in	 the	clinic,	these	data	show	that	co-treatment	of	brusatol	and	cisplatin	may	be	a	more	effective	option	than	cisplatin	alone.			I	hypothesise	that	whilst	NRF2	may	be	inhibited	at	2-hours,	this	does	not	leave	enough	time	for	the	downstream	consequences	of	NRF2	inhibition	to	be	realised.	Hence	 the	next	 step	 should	be	 to	optimise	a	 time-point	where	NRF2	 regulated	proteins	 are	 downregulated	 due	 to	 brusatol	 mediated	 NRF2	 inhibition.	 Once	optimised,	cells	will	be	treated	with	cisplatin	when	defence	proteins	regulated	by	NRF2	 are	 at	 their	 lowest	 levels,	 hypothetically	 allowing	 for	 enhanced	 cisplatin	cytotoxicity.		
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Figure	 3.4.	 Pre-treatment	 with	 400nM	 brusatol	 for	 2	 hours	 significantly	
increases	 the	 sensitivity	 of	 EJ	 cells	 to	 the	 cytotoxic	 effects	 of	 cisplatin.	EJ	cells	were	cultured	either	with	vehicle	or	brusatol	at	5nM	(A),	10nM	(B),	20nM	(C),	50nM	(D),	100nM	(E),	200nM	(F)	and	400nM	(G)	for	2-hours	prior	to	a	48-hour	exposure	to	a	titre	of	cisplatin	concentrations	ranging	from	10nM	to	1mM.	The	 cell	 viability	 was	 then	 determined	 using	 the	 MTT	 assay	 and	 data	 was	normalised	to	control	(brusatol	plus	cisplatin:	vehicle	and	brusatol;	vehicle	plus	cisplatin:	vehicle	only).	(H)	A	comparison	of	cisplatin	IC50	values	in	combination	with	cisplatin	or	vehicle.	Data	shown	is	mean	of	three	independent	experiments.	The	average	IC50	values	are	plotted	with	SD.	Statistical	analysis	was	performed	using	a	one-way	ANOVA		(*p=0.05).		
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Figure	 3.5.	 Pre-treatment	 with	 400nM	 brusatol	 for	 2	 hours	 significantly	
increases	 the	 sensitivity	of	253-J	 cells	 to	 the	 cytotoxic	effects	of	 cisplatin.	253-J	cells	were	cultured	either	with	vehicle	or	brusatol	at	5nM	(A),	10nM	(B),	20nM	(C),	50nM	(D),	100nM	(E),	200nM	(F)	and	400nM	(G)	for	2-hours	prior	to	a	48-hour	 exposure	 to	 a	 titre	 of	 cisplatin	 concentrations	 ranging	 from	 10nM	 to	1mM.	The	cell	viability	was	then	determined	using	the	MTT	assay	and	data	was	normalised	to	control	(brusatol	plus	cisplatin:	vehicle	and	brusatol;	vehicle	plus	cisplatin:	vehicle	only).	(H)	A	comparison	of	cisplatin	IC50	values	in	combination	with	cisplatin	or	vehicle.	Data	shown	is	mean	of	three	independent	experiments.	Statistical	 analysis	 was	 performed	 using	 a	 one-way	 ANOVA.	 The	 average	 IC50	values	are	plotted	with	SD.		(*p=0.05).		
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Figure	3.6.	Pre-treatment	with	brusatol	 for	2	hours	does	not	 significantly	
increases	the	sensitivity	of	MGH-U3	cells	to	the	cytotoxic	effects	of	cisplatin.	MGH-U3	 cells	were	 cultured	 either	with	 vehicle	 or	 brusatol	 at	 5nM	 (A),	 10nM	(B),	20nM	(C),	50nM	(D),	100nM	(E),	200nM	(F)	and	400nM	(G)	for	2-hours	prior	to	a	48-hour	exposure	to	a	titre	of	cisplatin	concentrations	ranging	from	10nM	to	1mM.	The	cell	viability	was	then	determined	using	the	MTT	assay	and	data	was	normalised	to	control	(brusatol	plus	cisplatin:	vehicle	and	brusatol;	vehicle	plus	cisplatin:	vehicle	only).	(H)	A	comparison	of	cisplatin	IC50	values	in	combination	with	cisplatin	or	vehicle.	Data	shown	is	mean	of	three	independent	experiments.	Statistical	 analysis	 was	 performed	 using	 a	 one-way	 ANOVA.	 The	 average	 IC50	values	are	plotted	with	SD.			
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Figure	 3.7.	 Pre-treatment	 with	 concentrations	 at	 100nM	 and	 greater	 of	
brusatol	for	2	hours	significantly	increases	the	sensitivity	of	RT112	cells	to	
the	cytotoxic	effects	of	cisplatin.	RT112	cells	were	cultured	either	with	vehicle	or	brusatol	at	5nM	(A),	10nM	(B),	20nM	(C),	50nM	(D),	100nM	(E),	200nM	(F)	and	 400nM	 (G)	 for	 2-hours	 prior	 to	 a	 48-hour	 exposure	 to	 a	 titre	 of	 cisplatin	concentrations	 ranging	 from	 10nM	 to	 1mM.	 The	 cell	 viability	 was	 then	determined	using	 the	MTT	assay	and	data	was	normalised	 to	control	 (brusatol	plus	 cisplatin:	 vehicle	 and	 brusatol;	 vehicle	 plus	 cisplatin:	 vehicle	 only).	 (H)	 A	comparison	 of	 cisplatin	 IC50	 values	 in	 combination	 with	 cisplatin	 or	 vehicle,	Data	shown	 is	mean	of	 three	 independent	experiments.	Statistical	analysis	was	performed	by	one-way	ANOVA	(***p=<0.001,	*p=0.05).		
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G H
[Brusatol]	
nM		
IC50	[cispla5n]	
(μM)	
IC50	[cispla5n]
+	Brusatol	(μM)	
5	 26.92	±7.19	 30.28	±10.44	
10	 20.20	±4.69	 21.06	±6.54	
20	 28.09	±7.56	 20.27	±6.14	
50	 30.67	±8.3	 16.75	±5.49	
100	 31.21	±9.45	 4.95	±2.44		***	
200	 21.56	±7.48		 3.11	±1.82		*	
400	 19.64	±6.77	 1.11	±0.73		*	
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Figure	 3.8.	 Pre-treatment	 with	 concentrations	 at	 200nM	 of	 brusatol	 and	
higher	for	2	hours	significantly	increases	the	sensitivity	of	RT112-CP	cells	
to	the	cytotoxic	effects	of	cisplatin.	RT112-CP	cells	were	cultured	either	with	vehicle	 or	 brusatol	 at	 5nM	 (A),	 10nM	 (B),	 20nM	 (C),	 50nM	 (D),	 100nM	 (E),	200nM	(F)	and	400nM	(G)	for	2-hours	prior	to	a	48-hour	exposure	to	a	titre	of	cisplatin	concentrations	ranging	from	10nM	to	1mM.	The	cell	viability	was	then	determined	using	 the	MTT	assay	and	data	was	normalised	 to	control	 (brusatol	plus	 cisplatin:	 vehicle	 and	 brusatol;	 vehicle	 plus	 cisplatin:	 vehicle	 only).	 (H)	 A	comparison	 of	 cisplatin	 IC50	 values	 in	 combination	 with	 cisplatin	 or	 vehicle.	Data	shown	 is	mean	of	 three	 independent	experiments.	Statistical	analysis	was	performed	by	one-way	ANOVA	(*p=0.05).			
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nM		
IC50	[cispla5n]	
(μM)	
IC50	[cispla5n]
+	Brusatol	(μM)	
5	 119.3±27.42	 118	±34.07	
10	 134.2	±42.99	 96.41	±19.28	
20	 131.9	±40.75	 127.5	±30.45	
50	 155.3	±64.95	 111.2	±44.4	
100	 131.8	±41.9	 33.71	±10.04	
200	 109.1	±21.87	 15.76	±5.91		*	
400	 95.83	±22.91	 3.50	±3.39		*	
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3.2.5	Optimisation	of	brusatol	concentration	and	pre-treatment	time	prior	
to	cisplatin	addition		
	
3.2.5.1	Optimisation	of	NRF2	antibodies	for	western	blot			In	 order	 to	 optimise	 a	 time-point	 where	 NRF2	 regulated	 proteins	 are	 at	 their	lowest	levels	post-brusatol	exposure,	three	antibodies	against	NRF2	were	tested	(Fig	 3.9):	 ProteinTech	 16396-1-AP	 (PT);	 Santa	 Cruz	 H300	 (H300);	 MBL	 life	sciences	M200	(M200).	An	antibody	raised	against	HO-1,	a	protein	regulated	by	NRF2,	 was	 tested	 [288].	 HO-1	 is	 documented	 as	 being	 sensitive	 to	 changes	 in	NRF2	 levels,	 however	 it	 is	 reported	 as	 highly	 overexpressed	 in	 some	 BCs	therefore	there	was	benefit	in	checking	its	status	within	this	cell	line	panel	[135,	289-291].	The	cell	line	panel	consists	of	two	MIBC	cell	lines	(EJ,	253-J)	and	two	NMIBC	cell	lines	(MGH-U3	and	RT112),	under	basal	conditions	and	treated	for	2-hours	with	 CDDO-Me,	 a	 pharmacological	 inducer	 of	 NRF2	 accumulation.	 Upon	comparison	of	PT,	H300,	and	M200	anti-NRF2	antibodies,	PT	was	found	to	detect	NRF2	 the	most	 reliably,	 with	 no	 non-specific	 binding	 at	 75KDa	 as	 noted	with	H300	and	M200,	therefore	PT	will	be	used	henceforth	for	NRF2	Immunoblotting.	The	 cell	 lines	 originating	 from	MIBC	 were	 shown	 to	 have	 marked	 differential	expression	of	HO-1	when	compared	to	NMIBC	cell	lines	furthermore,	no	change	in	HO-1	levels	was	observed	following	stimulation	with	CDDO-Me,	making	HO-1	a	poor	choice	as	a	downstream	marker	of	NRF2	activity	in	this	panel	of	cell	lines.	Therefore	 another	 protein	 regulated	 by	 NRF2,	 NQO1,	 was	 tested	 as	 a	documented	sensitive	marker	of	NRF2	activity	[292].												
	 106	
								
	
Figure	3.9.	Comparison	of	NRF2	targeting	antibodies,	and	evaluation	of	HO-
1	as	a	downstream	marker	of	NRF2	activity	by	western	blot.	PT:	ProteinTech	anti-NRF2	 rabbit	 polyclonal	 16396-1-AP,	 H300:	 Santa	 Cruz	 anti-NRF2	 rabbit	polyclonal	 sc-13032,	 M200:	 MBL	 life	 science	 anti-NRF2	 mouse	 monoclonal.	 -	Basal,	+	2-hour	treatment	with	100nM	CDDO-Me.	Data	is	representative	of	three	independent	experiments.												
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3.2.5.2	Determination	of		basal	NRF2,	KEAP1	and	NQO1	levels	in	the	5	UCC	
cell	line	panel		The	 relative	 basal	 expression	 of	 NRF2,	 its	 regulating	 partner	 KEAP1	 and	downstream	protein	NQO1	were	determined	by	western	blot	 (Fig	3.10).	There	was	no	significant	difference	in	NRF2	levels	between	MIBC	and	NMIBC	cell	lines.	However,	 upon	 comparison	 of	 the	 cisplatin	 naïve	 RT112	 cell	 line	 and	 the	cisplatin	resistant	RT112-CP	cell	line	the	later	expressed	NRF2	at	a	significantly	greater	level	(p=<0.0001).				Interestingly	 there	 was	 an	 inversely	 proportional	 relationship	 between	 the	expression	 of	 NRF2	 in	 RT112	 and	 RT112-CP	 cell	 lines	 and	 	 KEAP1	 levels	(<p=0.01).	The	low	levels	of	KEAP1	in	RT112-CP	cells	may	explain	the	elevated	levels	of	NRF2,	potentially	due	to	epigenetic	silencing	of	KEAP1	[293].			NQO1	levels	correlated	well	with	NRF2	levels	across	the	cell	line	panel.	A	marked	difference	 in	 NQO1	 levels	 was	 observed	 between	 RT112	 and	 RT112-CP	 cells	(p=<0.0001).	 Based	 on	 these	 findings	 NQO1	 was	 used	 as	 a	 marker	 of	 NRF2	activity	henceforth.					
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Figure	3.10.	Differential	levels	of	NRF2,	KEAP1	and	NQO1	in	EJ,	253-J,	MGH-
U3,	 RT112	 and	 RT112-CP	 cells.	 (A)	 Western	 blots	 for	 probing	 for	 NRF2,	KEAP1,	NQO1	and	β-actin.	Mean	NRF2	(B),	KEAP1	(C)	and	NQO1(D)	expression.	A	is	representative	of	three	independent	experiments,	whilst	B,	C,	D	are	mean	of	three	 independent	experiments.	Mean	NRF2,	NQO1	and	KEAP1	expression	was	plotted	 after	 normalisation	 with	 actin	 +	 SD.	 One-way	 ANOVA	 was	 used	 to	compare	the	statistical	significance	between	the	expression	of	NRF2,	NQO1	and	KEAP1	in	RT112	compared	to	RT112-CP	cells	(**<p=0.01	****	p=<0.0001).	253-J	cells	treated	for	2-hours	with	500nM	brusatol	were	used	as	a	negative	control	of	NRF2	expression,	where	as	HCT116	cells	treated	with	10μM	of	the	proteasome	inhibitor	MG132	were	used	as	a	positive	control	for	NRF2	expression.		
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3.2.5.3	Investigation	into	the	concentration-dependent	effects	of	brusatol	on	
NRF2	levels	in	the	5	UCC	cell	line	panel	
	Next	 the	 effect	 of	 increasing	 concentrations	 of	 brusatol	 on	 NRF2	 levels	 was	evaluated	in	the	5	UCC	cell	lines	(Fig	3.11).	Cells	were	treated	for	2	hours	with	a	titre	of	concentrations	ranging	from	5	to	1000nM,	each	normalised	to	a	vehicle	control.			When	 compared	 to	 the	 vehicle	 control,	 EJ	 cells	 (A,	 B)	 displayed	 a	 significant	reduction	in	NRF2	levels	at	concentrations	greater	than	10nM	of	brusatol,	with	a	30%	 decrease	 in	 relative	 NRF2	 levels	 being	 observed	 (p=0.045),	 with	 NRF2	levels	decreasing	further	to	30%	at	50nM	(p=<0.0001).	The	253-J	cell	line	(C,	D)	followed	 a	 similar	 trend	 to	 EJ	 cells,	 however	 253-J	 cells	were	 less	 sensitive	 to	brusatol,	 with	 59%	 relative	 NRF2	 levels	 being	 observed	 at	 50nM	 (p=0.0084).	MGH-U3	 cells	 (E,	 F)	 exhibited	 a	 marked	 reduction	 in	 NRF2	 levels	 at	concentrations	 50nM	 and	 greater,	 where	 a	 77%	 decrease	 in	 the	 relative	expression	 of	 NRF2	was	 noted	 (p=0.0001).	 Although	 NRF2	 levels	 vary	 greatly	between	 RT112	 and	 RT112-CP	 cell	 lines,	 they	 respond	 in	 a	 similar	concentration-dependent	 manner	 to	 each	 other,	 with	 the	 two	 cell	 lines	displaying	 a	 highly	 significant	 (p=<0.0001)	 decrease	 in	 NRF2	 levels	 at	concentrations	of	50nM	and	greater,	where	14%	and	7%	relative	expression	was	noted	in	RT112	and	RT112-CP	cells	respectively.			Based	 on	 these	 data	 where	 all	 UCC	 cell	 lines	 show	 similar	 sensitivity	 to	 the	inhibitory	 effects	 of	 brusatol	 on	 NRF2	 levels,	 the	 similar	 cytotoxic	 effects	 of	cisplatin	 (excepting	 the	 cisplatin	 resistant	 RT112-CP	 cell	 line)	 and	 the	availability	 of	 a	 model	 of	 cisplatin	 resistance	 with	 high	 NRF2	 levels	 and	downstream	 proteins	 levels,	 RT112	 and	 RT112-CP	 cell	 lines	 will	 be	 used	 for	further	 investigation	 into	 the	 potential	 chemo-potentiating	 benefit	 of	 brusatol.	This	 is	 despite	 the	 cell	 lines	originating	 from	NMIBC,	 rather	 than	MIBC,	where	cisplatin	is	a	common	treatment	option.					
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Figure	3.11.	Brusatol	 exposure	 reduces	NRF2	 levels	 in	UCC	 cell	 lines	 in	 a	
concentration	 dependent	 manner.	 	 253-J	 (A,	 B),	 EJ	 (C,	 D),	 MGH-U3	 (E,	 F),	RT112	 (G,	 H)	 and	 RT112-CP	 (I,	 J)	 cell	 lines	 were	 treated	 for	 2-hours	 with	 a	
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titration	of	brusatol	concentrations	ranging	from	5nM	to	1μM,	before	being	lysed	and	 analysed	 via	 western	 blot.	 Dose-response	 data	 was	 expressed	 as	 a	percentage	of	vehicle.	Data	shown	in	B,	D,	F,	H,	J,	and	K	is	representative	of	three	independent	experiments,	whilst	data	shown	in	A,	C,	E,	G	and	I	is	mean	of	three	independent	 experiments,	 plotted	with	 SD.	HCT116	 cells	 treated	with	10μM	of	MG132	were	used	as	a	positive	 control	of	NRF2	expression.	Statistical	analysis	was	 performed	 by	 one-way	 ANOVA	 (****p=<0.0001,	 ***	 p=<0.001,	 **p=<0.01,	*p=<0.05).																
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3.2.5.4	Investigation	into	the	time-dependent	effects	of	brusatol	on	NRF2	and	
NQO1	levels	in	RT112	and	RT112-CP	cells		Theoretically,	for	cells	to	be	maximally	sensitive	to	cisplatin	its	defence	proteins	must	 be	 at	 their	 lowest	 possible	 levels.	 Here	 the	 effect	 of	 50nM	 brusatol	 was	assessed	over	a	48-hour	time-course,	where	its	effect	on	NRF2	and	NQO1	levels	was	investigated	(Fig	3.12).	A	significant	decrease	in	NRF2	levels	was	observed	at	 the	 2-hour	 time	 point	 in	 both	 RT112	 and	 RT112-CP	 cell	 lines	 (p=<0.0001).	Although	a	slight	decrease	in	NQO1	levels	was	observed	at	12	hours	this	change	was	not	significant	(RT122	p=0.49,	RT112-CP	p=0.57).	The	 lack	of	a	significant	change	 in	NQO1	 levels	 cast	 doubt	 over	 the	 sensitivity	 of	NQO1	 as	 a	marker	 of	NRF2	activity	in	these	cell	lines.				
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Figure	3.12.	Brusatol	exposure	decreases	NRF2	levels	in	a	time	dependent	
manner,	although	causes	no	significant	change	in	NQO1	expression	over	48	
hours.	 RT112	 and	 RT112-CP	 cell	 lines	 were	 treated	 with	 50nM	 brusatol	 or	vehicle	and	lysed	at	2,	6,	12,	24	and	48	hours,	prior	to	western	blotting.	RT112	(A)	 and	 RT112-CP	 (B)	 cells	 were	 probed	 for	 NRF2	 (C,	 D),	 and	 NQO1	 (E,	 F)	respectively.	Densitometry	was	used	to	quantify	the	western	blot	data	which	was	
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normalised	 to	 actin	 and	 is	 representative	 of	 three	 independent	 experiments	 +	SD.	 A	 and	 B	 are	 representative	 of	 three	 independent	 experiments.	 Statistical	analysis	was	performed	via	one-way	ANOVA	(****	p=<0.0001,	 ***	p=<0.001,	 **	p=<0.01).		
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3.2.5.5	Investigation	into	the	sensitivity	of	NQO1	as	a	marker	of	NRF2	
activity			Next,	the	sensitivity	of	NQO1	as	a	marker	of	NRF2	activity	was	tested	through	the	comparison	of	NRF2	siRNA	Knockdown	with	a	24-hour	 treatment	with	100nM	brusatol	 (Fig	 3.13).	 A	 24-hour	 time	 point	 was	 chosen	 to	 allow	 for	 potential	downstream	 effects	 of	 brusatol	 mediated	 NRF2	 inhibition	 to	 be	 realised.	Furthermore,	 a	 concentration	 of	 100nM,	 double	 the	 concentration	 used	 in	 the	prior	 experiment,	 was	 selected	 to	 increase	 the	 opportunity	 for	 downstream	consequences	of	NRF2	inhibition	to	occur	–	NQO1	inhibition	has	been	previously	noted	at	a	concentration	of	80nM	brusatol,	although	in	A549	cells	[172].		NRF2	 siRNA	 significantly	 inhibited	 NRF2	 levels	 (p=0.0003),	 whilst	 no	 change	was	observed	in	NRF2	levels	following	a	24-hour	treatment	of	100nM	brusatol,	in	 agreement	 with	 the	 previous	 time	 course	 experiment.	 Furthermore,	 no	significant	 change	 in	 NQO1	 levels	 was	 noted	 after	 a	 24-hour	 exposure	 with	100nM	brusatol,	 however,	 a	 significant	 decrease	 in	NQO1	 levels	was	 observed	when	comparing	control	 siRNA	and	NRF2	siRNA	 treatments	 (RT112	p=0.0101,	RT112-CP	p=0.0003).		
	These	data	confirm	NQO1	as	a	sensitive	marker	of	NRF2	pathway	 inhibition	 in	RT112-CP	 cells.	 However,	 due	 to	 the	 72-hour	 time	 period	 needed	 to	 induce	sufficient	 NRF2	 knockdown	 in	 these	 cells,	 it	 was	 not	 possible	 to	 compare	 the	effects	of	NRF2	siRNA	and	brusatol	at	a	common	time	point.			
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Figure	 3.13.	 NQO1	 is	 sensitive	 to	 NRF2	 depletion	 by	 siRNA	 knockdown,	
although	brusatol	 does	not	 significantly	 alter	NQO1	 levels.	 RT112-CP	 cells	were	treated	with	NRF2	targeting	siRNA,	or	brusatol	for	24-hours,	the	effect	on	relative	levels	of	NRF2	was	examined	(A,	C),	as	was	the	effect	of	these	treatments	on	 NQO1	 levels	 (B,	 C).	 A	 is	 representative	 of	 three	 independent	 experiments.	NRF2	 and	 NQO1	 (B,	 C)	 western	 blotting	 data	 analysed	 by	 densitometry	normalised	to	β-actin	and	is	mean	of	three	independent	experiments.	Statistical	analysis	 was	 performed	 using	 a	 one-way	 ANOVA	 (***p=<0.001,	 **p=<0.01,	*p=<0.05).						
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3.2.6	Brusatol	as	an	inhibitor	of	protein	synthesis		
	
3.2.6.1	Comparison	of	the	effects	of	brusatol	and	CHX	on	NRF2	levels	in	
RT112-CP	cells		With	 brusatol	 not	 causing	 any	 significant	 effects	 downstream	 of	 NRF2	 and	reports	of	brusatol	potentially	acting	as	an	inhibitor	of	protein	synthesis,	rather	than	a	specific	inhibitor	of	NRF2,	it	is	possible	that	NRF2	levels	are	reduced	as	a	consequence	of	the	short	half-life	of	NRF2	and	the	inhibition	of	de	novo	synthesis	of	NRF2	by	brusatol	[294].				To	 determine	 whether	 concurrent	 results	 are	 observed	 in	 a	 UCC	 cell	 lines	 as	stated	 in	 recent	 literature	 implicating	 brusatol	 as	 a	 global	 inhibitor	 of	 protein	synthesis	where	A549	cells	have	been	studied.	The	effect	of	the	protein	synthesis	inhibitor	 CHX	 was	 compared	 to	 brusatol	 in	 terms	 of	 NRF2	 inhibition,	 here	RT112-CP	cells	were	subject	to	a	2-hour	exposure	of	50nM	brusatol	and	5μg/ml	CHX,	 both	 concentrations	 being	 used	 by	 Vartanian	 et	 al	 	 (Fig	 3.14)	 [294].	 A	marked	significant	decrease	in	relative	NRF2	levels	was	noted	with	both	agents	(Brusatol	p=0.0001,	CHX	p=<0.0001)	(Fig	3.14).			The	similar	 levels	of	NRF2	 inhibition,	within	 the	same	time-point,	by	both	CHX	and	 brusatol	 are	 concurrent	 with	 recent	 literature	 implicating	 brusatol	 in	inhibition	of	protein	synthesis.												
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Figure	3.14.	Exposure	to	Brusatol	and	CHX	reduces	NRF2	levels	in	RT112-
CP	 cells.	RT112	 cells	 were	 dosed	 with	 either	 50nM	 brusatol,	 5μg/ml	 CHX	 or	vehicle	 for	 2-hours	 before	 being	 lysed	 and	 having	 the	 expression	 of	 NRF2	analysed	by	western	immunoblot.	Densitometry	was	used	to	quantify	blots,	with	NRF2	 expression	 being	 normalised	 to	 actin.	 Data	 is	 representative	 of	 three	
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separate	 experiments	 +	 SD.	 Statistical	 analysis	 was	 performed	 by	 one-way	ANOVA.	(***p=<0.001).																																													
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3.2.6.2	Brusatol	inhibits	growth	of	RT112	and	RT112-CP	cell	lines.			Due	 to	 time	 limitations	 only	 one	 further	 parameter	 was	 investigated,	 firstly	RT112	 and	 RT112-CP	 cells	 were	 dosed	 with	 either	 50nM	 brusatol	 and	photographed	 at	 regular	 intervals	 for	 48-hours	 (Fig	 3.15).	 Here	 inhibition	 in	growth	 was	 visible	 in	 brusatol	 treated	 cells,	 when	 compared	 to	 the	 vehicle	control.	This	effect	was	most	apparent	at	the	24-	and	48-hour	time	points	where	the	brusatol	 treated	 cells	 are	80%	 (RT112)	 and	90%	 (RT112-CP)	 confluent,	 in	comparison	to	the	cells	in	the	vehicle	control	which	were	growing	on	top	of	the	confluent	monolayer.			These	 data	 support	 findings	 by	 Vartanian	 et	 al.	 However,	 with	 NRF2	 being	implicated	 in	 cell	 growth	 and	 proliferation	 in	 cancers,	 a	 reduction	 in	proliferation	would	be	anticipated	with	a	specific	inhibitor	of	NRF2	activity.																					
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Figure	3.15.	Brusatol	slows	the	growth	of	RT112	and	RT112-CP	cells.	RT112	(A)	and	RT112-CP	(B)	cells	were	treated	with	50nM	brusatol	or	vehicle	(DMSO)	and	imaged	at	0-hours,	2-hours,	6-hours,	12-hours,	24-hours	and	48-hours.	Data	is	representative	of	three	separate	experiments.							
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3.3	Discussion	
	In	recent	years,	there	has	been	an	increasingly	large	interest	in	the	role	of	NRF2	in	cancer.	Studies	have	implicated	NRF2	in	many	cancers	including	those	of	the	bladder,	pancreas,	stomach	and	skin	[129,	133].	And	whilst	siRNA	knockdown	of	NRF2	 in	 RT112-CP	 cells	 has	 been	 previously	 shown	 to	 partially	 restore	 their	sensitivity	 to	 cisplatin,	 a	 specific	 pharmacological	NRF2	 inhibitor	 has	not	 been	tested	as	a	method	of	chemopotentiation	in	BC	[134].			In	this	chapter	brusatol,	a	compound	originating	from	the	South	East	Asian	plant	
Brucea	Javanica,	has	been	investigated.	Brusatol	has	been	shown	in	a	number	of	instances	to	cause	potent,	specific	inhibition	of	NRF2	[172,	174].			The	primary	aim	of	this	study	was	to	define	the	response	to	brusatol	in	terms	of	sensitivity	 to	 the	 cytotoxic	 effects	 of	 cisplatin.	 A	 key	 secondary	 aim	 was	 to	determine	the	response	to	brusatol	in	terms	of	cell	viability,	and	NRF2	levels,	to	allow	optimisation	of	a	time	point	where	cisplatin	would	be	subject	to	minimal	efflux	or	catabolism,	theoretically	maximising	potentiation	of	its	cytotoxic	effects.	It	 was	 found	 that	 brusatol	 inhibited	 NRF2	 levels	 in	 a	 time	 and	 concentration	dependent	manner,	with	50nM	being	sufficient	for	marked	NRF2	inhibition	in	all	UCC	cell	lines,	with	maximal	effects	at	2-hours,	returning	to	baseline	by	6-hours.	These	 data	 are	 in	 line	 with	 observations	 by	 Olayanju	 et	 al,	 where	 a	 marked	decrease	in	relative	levels	of	NRF2	was	reported	at	concentrations	greater	than	30nM	in	the	mouse	hepatoma	cell	line	Hepa-1c1c7	[174].	The	transient	nature	of	NRF2	inhibition	in	vitro	was	also	demonstrated	in	the	same	cell	line,	although	the	aforementioned	work	used	a	larger	range	of	time	points	between	0-	and	8-hours,	demonstrating	 marked	 inhibition	 of	 NRF2	 from	 30-minutes,	 with	 replenished	NRF2	levels	being	noted	after	8	hour	[174].			The	low	duration	of	brusatol	induced	NRF2	inhibition	is	attractive	in	the	setting	of	BC	as	many	patients	who	present	with	BC	also	have	co-morbidities	including	kidney	damage.	With	NRF2	being	one	of	 the	chief	 cell	defence	pathways	 in	 the	kidneys	 sustained	 NRF2	 inhibition	 after	 systemic	 brusatol	 treatment	 with	
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nephrotoxic	cisplatin	based	chemotherapy	may	lead	to	increased	kidney	damage	[295].	Although,	Ren	et	al	have	demonstrated	sustained	reduction	of	NRF2	levels	by	brusatol	in	vivo,	with	intratumoural	NRF2	suppression	being	noted	up	to	48-huors	post	treatment	 in	an	A549	murine	xenograft	model	[172].	Unfortunately,	no	 studies	 to	 date	 have	 analysed	 the	 systemic	 consequences	 of	 brusatol	treatment	in	vivo.			In	 the	 BC	 cell	 lines	 used	 in	 this	 thesis	 it	 was	 essential	 to	 determine	 whether	brusatol	 induced	 disruptions	 in	 NRF2	 signalling	 were	 translated	 into	 reduced	levels	 of	 detoxification	 proteins	 with	 an	 ARE	 in	 their	 promoter	 region.	 Thus,	NQO1	 levels	were	evaluated	over	48-hours	 in	response	 to	50nM	brusatol,	with	no	significant	change	being	observed.	This	cast	doubt	over	the	utility	of	NQO1	as	a	marker	of	NRF2	activity,	as	a	result	siRNA	knockdown	was	performed	to	test	the	worth	of	NQO1	as	a	marker	of	NRF2	activity.	This	was	tested	alongside	a	24-hour	 treatment	with	100nM	brusatol,	 in	 contrast	 to	 the	significant	 response	 to	NRF2	siRNA,	brusatol	caused	no	change	in	NQO1	levels.			Recently	 a	 vast	 proteomic	 analysis	 undertaken	 by	 Vartanian	et	al	has	 revealed	that	 brusatol	may	 not	 function	 as	 a	 specific	 inhibitor	 of	 NRF2,	 but	 as	 a	 global	inhibitor	 of	 protein	 synthesis	 [294].	 The	 reasoning	 for	 the	 rapid	 inhibition	 of	NRF2	protein	expression	being	due	to	the	short	half-life	of	the	NRF2	protein,	and	the	inhibition	of	protein	synthesis	machinery	essential	for	the	synthesis	of	NRF2	[294].	Vartanian	et	al	 reached	 this	 conclusion	 through	analysis	of	 the	effects	of	brusatol	 on	 the	 proteome	 of	 the	A549	 non-small	 cell	 lung	 cancer	 (NSCLC)	 cell	line.	They	demonstrated	 the	most	dramatically	decreased	proteins	being	 those	with	 short	 half-lives,	 and	 in	 fact	 the	 only	 proteins	 to	 be	 upregulated	 were	multiple	 components	 of	 the	 ribosome,	 suggesting	 a	 role	 in	 the	 regulation	 of	protein	 synthesis	 [294].	 Furthermore,	 their	 findings	 were	 compared	 with	marked	parity	to	the	well-used	protein	synthesis	inhibitor,	CHX.			With	no	significant	change	in	NQO1	levels	in	response	to	brusatol	treatment,	and	gaining	 insight	on	brusatol	 from	Vartanian	et	al,	where	 they	had	demonstrated	that	CHX	leads	to	similar	potent	inhibition	of	NRF2.	It	was	then	sought	to	draw	
	 125	
parallels	between	brusatol	activity	in	NSCLC	and	UCC	cell	lines,	thus	the	effect	of	CHX	 on	 NRF2	 levels	 was	 compared	 with	 the	 effect	 of	 brusatol.	 A	 highly	significant	 decrease	 in	 NRF2	 levels	 was	 observed	 with	 both	 treatments.	Indicating	 that	 inhibition	of	protein	synthesis	by	CHX	causes	a	similar	effect	 to	brusatol	in	terms	of	relative	NRF2	protein	expression.			Throughout	the	process	of	mitosis,	the	protein	synthesis	machinery	is	essential	for	successful	proliferation,	therefore	the	effects	of	brusatol	on	cell	growth	were	analysed.	 RT112	 and	 RT112-CP	 cells	 were	 treated	 with	 brusatol,	 and	photographed	 for	 48-hours.	 At	 the	 24-hour	 and	 48-hour	 time	 points,	 the	difference	 in	 cell	 growth	 is	 very	 noticeable,	 with	 vehicle	 treated	 cells	 being	crowded,	and	growing	above	the	monolayer,	whilst	brusatol	treated	cells	had	yet	to	 reach	 confluence.	 This	 qualitative	 data	 demonstrates	 that	 cell	 growth	 is	partially	 inhibited	 in	 UCC	 cells,	 possibly	 due	 to	 inhibited	 protein	 synthesis.	Although,	NRF2	has	been	 implicated	 in	 cell	 growth	 and	proliferation	 in	 cancer	[296].			Vartanian	et	al	demonstrated	a	relationship	between	the	doubling	time	of	a	cell	line,	 and	 its	 susceptibility	 to	 the	 cytotoxic	 effects	 of	 brusatol	 –	 a	 trait	which	 is	supportive	 of	 the	 protein	 synthesis	 inhibitor	 hypothesis	 as	 cells	 which	 are	dividing	at	a	faster	rate	are	more	likely	to	have	an	increased	dependency	on	the	protein	synthesis	machinery.			To	 determine	 whether	 the	 relationship	 between	 sensitivity	 to	 the	 cytotoxic	effects	 of	 brusatol	 and	 cell	 doubling	 time	 were	 similar	 when	 the	 work	 of	
Vartanian	et	al	was	comparable	to	the	data	in	this	thesis,	published	average	cell	doubling	 times	were	 compared	 to	 the	mean	brusatol	 IC50s	 determined	 in	 this	chapter.	 It	was	hypothesised	that	brusatol	will	exert	 increased	cytotoxic	effects	on	 the	 fastest	 dividing	 cells,	 possibly	 due	 to	 the	 increased	 demand	 put	 on	 the	hypothetically	 non-functional	 protein	 synthesis	 machinery.	 Near-significant	(p=0.0793)	positive	linear	correlation	(Pearson	r	=	0.8338),	as	some	correlation	can	be	observed	this	may	become	a	significant	correlation	if	a	larger	panel	of	cell	lines	was	utilised	(Fig	3.16).		
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Figure	3.16.	Correlation	between	cell	doubling	time	and	brusatol	IC50	in	EJ,	
253-J,	 MGH-U3,	 RT112	 and	 RT112-CP.	 Average	 brusatol	 IC50	 values	 were	compared	to	published	mean	cell	doubling	times	for	each	cell	line.	The	data	was	subject	 to	 two-tailed	 Pearson’s	 correlation	 analysis	 (Pearsons	 r	 0.8338,	p=0.0793).			Collectively	 the	 data	 questioning	 the	 specificity	 of	 brusatol	 do	 not	 definitively	prove	that	brusatol	 is	an	 inhibitor	of	protein	synthesis,	however,	 these	data	do	for	 the	most	 part	 correspond	with	what	 has	 been	observed	by	Vartanian	et	al,	and	offer	a	potential	explanation	for	brusatol	inability	to	inhibit	NQO1,	as	NQO1	has	 a	 half-life	 of	 18-hours	 compared	 to	 just	 15-minutes	 for	 NRF2	 [297,	 298].	Additionally,	 these	 data	 may	 explain	 why	 no	 significant	 effect	 in	 terms	 of	cisplatin	potentiation	is	noted	at	50nM	of	brusatol,	a	concentration	that	leads	to	drastic	 inhibition	of	NRF2	 levels.	Moreover,	 it	might	be	 expected	 that	with	 the	RT112-CP	cell	 line	expressing	NRF2	at	 a	 considerably	higher	 level	 than	RT112	cells	that	the	sensitivity	to	the	combined	effects	of	brusatol	and	cisplatin	may	be	higher,	 especially	 considering	 the	 comparable	 efficiency	 of	 brusatol	 mediated	NRF2	depletion	in	both	cell	lines,	although	the	converse	it	true.		Interestingly	brusatol	did	not	 inhibit	proteins	downstream	of	NRF2	however	 it	did	significantly	increase	the	sensitivity	of	UCC	cell	lines	to	the	cytotoxic	effects	of	 cisplatin.	 Although,	 at	 concentrations	 where	 brusatol	 addition	 is	 most	
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beneficial,	brusatol	 is	highly	cytotoxic.	 In	comparison	to	cisplatin	brusatol	 is	an	order	of	magnitude	more	potently	cytotoxic	to	UCC	cells.	So	rather	than	brusatol	acting	 synergistically	with	 cisplatin,	 the	 observed	 effects	 are	more	 likely	 to	 be	additive	 cytotoxic	 effects.	 Although,	 further	 analysis	 would	 be	 required	 to	determine	this	relationship.				CHX	does	not	have	therapeutic	benefits	due	to	its	toxic	side	effects	including	DNA	damage,	 teratogenesis,	 and	 other	 reproductive	 effects	 including	 sperm	 toxicity	[299].	However,	whilst	brusatol	may	not	be	a	specific	 inhibitor	of	NRF2,	 it	may	have	 some	 therapeutic	benefit	 in	 the	 setting	of	BC.	The	early	 research	 into	 the	therapeutic	benefit	of	silvestrol,	a	compound	 isolated	 from	the	Aglaia	foveolata	plant,	 with	 potent	 cytotoxic	 effects	 is	 promising,	 demonstrating	 potential	usefulness	of	 translational	 inhibitors	 in	the	treatment	of	cancer	[300].	Parallels	may	 be	 drawn	 between	 brusatol	 and	 silvestrol	 in	 that	 they	 both	 show	 some	effect	 when	 combined	 with	 therapeutic	 agents,	 with	 cisplatin	 being	 shown	 to	combine	well	with	brusatol	both	 in	 this	 thesis	and	 in	work	by	Ren	et	al,	whilst	silvestrol	has	a	synergistic	effect	with	cisplatin	in	nasopharyngeal	carcinoma	cell	lines	[301].	Furthermore,	both	agents	also	have	potent	growth	inhibitory	effects	in	the	Nanomolar	range.			The	 therapeutic	 potential	 of	 the	 translation	 inhibitor	 silvestrol	 has	 been	evaluated	 in	 a	 number	 of	 cancer	 models	 including:	 hepatocellular	 carcinoma	(HCC)	 where	 silvestrol	 potently	 inhibited	 growth	 of	 HCC	 cell	 lines,	 mouse	xenograft	models	 showed	similar	potency	with	 increased	survival	noted,	and	a	synergistic	relationship	with	other	therapeutic	agents	sorafenib	and	rapamycin	[302];	chronic	lymphocytic	leukaemia	(CLL)	and	acute	lymphoblastic	leukaemia	(ALL)	where	a	significant	increase	in	efficacy	was	noted	in	vitro	whilst	in	vivo	an	increase	 in	 survival	 without	 discernible	 off	 target	 toxicity	 was	 noted	 in	 a	xenograft	mouse	model	[303].			In	 conclusion,	 brusatol	 is	 a	 potent	 inhibitor	 of	 UCC	 cell	 growth,	 and	 in	combination	 with	 cisplatin	 at	 concentrations	 above	 100nM	 in	 RT112	 cells,	200nM	in	RT112-CP	cells	and	400nM	for	EJ	and	253-J	cells	significantly	inhibits	
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cell	growth	more	than	either	agent	alone.	However,	it	is	likely	that	brusatol	is	not	a	specific	inhibitor	of	NRF2.			Further	investigation	beyond	this	must	investigate	the	effect	that	brusatol	has	on	normal	urothelial	cells,	BC	xenograft	models	and	on	murine	health,	considering	liver	 function,	 cardiac	 function,	 renal	 function,	 and	 neurological	 function	 at	 a	broad	range	of	concentrations	and	durations	to	determine	whether	brusatol	is	a	suitable	candidate	 for	human	 trials.	 	With	cancer	cells	being	 fast	dividing	cells,	highly	 reliant	on	protein	synthesis	machinery,	 there	 is	a	good	rationale	 for	 the	usage	of	well	tolerated	inhibitors	of	protein	synthesis.	However,	effects	on	high-turnover	 normal	 tissue	 in	 the	 human	 body	 may	 lead	 to	 side	 effects	 including	myleosuppression,	 and	 neutropenia.	 Furthermore,	 sustained	 inhibition	 of	proteins	 involved	 in	 cellular	 detoxification,	 and	DNA	 repair	may	 leave	 healthy	tissue	 vulnerable	 when	 used	 in	 combination	 with	 cytotoxic	 chemotherapy	agents.		
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4.1	Introduction		
	CD40-ligation	 has	 a	multifaceted	 role	 in	 human	 physiology	 having	 a	 profound	effect	on	a	plethora	of	cells	throughout	the	body.	However,	the	effects	of	CD40L-binding	are	highly	context	dependent.			In	cells	of	the	immune	system	CD40-ligation	leads	to	activation	and	maturation	of	dendritic	cells	from	immature	peripheral	blood	monocytes	(PBMCs),	whereas	in	 the	 context	 of	 BC,	 CD40-ligation	 has	 been	 linked	 to	 tumour	 cell	 death.	 The	downstream	 effects	 of	 CD40-ligation	 are	 mediated	 by	 a	 group	 of	 adaptor	proteins	named	TRAFs.			In	 BC,	 CD40	 expression	 is	 associated	 predominantly	 with	 NMIBCs,	 however	 a	large	 proportion	 of	 MIBCs	 also	 express	 CD40.	 This	 contrasts	 with	 normal	urothelium,	which	is	predominantly	CD40-negative.	It	is	hypothesised	that	CD40	expression	 is	 central	 to	 the	 excellent	 response	 to	 BCG	 intravesical	 therapy	 in	NMIBC	patients.			The	inability	to	control	metastasis	is	the	leading	cause	of	death	in	patients	with	cancer,	 therefore,	 this	chapter	aims	to	determine	whether	CD40-ligation	affects	the	invasive	nature	of	BC	cells,	in	an	organotypic	three-dimensional	model	of	BC.	The	behaviour	of	two	CD40-positive	cell	lines,	RT112	and	EJ,	will	be	investigated	in	 this	 model,	 originating	 from	 a	 papillary	 NMIBC	 and	 a	 MIBC,	 respectively.	These	 cell	 lines	 were	 chosen	 as	 they	 will	 allow	 insight	 into	 whether	 CD40-ligation	 can	 increase	 the	 invasiveness	 of	 cells,	 or	 decrease	 the	 invasiveness.	Furthermore,	RNA-microarray	data	was	cross-referenced	to	determine	whether	any	 genes	 involved	 invasion	 are	 differentially	 expressed	 as	 a	 result	 of	 CD40-ligation.		
	The	non-cleavable	mCD40L	construct,	delivered	by	an	adenoviral	vector,	used	in	this	 chapter	 is	 described	 in	 detail	 in	 the	 referenced	 work	 [180].	 Briefly,	 a	replication-deficient	 E1,	 E3	 deleted	 recombinant	 adenovirus	 was	 utilised	 to	express	either	AdNclCD40L,	or	GFP	control	(AdMock)	(Fig	4.1).		
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Figure	 4.1.	 Diagram	 of	 homologous	 recombination,	 and	 adenovirus	
packaging	in	HEK293	cells.	Three	steps	are	involved:	1)	Generation	of	the	gene	
Or
i
Pac	I	
Pac	I	
Pac	I	
LITR RITRES Promoter NclCD40L poly	A Adenoviral	DNA
Digest	with	Pac	I	
Transfect	HEK293	cells
Virus	production	
in	HEK293	cells
Homologous	
Recombination	
in	Bacteria
Shuttle	Vector
Vector	Backbone
	 132	
expressing	 construct;	 2)	 Constructing	 the	 adenovirus	 expressing	 the	 gene	 of	interest;	3)	Production	of	the	virus	in	mammalian	cells.																																
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4.1.1	Chapter	aims			
• To	determine	whether	CD40-ligation	influences	urothelial	cell	carcinoma	cell	invasion	in	a	three-dimensional	model	of	BC.		
• To	 understand	 more	 about	 the	 mechanisms	 behind	 CD40-ligation	dependent	modulation	of	tumour	cell	invasion.		
	
Hypothesis:	 CD40-ligation	 will	 modulate	 UCC	 cell	 invasion	 in	 an	 organotypic	model	of	BC.	
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4.2	Results	
	
4.2.1	UCC	cells	differentially	express	CD40	
	To	select	cell	lines	appropriate	for	further	analysis	the	relative	basal	expression	of	 CD40	 was	 assessed	 by	 western	 immunoblot	 in	 EJ,	 253-J,	 and	 RT112	 cell	lysates	 (Fig	 4.2).	 All	 cell	 lines	 expressed	 CD40;	with	 EJ	 expressing	 the	 highest	levels	and	RT112	cells	expressing	the	lowest	levels.			EJ	and	RT112	cells	were	selected	for	further	analysis,	as	both	are	CD40-positive,	with	 EJ	 cells	 originating	 from	 a	 ≥T3G3	 (MIBC)	 tumour	 whilst	 RT112	 cells	originate	from	a	≤T1	G1	(NMIBC)	lesion..	This	model	allows	comparison	between	the	two	disease	states,	and	insight	into	whether	CD40-ligation	is	a	pro-	or	anti-tumour	invasion	event	in	UCC.																					
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Figure	 4.2.	 UCC	 cells	 express	 CD40	 in	 a	 differential	manner.	50µg	 of	 total	protein	 lysates	of	EJ,	253J	and	RT112	were	analysed	by	western	blot	 for	CD40	expression	and	β-actin	as	a	loading	control.	(n=1).								
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4.2.2	EJ	transfection	with	AdNclCD40L		The	effect	of	CD40-ligation	on	BC	invasion	was	studied	in	an	organotypic	model	of	BC.	Initially,	EJ	cells	were	infected	with	either	AdNclCD40L	or	AdMock	virus	at	a	 low	 MOI	 (1MOI),	 to	 avoid	 a	 profound	 apoptotic	 induction	 and	 a	 saturated	response).	CD40L	expression	was	confirmed	by	western	blotting	24-hours	post-infection	(Fig	4.3),	where	CD40L	expression	was	detected	in	AdNclCD40L	but	not	AdMock-transfected	 cells.	 Furthermore,	 no	 significant	 difference	 in	 cell	morphology	between	each	condition	was	detected.																										
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Figure	 4.3.	 Infection	 with	 1	 MOI	 AdNclCD40L	 initiates	 CD40L	 protein	
expression	 in	UCC	cells.	EJ	 cells	were	 infected	with	1	MOI	AdNclCD40L	or	
AdMock.	 Protein	 lysates	 were	 then	 prepared	 and	 analysed	 by	 western	immunoblot.	 β-actin	 was	 used	 to	 demonstrate	 even	 protein	 loading.	 Data	 is	representative	of	three	independent	experiments.					
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4.2.3	CD40-ligation	attenuates	tumour	cell	invasion	in	an	organotypic	
model	of	bladder	cancer		
	The	 effect	 of	 CD40-ligation	 on	 tumour	 cell	 invasion	 was	 assessed	 in	 an	organotypic	model	of	BC	(Fig	4.4).		Here,	EJ	and	RT112	cells	infected	with	1	MOI	AdNclCD40L	were	compared	to	AdMock	and	basal	controls.	Cells	were	 infected	overnight,	before	being	applied	to	a	pseudostroma	consisting	of	HFFs,	collagen,	and	matrigel,	 then	being	 raised	up	onto	a	 stainless-steel	platform.	This	mimics	the	 interface	 between	 the	 internal	 environment	 of	 the	 bladder	 and	 bladder	tumour	 noted	 in	 vivo,	 furthermore,	 the	 media	 beneath	 is	 representative	 of	underlying	 vasculature	 offering	 a	 supply	 of	 oxygen,	 moisture	 and	 nutrition.	Organotypic	 models	 were	 formalin	 fixed	 and	 paraffin	 embedded	 after	 two	weeks,	before	sectioning	and	H&E	staining	for	microscopic	observation.			Under	basal	conditions	the	EJ	cell	line	invaded	the	stroma	extensively,	as	single	cells,	 and	 occasionally	 in	 small	 groups	 (Fig	 4.4,	 4.5,	 4.7).	 Some	 cellular	accumulation	had	occurred	above	the	stroma,	1	cell	thick	under	basal	conditions	and	2	cells	thick	when	infected	with	AdMock,	however	most	cells	display	marked	invasiveness.	 Interestingly,	 invasiveness	 was	 attenuated	 partially	 by	 infection	with	 AdMock.	 This	 contrasts	 with	 the	 behaviour	 of	 RT112	 cells	 (Fig	 4.4,	 4.6),	where	under	basal	 conditions	no	 invasiveness	was	demonstrated,	 furthermore	cellular	accumulation	occurred	above	the	matrix,	at	6	cells	thick	in	some	regions.	The	 morphology	 of	 RT112	 cell	 accumulation	 in	 this	 model	 is	 like	 papillary	lesions	in	vivo.												
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Figure	 4.4.	 Comparison	 of	 basal	 RT112	 (A)	 and	 EJ	 (B)	 cell	 growth	
characteristics	 in	 a	 three-dimensional	 organotypic	 model	 of	 bladder	
cancer.	 Black	 arrows	 indicate	 a	 defined	 tumour-stroma	 boarder	 (A),	 and	invading	tumour	cells	(B).	Data	is	representative	of	3	independent	experiments.		
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The	effects	of	CD40-ligation	on	both	EJ	(Fig	4.4,	4.5,	4.7)	and	RT112	(Fig	4.4,	4.6)	cell	 growth	 were	 very	 evident.	 In	 RT112	 cells,	 marked	 cell	 death	 occurred,	making	 it	 impossible	 to	 discern	 between	 the	 no	 UCC	 control	 sample	 and	 the	AdNclCD40L	 condition,	 whereas	 there	 was	 little	 difference	 in	 morphology	between	 either	 AdMock	 infected	 or	 uninfected	 RT112	 cells.	Marked	 cell	 death	was	 also	 observed	 in	 EJ	 cells,	 along	 with	 attenuated	 invasion,	 however	 a	population	 of	 cells	 survived	 both	 above	 the	 stroma,	 and	 a	 small	 number	 also	invaded.	 There	was	 significant	 disparity	 between	 AdMock	 control	 and	 EJ	 cells	under	 basal	 conditions,	 highlighting	 the	 growth-inhibitory	 effects	 of	 the	adenoviral	vector	alone.			As	 the	 adenoviral	 vector	 is	 conditionally	 replicating,	 it	 was	 hypothesised	 that	cells	 invading	 the	 stroma	 may	 be	 those	 that	 have	 replicated	 and	 no	 longer	express	CD40L,	furthermore,	as	a	low	MOI	used,	it	is	possible	a	number	of	cells	escaped	sufficient	CD40-ligation.	To	determine	whether	there	was	a	difference	in	CD40L	 expression	 in	 invading	 cells	 when	 compared	 to	 non-invading	 cells,	AdNclCD40L	infected	sections	will	be	stained	by	IHC	probing	for	CD40L.									
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Figure	 4.5.	 H&E	 stained	 cross	 sections	 of	 EJ	 cell	 three-dimensional	
organotypic	 invasion	 assays.	A)	 collagen/fibroblast/matrigel	 matrix	 only,	 B)	basal,	C)	AdMock,	D)	AdNclCD40L.	Data	 is	 representative	of	 three	 independent	experiments.		
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Figure	 4.6.	 H&E	 stained	 cross	 sections	 of	 RT112	 cell	 three-dimensional	
organotypic	 invasion	 assays.	A)	 collagen/fibroblast/matrigel	 matrix	 only,	 B)	basal,	C)	AdMock,	D)	AdNclCD40L.	Data	 is	 representative	of	 three	 independent	experiments.		
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Figure	 4.7.	 CD40-ligation	 limits	 EJ	 cell	 invasion	 and	 leads	 to	marked	 cell	
death	 in	 an	 organotypic	model	 of	 bladder	 cancer.	A)	 Basal,	 B)	 AdMock,	 C)	AdNclCD40L,	D)	Average	 invasion	depth.	A,	B	 and	C	 are	 representative	 images	from	 three	 independent	 experiments.	 Statistical	 analysis	 performed	using	one-way	ANOVA	(p<0.0001).	Data	is	representative	of	three	separate	experiments.		
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With	some	tumour	cells	still	invading	into	the	stroma	under	AdNclCD40L	treated	conditions,	 staining	 will	 be	 undertaken	 to	 determine	 whether	 these	 cells	 are	CD40L-null.	 If	 invading	 cells	 were	 null,	 whilst	 non-invading	 cells	 were	AdNclCD40L	positive,	this	would	further	suggest	a	role	for	CD40-ligation	in	the	attenuation	of	tumour	invasion.																									
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4.2.3.1	CD40L	immunostaining			To	determine	whether	invading	cells	were	CD40L-null,	whilst	non-invasive	cells	express	CD40L,	organotypic	sections	were	stained	by	IHC	for	CD40L.			
4.2.3.1.1	Anti-CD40L	displays	specific	binding	by	western	blotting			Firstly,	the	specificity	of	this	anti-CD40L	antibody	was	assessed	by	western	blot	(Fig	4.8),	where	bands	were	only	detected	in	AdNclCD40L	treated	EJ	cells,	in	the	appropriate	 region	 (~32kDa),	 whilst	 no	 expression	 was	 evident	 in	 AdMock	treated,	and	untreated	cells	(Fig	4.8).	The	specificity	of	this	antibody	indicates	a	likelihood	of	specific	behaviour	in	IHC.																								
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Figure	 4.8.	 Western	 blot	 of	 EJ	 cell	 lysates	 treated	 as	 indicated.	 Protein	lysates	 were	 prepared	 from	 untreated	 EJ	 cells,	 and	 EJ	 cells	 treated	 with	AdNclCD40L	 or	 AdMock	 for	 24-hours	 prior	 to	 western	 blotting.	 Anti-CD40L	(SC978)	was	used	to	probe	for	CD40L.	Specific	binding	to	CD40L	was	displayed,	with	no	binding	in	either	basal	or	AdMock	treated	cells.	(n=1).	
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4.2.3.1.2	AdNclCD40L	expression	is	confined	to	non-invading	cells		
	Here	 the	expression	of	CD40L	was	 tested	 in	organotypic	cross-sections	 treated	with	either	AdMock	or	AdNclCD40L.	Staining	with	a	1:100	dilution	of	anti-CD40L	(Fig	 4.9E,F)	 led	 to	 marked	 staining	 in	 both	 AdNclCD40L	 treated	 cells,	 and	AdMock	infected	cells.	No	expression	was	noted	 in	the	1:1000	AdMock	control,	isotype	 control	 and	 no	 primary	 antibody	 control	 (Fig	 4.9C,D).	 Staining	 with	1:1000	 anti-CD40L	 revealed	 moderate	 to	 strong	 diffuse	 expression	 of	AdNclCD40L	in	the	epithelial	layer,	whilst	no	expression	was	noted	any	invading	tumour	 cells	 (Fig	 4.9A).	With	 only	 non-invading	 cells	 expression	 AdNclCD40L,	this	data	indicates	a	potential	role	in	the	attenuation	of	tumour	cell	invasion	for	CD40.																							
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Figure	4.9.	Non-invading	EJ	 cells	express	mCD40L.	 IHC	 optimisation	 results	pH9	 antigen	 retrieval	 1:100	 and	 1:1000	 primary	 antibody	 concentration	 in	 EJ	organotypic	 sections.	 A)	 mCD40L	 transfected	 cells	 stained	 with	 1:1000	 anti-CD40L	exhibiting	CD40L	specific	staining,	B)	Isotype	control,	C)	AdMock	control	probed	 with	 1:1000	 primary	 antibody,	 D)	 No	 primary	 antibody	 control,	 E)	mCD40L	 transfected	cells	 stained	with	1:100	primary	antibody	exhibiting	non-specific	 staining,	 F)	 AdMock	 transduced	 cells	 stained	 with	 1:100	 primary	antibody	exhibiting	non-specific	staining.		(n=1).					
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4.2.4	RNA	microarray	in	EJ	cells	displays	differential	expression	in	genes	
implicated	in	tumour	invasion	by	bladder	gene	expression	profiling.			In	 order	 to	 further	 dissect	 the	 role	 of	 CD40-ligation	 in	 tumour	 cell	 invasion,	 a	RNA	 microarray	 was	 consulted.	 In	 this	 microarray,	 performed	 by	 Taha	Elmetwali,	 EJ	 cells	 were	 untreated,	 infected	 with	 AdMock,	 or	 infected	 with	AdNclCD40L	Differential	expression	was	noted	in	a	plethora	of	genes,	therefore	the	UCC	microarray	data	discussed	in	chapter	5	was	employed	to	select	the	most	dysregulated	genes	involved	in	MIBC	when	compared	to	grade	3	NMIBC.	It	was	hypothesised	that	these	genes	may	be	potential	drivers	of	muscle	invasion.	OPN,	and	MMP1,	 two	 genes	 dysregulated	 between	 normal	 bladder	 tissue	 and	MIBC	were	 included	 in	 the	 selection	 process	 as	 there	 is	 a	 significant	 body	 of	 data	implicating	them	in	tumour	cell	invasion	[198,	200,	202,	203,	206,	222,	261,	304-307].	A	literature	review	was	conducted	to	determine	the	role	of	each	candidate	in	tumour	invasion	(Table	4.1).			Interestingly	only	one	queried	gene	was	upregulated	post	CD40-ligation,	MMP1,	a	protein	implicated	in	remodelling	of	the	ECM,	facilitating	tumour	cell	invasion.	Seven	genes	were	downregulated:	FAM83D	–	linked	with	invasion	in	HCC;	CENP1	–	 implicated	 in	 mitosis;	 FN1	 –	 implicated	 in	 tumour	 cell	 invasion;	 CENPF	 –	implicated	 in	mitosis;	TOP2A	 –	 alters	DNA	 topography,	TOP2A	 inhibitors	 show	promise	 in	 some	 cancers;	TPX2	 –	 implicated	 in	mitosis;	ANLN	 –	 implicated	 in	EMT,	invasion	and	metastasis.	No	change	was	noted	in	the	mRNA	expression	of:	
RARRES1	 –	a	potential	 repressor	of	 invasion;	MAN1C1;	RASSF2	 –	potential	TSP;	
OPN/	 SPP1	 –	 implicated	 in	 BC	 invasion	 and	 metastasis;	 and	 FBXW7	 –	 TSP,	regulated	by	FAM83D.			Based	on	the	insight	gained	from	these	data,	four	genes	were	selected	based	on	evidence	 indicating	 a	 role	 in	 invasion,	 and	 the	 level	 of	 change	 in	 expression	observed	in	the	AdNclCD40	RNA	microarray,	for	use	in	further	analysis:	MMP1,	
FN1,	 FAM83D	 and	 ANLN.	 The	 relative	 change	 of	 expression	 in	 these	 genes	 is	displayed	in	figure	4.10.	
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Table	4.1.	Gene’s	dysregulated	in	MIBC	when	compared	to	grade	3	NMIBC	
or	normal	bladder	tissue.	Genes	selected	for	further	analysis	in	bold.		
Gene	 ID	
Fold	
Change	
(MIBC	
vs	G3	
NMIBC)	
Fold	
Change	
(Norma
l	vs	
MIBC)	
Change	in	EJ	
AdNclCD40L	
microarray	 Role		
Family	
with	
sequence	
similarity	
83,	
member	D	
FAM8
3D	 7.87	 	-	 Down	
Affects	
proliferation	and	
invasion	in	HCC,	
negative	regulator	
of	FBXW7	(TSP),	
expression	linked	
with	decreased	
overall	survival	in	
a	number	of	
cancers	[239,	308,	
309].	Retionic	Acid	receptor	responder	(tazarotene	induced)	1	 RARRES1	 5.97	 	-	 No		 May	repress	invasion	[310].	
Centromere	protein	I	 CENPI	 5.92	 	-	 Down		
Essential	for	proper	mitotic	progression,	chromosomal	alignment	and	segregation	[311].		
Fibronecti
n	1	 FN1	 5.86	 	-	 Down		
Promotes	invasion	
[312,	313].	Centromere	protin	F	(350/400KDa	(mitosin)	 CENPF	 5.76	 5.18	 Down		
Cell	cycle	protein,	
FOXM1	and	CENPF	are	synergistic	drivers	of	prostate	cancer	[314].		N	mannosidase,	alpha,	clas	1C,	member	1	 MAN1C1	 5.52	 	-	 No		
Involved	in	maturation	of	Asn-linked	oligosaccharides	[315].		
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Topoisomerase	(DNA)	II	alpha	170	Kda	 TOP2A	 5.32	 7.08	 Down	
Alters	topologic	states	of	DNA	during	transcription,	TOP2A	inhibitors	exist	[316].	
TPX2,	microtubule-associated,	homolog	(Xenopus	laevis)	 TPX2	 5.28	 7.52	 Down		
Required:	for	normal	assembly	of	mitotic	spindles;	for	assembly	of	microtubules	during	apoptosis;	for	chbromatin	and/or	kinetochore	dependent	microtubule	nucleation	[317].		
Ras	association	(RalGDS/AF-6)	domain	family	member	2	 RASSF2	 5.05	 	-	 No		
Potential	TSP,	acts	as	a	KRAS-specific	effector	protein,	may	promote	apoptosis	and	cell	cycle	arrest.	Stabilises	STK/MST2	by	protecting	it	from	proteasomal	degradation	[318].		
Anillin,	
actin	
binding	
protein		 ANLN	 5.01	 8.5	 Down	
Critical	for	cell	
division,	and	may	
promote	EMT	and	
cell	migration	
through	
cytoskeletal	
remodelling	-	
implicit	in	
invasion	and	
metastasis	[250,	
319].	Osteopontin	/	Secreted	Phosphoprotein	1	(OPN)	 SPP1	 -	 10.98	 No		
Implicated	in	invasion	in	a	number	of	cancers	[260,	320,	321].	
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Matrix	
Metallopr
oteinase	1	
MMP
1	 -	 6.49	 Up			
Collagenase,	
involved	in	ECM	
remodelling	and	
invasion.	Secreted	
as	a	
preproprotein,	
may	cleave	
membrane-bound	
CD40	[322].		
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Figure	 4.10.	 CD40-ligation	 induced	 changes	 in	 expression.	Determined	 by	RNA	microarray;	MMP1	 (A),	FN1	 (B),	FAM83D	 (C)	 and	ANLN	 (D)	 relative	 gene	expression.		
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4.2.4.1	Expression	of	the	invasion	markers	MMP1,	FAM83D,	ANLN	and	FN1	is	
modulated	by	CD40-ligation	in	EJ	and	RT112	cells		
	
4.2.4.1.1	Protein	level		
	The	 downstream	 consequences	 of	 CD40-ligation	were	 tested	 in	 EJ	 and	 RT112	cells.	 Here,	 both	 cell	 lines	 were	 infected	 with	 either	 AdNclCD40L	 or	 AdMock,	prior	 to	 lysis	 24-hours	 later	 and	 extraction	 of	 protein	 and	 RNA.	 Initially	AdNclCD40L	protein	expression	was	confirmed	by	western	blot,	prior	to	probing	for	MMP1	and	FN1	 (Fig	4.11).	The	expression	of	MMP1	 in	AdMock-transduced	cells	 was	 low	 in	 both	 cell	 lines.	 Interestingly,	 FN1	 expression	 was	 markedly	higher	 in	 RT112	 cells	 compared	 to	 EJ	 cells.	 No	 significant	 change	 in	 the	expression	of	either	MMP1	or	FN1	was	observed	in	RT112	cells.			However,	 EJ	 cells	 demonstrated	 a	 marked	 upregulation	 in	 MMP1	 levels,	concordant	with	AdNclCD40L	microarray	data.	Interestingly,	and	converse	to	the	RNA	microarray	data,	FN1	levels	were	markedly	increased	in	EJ	cells.			To	confirm	the	expression	of	FN1,	MMP1,	FAM83D	and	ANLN	at	the	RNA	level	in	RT112	 and	 EJ	 cells,	 reverse-transcription	 polymerase	 chain	 reaction	 (RT-PCR)	was	employed	next.		
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Figure	4.11.	Consequences	of	CD40-ligation	on	FN1	and	MMP1	expression.	EJ	 and	 RT112	 cells	 were	 infected	 either	 with	 1MOI	 AdMock	 (Mock),	 or	AdNcCD40L	 (Ligand).	 50μg	 of	 protein	 was	 loaded.	 β-actin	 was	 used	 to	demonstrate	equal	protein	loading.	(n=1).	
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4.2.4.1.2	RNA	level		
	Endpoint	 RT-PCR	 was	 performed	 utilising	 cDNA	 generated	 from	 total	 RNA	extracted	from	EJ	and	RT112	cells	infected	with	AdMock,	or	AdNclCD40L	for	24	hours.	 The	 expression	 of	 MMP1,	 FN1,	 FAM83D	 and	 ANLN	 was	 investigated	together	with	GAPDH	to	ensure	equal	loading	(Fig	4.12).		
	RT-PCR	confirmed	expression	of	MMP1,	FN1,	FAM83D	and	ANLN	at	the	RNA	level	in	both	cell	lines.			At	 the	 protein	 level	 these	 data	 suggest	 that	 CD40-ligation	may	 increase	 some	pro-invasive	 signalling	 in	 EJ	 cells	 (Fig	 4.11),	 with	 increases	 in	MMP1	 and	 FN1	levels	being	noted	in	EJ	cells.	In	contrast,	the	microarray	data	(Fig.	4.10)	displays	a	 2.4-fold	 decrease	 in	 FN1	 RNA	 levels	 in	 EJ	 cells	 with	 increased	 RNA	 levels	observed	 solely	 in	 MMP1.	 One	 potential	 explanation	 of	 the	 CD40L	 induced	attenuation	 of	 invasion	 observed	 in	 this	 model	 is	 the	 high	 level	 of	 apoptotic	induction	resulting	from	membrane-bound	CD40-ligation	may	lead	to	decreased	cell	numbers	attenuating	the	extent	of	invasion.		
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Figure	4.12.	Confirmation	of	MMP1,	FAM83D,	ANLN	and	FN1	RNA	expression	
in	 EJ	 and	 RT112	 cells.	 Agarose	 gel	 image	 of	 RT-PCR	 fragments	 of	 MMP1,	
FAM83D,	ANLN,	FN1	and	a	GAPDH	loading	control	(n=1).		
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4.3	Discussion		Over	the	past	decade	interest	in	CD40,	a	receptor	studied	extensively	in	immune	biology,	in	cancer	has	grown	greatly	[323].	However,	the	role	of	CD40	in	tumour	cell	 invasion	 remains	 unclear.	 In	 this	 chapter	 expression	 of	 a	 non-cleavable	membrane-bound	 CD40L	 construct,	 delivered	 by	 a	 conditionally	 replicating	adenovirus,	 was	 initiated	 in	 UCC	 cells	 to	 study	 the	 consequences	 of	 CD40-ligation,	in	terms	of	tumour	cell	invasion	and	downstream	effects.	 	The	primary	aim	of	this	study	was	to	determine	whether	CD40-ligation	plays	a	supportive,	or	inhibitory	role	on	BC	cell	invasion.	The	secondary	aim	was	to	determine	whether	this	effect	was	due	to	downstream	CD40-ligation	induced	differential	expression.			Initially	 western	 blot	 was	 used	 to	 determine	 the	 relative	 basal	 expression	 of	CD40.	 CD40	was	 expressed	 in	 all	 cell	 lines	 tested	 and	 at	 highest	 levels	 in	 the	MIBC	cells,	EJ	and	253-J,	respectively.	Interestingly,	NMIBCs	express	the	highest	levels	of	CD40	(89%),	compared	to	a	smaller	proportion	of	MIBCs	(62%)	[178].			Choosing	the	appropriate	type	of	CD40	ligand	is	essential,	due	to	differing	effects	between	mCD40L	and	sCD40L.	AdNclCD40L	was	used	after	initial	consideration	of	 rsCD40L.	 Although	 rsCD40L	 does	 not	 cause	 cell	 death	 in	 BC	 cells	 without	inhibition	of	protein	synthesis,	it	only	leads	to	short-lived	transient	activation	of	CD40,	 unsuitable	 in	 a	 multi-day	 assay	 comparatively,	 AdNclCD40L	 invokes	sustained	 mCD40L	 expression,	 and	 downstream	 activation	 of	 CD40	 pathway	[180,	 186].	 Studies	 into	 the	 downstream	effects	 of	mCD40L-ligation	 have	 used	high	 amounts	 of	 virus,	 in	 the	 region	 of	 100	MOI	 [180,	 186].	 Due	 to	 apoptotic	induction	 potential	 of	mCD40L	 on	 EJ	 cells,	 lower	MOI	was	 utilised	 (1	MOI)	 to	allow	 for	 low-level	 expression	 of	 mCD40L	 and	 associated	 downstream	 events	without	 triggering	 apoptotic	 cell	 death	 induction.	 Following	 24-hour	 infection	with	 AdNclCD40L,	 total	 protein	 lysates	 were	 prepared	 and	 expression	 of	mCD40L	 was	 detected	 by	 western	 blot.	 Notably,	 there	 was	 no	 phenotypic	changes	between	different	treatments,	or	apparent	cell	viability	reduction	at	24-hours.						
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Consistent	with	other	reports,	RT112	cells	behaved	in	a	non-invasive	manner	in	an	organotypic	model	of	BC	(Fig	4.13)	[324].	Interestingly,	RT112	cells	displayed	a	 papillary-like	 morphology	 in	 this	 model,	 similar	 to	 their	 morphology	 the	originating	 tumour	 [272].	 Consistent	 with	 their	 origin,	 EJ	 cells	 demonstrated	highly	 invasive	 behaviour	 where	 invasion	 was	 seen	 predominantly	 as	 single	cells,	similar	behaviour	has	also	been	noted	in	vivo	[325].	In	RT112	cells	treated	with	AdMock	a	tighter	epithelium	was	formed,	4-6	cells	 in	thickness,	compared	to	the	12-14	cells	observed	in	untreated	RT112	cells.	Interestingly,	inhibition	in	cell	 growth,	 and	 increased	 cell	 death	 has	 been	 reported	 with	 the	 use	 of	adenoviral	 vectors	 [326].	 The	 adenoviral	 vector	 also	 affected	 behaviour	 of	 EJ	cells	 in	an	organotypic	model,	partially	attenuating	 invasion.	However,	marked	invasion	 occurred,	 displaying	 a	 similar	 diffuse	 pattern	 to	 untreated	 cells.	 	 The	effect	 of	AdNclCD40L	 treatment	 on	EJ	 cell	was	marked,	 causing	near	 complete	inhibition	 tumour	 cell	 invasion,	 accompanied	 by	 marked	 cell	 death,	 whilst	AdNclCD40L	treatment	resulted	in	RT112	cell	death,	to	the	extent	that	sections	resemble	the	no	UCC	cell	control.	Interestingly,	 in	EJ	cells	the	greatest	decrease	in	 invasion	 correlated	 with	 adenoviral	 infection,	 where	 invasion	 depth	 was	reduced	 by	 60%	 compared	 to	 cells	 under	 basal	 conditions,	 whereas	 a	 smaller	decrease	 of	 49%	was	 noted	 between	 AdMock	 and	 AdNclCD40L	 infected	 cells,	highlighting	the	growth-inhibitory	effects	of	this	adenoviral	vector.	Additionally,	assessment	of	 efficacy	of	 infection	was	not	 tested	as	published	work	using	 the	same	viral	stocks	in	EJ	cells	has	demonstrated	comparable	infection	rates	upon	examination	of	green	fluorescent	protein	(GFP)	expression	[180,	186].	Although	there	 is	 potential	 for	 differential	 infection	 rates	 between	 experiments,	 positive	CD40L	 staining	 in	 non-invading	 AdNclCD40L	 transduced	 EJ	 cells,	 compared	 to	absence	 in	 invading	 cells,	 indicates	 CD40-ligation	 is	 a	 driver	 of	 the	 displayed	anti-invasive	behaviour.			
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Figure	 4.13.	 In	 vitro	 behaviour	 of	 RT112	 cells	 is	 similar	 to	 that	 in	 the	
parent	 tumour	of	RT112.	 (A)	 Parent	 Tumour	H&E,	 papillary	 transitional	 cell	carcinoma	 of	 the	 human	 bladder	 [272].	 (B)	 RT112	 cell	 line	 in	 an	 organotypic	model	of	BC,	H&E.	Shares	papillary	morphology	of	parent	tumor.			Based	on	the	observations	in	EJ	cells,	where	near	complete	inhibition	of	tumour	cell	invasion	occurred,	it	was	hypothesised	that	the	invasive	cells	do	not	express	mCD40L.	To	 test	 this	hypothesis	organotypic	 sections	were	 stained	 for	CD40L,	staining	 revealed	 positive	 staining	 in	 non-invading	 cells,	 whilst	 all	 other	 cells	were	 negative	 for	 CD40L	 expression.	 These	 data	 indicate	 an	 inhibitory	 role	 of	CD40L,	in	terms	of	tumour	cell	invasion.	To	determine	whether	this	effect	was	a	result	of	downstream	modulation	of	genes	involved	in	invasion,	a	BC	microarray,	presented	 in	 chapter	 5,	 was	 consulted.	 A	 table	 of	 the	 most	 differentially	expressed	 genes	 between	MIBC	 and	 grade	 3	NMIBC	was	 consulted	 (Table	 4.1,	5.3),	 with	 the	 addition	 of	 two	 highly	 differentially	 expressed	 genes	 from	 a	comparison	of	MIBC	with	normal	bladder	tissue,	OPN	and	MMP1.	The	data	in	this	table	 was	 cross-referenced	 with	 data	 from	 a	 microarray,	 where	 EJ	 cells	 were	infected	with	AdMock	or	AdNclCD40L.	Candidate	genes	were	then	selected	based	on	 the	 response	 to	 CD40-ligation,	 and	 data	 implicating	 the	 gene	 in	 invasion.	
MMP1,	FN1,	FAM83D	and	ANLN	were	selected	for	further	analysis.			The	expression	of	all	four	markers	was	confirmed	at	the	RNA	level	by	endpoint	RT-PCR	 in	 both	 cell	 lines	 [327].	 Relative	 protein	 levels	 of	 FN1	 and	 MMP1	 in	response	 to	 AdNclCD40L	 were	 measured	 by	 western	 blot.	 In	 agreement	 with	microarray	data,	MMP1	was	markedly	upregulated	 in	EJ	cells,	whilst	 low	levels	
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were	noted	 in	RT112	 cells.	 In	RT112	 cells,	 relative	 FN1	 levels	were	high,	with	little	change	between	conditions.	Interestingly,	FN1	levels	in	EJ	cells	dramatically	increased,	in	discordance	with	microarray	data.	This	suggests	an	increase	in	FN1	protein	stability.	Potential	mechanisms	of	 increased	FN1	 levels	are	preferential	translation	of	remaining	FN1	RNAs	and	decreased	protein	breakdown	[328-331].			With	increases	in		FN1	and	MMP1,	and	only	small	decreases	in	RNA	expression	of	FAM83D	 and	 ANLN	 within	 this	 panel,	 evidence	 indicates	 increased	 levels	 of	some	markers	involved	in	tumour	invasion.	However,	inhibition	of	invasion	was	noted	in	organotypic	models	of	BC.	This	may	be	explained	by	the	use	of	a	small	panel	 of	 invasion	 markers,	 although	 these	 were	 selected	 from	 a	 list	 of	 13	dysregulated	 genes	 in	 MIBC,	 it	 is	 likely	 other	 genes	 implicit	 in	 tumour	 cell	invasion	were	not	included	in	this	panel.	Furthermore,	as	CD40-ligation	leads	to	altered	 expression	 of	 a	 plethora	 of	 genes,	 it	 is	 likely	 that	 those	 implicated	 in	invasion	 are	 differentially	 regulated.	 Similarly	 to	 the	 effect	 of	 mCD40L-CD40-ligation	 on	 cell	 death,	 where	 there	 is	 evidence	 for	 TRAF3	 dependent	 pro-apoptotic	signalling	and	TRAF6	dependent	cell	survival	signalling.	 It	 is	possible	that	CD40-ligation	initiates	the	expression	of	factors	both	positive	and	negative	in	tumour	invasion	promotion,	with	the	net	result	leading	to	inhibition	of	tumour	invasion.	 This	 notion	 is	 supported	 by	 reports	 of	 pro-	 and	 anti-	 invasion,	proliferation	and	 cell	 growth	 signalling	 resulting	 from	CD40-ligation	 in	 several	cancers	 [332-334].	 Although,	 inhibition	 of	 invasion	 may	 not	 be	 due	 to	 classic	invasive	signalling	pathways,	but	rather	owed	to	the	apoptosis	inducing	action	of	CD40-ligation	in	UCC	cells	[180].			Future	 work	 should	 focus	 on	 the	 development	 of	 treatments	 based	 on	 the	apoptotic	action	of	mCD40L.	The	development	of	mCD40L	expressing	liposomes	may	 prove	 useful	 in	 the	 treatment	 of	 NMIBC.	 A	 recombinant	 ectodomain	 of	apolipoprotein	 L1	 (APOL2)/TRAIL,	 expressed	 on	 the	 surface	 of	 liposomes,	 has	shown	marked	 anti-tumour	 activity	 [335].	 Furthermore,	 Systemic	 initiation	 of	CD40-signalling	by	agonistic	monoclonal	 antibodies	 (mAbs)	 allows	 for	 a	multi-modal	attack	on	tumour	cell	viability,	both	directly	through	apoptotic	induction	in	CD40-positive	cancer	cells,	and	immune	activation	where	antigen-presenting	
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cells	 (APCs)	 such	 as	 B	 cells,	 dendritic	 cells	 and	 monocytes	 are	 activated,	facilitating	an	increased	anti-tumour	immune	response	[192,	336].	Furthermore,	initial	 clinical	 trials	 of	 such	 agonistic	 CD40	 mAbs	 have	 demonstrated	 very	promising	 results,	with	 no	 disabling	 toxicity,	 both	 as	 standalone	 agents	 and	 in	combination	with	chemotherapy	[336].		In	 conclusion,	 these	 data	 demonstrate	 the	 ability	 of	 CD40-ligation	 to	 inhibit	tumour	cell	invasion,	and	to	invoke	marked	cell	death.	However,	changes	in	the	expression	of	downstream	markers,	particularly	increases	in	protein	expression	of	FN1	and	MMP1,	do	not	explain	the	attenuation	of	invasion	in	EJ	cells.		
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5.1	Introduction		Locally	 confined	 BC	 can	 be	 divided	 into	 NMIBC	 or	 MIBC.	 NMIBC	 may	 be	effectively	managed	surgically	by	TURBT,	and	 immunologically	by	 the	usage	of	BCG	 instillation.	 Treatment	 of	 MIBC	 requires	 radical	 intervention,	 either	 by	cystectomy	 or	 radical	 radiotherapy	 (with	 or	 without	 concurrent	 and	 neo-adjuvant	 chemotherapy).	 Less	 than	20%	of	NMIBCs	will	 recur	 and	progress	 to	MIBC	 with	 the	 passage	 of	 time.	 Several	 clinicopathological	 attributes	 are	associated	 with	 disease	 aggressiveness,	 and	 recent	 findings	 are	 discussed	 in	depth	 in	 the	 general	 introduction	 and	 general	 discussion	 sections.	 However	current	 clinicopathological	 factors	 applied	 in	 the	 clinic	 include	 tumour	 grade,	stage,	size,	presence	of	Cis	and	previous	recurrence,	all	of	which	are	associated	with	progression.		
	Unfortunately,	the	above	factors	are	not	sufficient	to	identify	patients	who	need	more	radical	therapy	at	diagnosis.	 In	the	case	of	MIBC,	stratification	of	patients	likely	 to	 progress	 to	 locally	 advanced	or	 devastating	MBC	would	 allow	a	more	personalised	approach	to	therapy.		
	Several	 recent	 studies	 have	 employed	 the	 usage	 of	 RNA	 microarrays	 to	investigate	 the	 expressional	 landscape	 of	 BC.	 Furthermore,	 identification	 of	differentially	expressed	genes	allows	for	the	dissection	aberrant	of	pathways	and	processes	 in	 BC.	 An	 increased	 knowledge	 of	 the	 expressional	 profiles	 of	 this	remarkably	 heterogeneous	 disease	 may	 allow	 for	 increased	 knowledge	 of	 BC	pathogenesis,	and	may	provide	clues	for	both	non-invasive	and	early	detection	in	BC,	potentially	unveiling	novel	targets	for	the	development	of	new	treatments.		
	This	 chapter	 uses	 gene	 expression	 analysis	 to	 identify	 dysregulated	 gene	expression	 in	 BC,	 identifying	 distinct	 molecular	 subgroups	 with	 similar	 and	opposing	 expressional	 profiles.	 Potential	 key	 pathways	 have	 been	 identified,	along	with	 a	marker	 of	 aggressive	MIBC.	 	 The	 expression	 of	 one	marker,	OPN,	was	further	assessed	in	tissue	by	immunohistochemistry.			
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The	 work	 carried	 out	 in	 section	 5.2	 was	 performed	 in	 collaboration	 with	 the	authors	 of	 the	 2017	 IJO	 paper	 “Gene	 expression	 profiling	 in	 bladder	 cancer	identifies	 potential	 therapeutic	 targets”.	 An	 asterisk	 (*)	 in	 the	 section	 heading	marks	experiments	that	 I,	Richard	Greensmith,	have	performed,	 in	sections	not	marked	with	 an	 asterisk	 experiments	 have	 been	undertaken	by	 authors	 of	 the	IJO	paper,	excluding	myself.		
5.1.2	Chapter	aims		
• To	 develop	 gene	 expression	 signatures	 with	 predictive	 and	 prognostic	value	
• To	gain	further	insight	into	the	expressional	landscape	of	BC	
	
	
Hypothesis:	Gene	expression	analysis	will	identify	molecularly	distinct	subtypes	of	BC.		
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5.2	Results	
	
5.2.1	Bladder	cancer	tissue	exhibits	specific	gene	expression	signatures			An	aggregate	of	418	genes	were	differentially	expressed	between	BC	and	normal	bladder	tissue	samples,	with	a	fold	change	above	2.5,	and	a	FDR	of	0.05.	Of	this	group,	 368	 genes	 displayed	 reduced	 expression	 in	 BC	 whilst	 50	 genes	 were	increased	 in	 expression	 in	 BC.	 Furthermore,	 hierarchal	 clustering	 separated	normal	bladder	tissue	and	BC	into	two	distinct	groupings	(Fig	5.1).																										
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Figure	5.1.	Hierarchal	clustering	separates	BC	samples	from	normal	tissue	
samples.	Numbers	at	the	bottom	of	the	figure	indicate	anonymised	patient	serial	numbers.		
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Of	 the	 50	 genes	 shown	 to	 be	 upregulated	 in	 BC	 compared	 to	 normal	 tissue,	multiple	were	involved	in	proliferation	(p	=	2.59	x	10-9),	including	components	of	the	 CDK1/CyclinB	 complex,	 required	 for	 progression	 from	 G2	 to	 M-phase.	Induction	of	Cyclin	B	transcription	is	mediated	by	FOXM1	(Fig	5.2).	Additionally,	the	 balance	 between	 nuclear	 export	 and	 import	 of	 Cyclin	 B1	 is	 affected	 by	 its	phosphorylation	 status	 mediated	 by	 upregulated	 polio-like	 kinase	 1	 (PLK1).	Lamin	 B,	 a	 substrate	 of	 CDK1/Cyclin	 B,	 leads	 to	 the	 depolymerisation	 of	 the	lamin	 nuclear-cytoskeleton,	 and	 kinesin	 family	 member	 1	 (KNSL1),	 which	 is	linked	with	spindle	apparatus	and	centrosomes.																										
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Figure	5.2.	Genes	 implicated	 in	mitosis	 are	upregulated	 in	BC	 (p	=	2.59	x	
10-9).	Key:	Genes	c	upregulated	(red	circled),		downregulated	(blue	circled).	The	bar	length	is	representative	of	the	degree	of	expressional	change.										
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5.2.1.1	Genes	implicated	in	epithelial-to-mesenchymal	transition	and	
myogenesis	are	downregulated	in	bladder	cancer			
	In	comparison	to	normal	tissue,	genes	downregulated	in	BC	included	a	number	of	 genes	 involved	 in	 myogenesis	 (p	 =	 1.22	 x	 10-10)	 (Fig	 5.3),	 including	 MEF2,	expressed	 during	 myogenesis.	 Myocyte	 enhancer	 factor	 2	 (MEF2)	 and	 the	myogenic	regulatory	 factor,	MyoD,	 interact	conferring	MyoD	activation,	 leading	to	 the	 expression	 of	 myosin	 light	 and	 heavy	 chains.	 	 Furthermore,	 genes	implicated	in	EMT	were	also	downregulated	in	BC	(p	=	1.41	x	10-9)	(Fig	5.4).	EMT	is	 a	key	process	during	myogenesis	 as	muscle	precursor	 cells	delaminate	 from	the	 dermomyotome	 and	 myoblasts	 invade	 the	 developing	 tissue	 before	differentiating	into	mature	myocytes.										
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Figure	 5.3.	 Genes	 implicated	 in	 myogenesis	 arte	 downregulated	 in	 BC	
samples	(p	=	1.22	x	10-10).	The	relative	expression	of	each	gene	is	represented	by	the	colour	and	intensity	of	the	circle,	with	blue	representing	downregulation	and	red	representing	upregulation.		
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Figure	 5.4.	 Downregulation	 of	 genes	 involved	 in	 EMT	 in	 BC	 samples	 (p	 =	
1.41	x	10	-9).	Key:	Genes	circled	in	blue	displayed	downregulation	within	the	BC	samples	 when	 compared	 to	 normal	 bladder	 tissue;	 the	 length	 of	 the	 adjacent	blue	bar	depicts	the	extent	of	the	downregulation.		
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5.2.1.2	Comparison	of	the	expressional	profiles	of	NMIBC	and	normal	bladder	
tissue	displays	segregation	into	two	groups	with	some	branching		A	 comparison	 was	 made	 between	 NMIBC	 and	 normal	 tissue.	 Here	 410	 genes	were	identified	with	changes	above	2.5-fold	(p<0.05,	FDR).	Of	the	410,	393	were	downregulated	 in	 NIMBC,	 and	 17	 were	 upregulated	 in	 NMIBC	 (Table	 5.1).		Hierarchical	 clustering	displayed	segregation	 into	 two	groups,	but	with	 further	divergence	in	one	cluster	(Fig	5.5).			
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Figure	5.5.	Hierarchical	clustering	displays	clustering	of	NMIBC	and	normal	
bladder	 tissue	 with	 further	 branching.	 The	 key	 to	 the	 right	 of	 the	 figure	denotes	 control	 and	 tumour	 sample	 labels,	 with	 anonymised	 patient	 serial	numbers	below.		
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Table	 5.1.	 Genes	 upregulated	 with	 greatest	 fold	 change	 in	 NMIBC	 versus	
normal	comparison.	A	fold-change	cut-off	of	2.5	and	FDR	<0.05	were	used	for	filtration.	
Gene	Symbol	 RefSeq	 p-value	 Fold-
Change	
HIATL1	 –	 no	 obvious	 cancer	
relevance	in	literature	
NM_032558	 9.39E-05	 3.39037	
ESRP1	–	shown	in	other	cancers	 NM_017697	 0.000779	 3.0231	
TOX3	 –	 Shown	 as	 a	 susceptibility	
factor	in	male	BCR		
NM_001080430	 0.000469	 2.80189	
HK2	 –	 role	 in	 glucose	metabolism	
in	cancer	cells		
NM_000189	 5.14E-05	 2.77546	
HIST1H3F–	 no	 obvious	 cancer	
relevance	in	literature	
NM_021018	 0.00206	 2.76721	
CDH26	 –	 no	 obvious	 cancer	
relevance	in	literature	
NM_177980	 0.00082	 2.75204	
ESRP2	 NM_024939	 4.09E-05	 2.74268	
ST14	 NM_021978	 0.000304	 2.73635	
MX2	 NM_002463	 0.000263	 2.72833	
CHMP4C	 NM_152284	 2.31E-05	 2.6807	
FABP6	 NM_001040442	 0.001337	 2.67814	
POF1B	 NM_024921	 0.000243	 2.677	
ZNF432	 NM_014650	 0.000244	 2.64633	
MYO5B	 NM_001080467	 0.000423	 2.60563	
ZNF841	 NM_001136499	 0.000197	 2.56588	
GRHL1	 NM_198182	 0.00166	 2.55212	
HIST1H2BH	 NM_003524	 0.002392	 2.50504	
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In-line	 with	 the	 observed	 changes	 between	 BC	 samples	 and	 normal	 tissues,	genes	implicated	in	myogenesis	and	EMT	were	downregulated	(p	=	4.8	x	10-12).	Intriguingly,	 genes	 implicated	 in	 the	 classical	 complement	 pathway	 were	markedly	 underexpressed	 in	 NMIBC	 compared	 to	 normal	 tissue,	 indicating	 a	potential	mechanism	of	immune	evasion	(p	=	5.12	x	10-10)	(Fig	5.6).		
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Figure	 5.6.	 Genes	 implicated	 in	 the	 classical	 complement	 pathway	 are	
downregulated	in	NMIBC	when	compared	to	normal	tissue	(p	=	5.12	x	10-
10).	Key:	 Blue	 circles	 represent	 downregulated	 genes	 and	 the	 blue	 bar	 to	 the	right	of	each	gene	denotes	the	level	of	downregulation.		
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5.2.1.3	Comparison	of	MIBC	and	normal	bladder	tissue	displays	segregation	
into	two	distinct	expressional	profiles		Hierarchal	 clustering	 displays	 marked	 segregation	 between	 MIBC	 and	 normal	bladder	tissue	samples	into	two	distinct	groups	(Fig	5.7).	In	total	404	genes	were	dysregulated	greater	than	3-fold.	(p<0.05	FDR).	Out	of	the	404	genes,	107	were	upregulated	 between	 MIBC	 and	 normal	 bladder	 tissue,	 whilst	 297	 were	decreased	in	expression.	Pathways	augmented	by	these	differentially	expressed	genes	are	noted	in	figure	5.8,	with	a	 list	of	genes	upregulated	by	at	 least	5-fold	being	presented	in	table	5.2.	Key	genes	implicated	in	chromosome	condension	in	prometaphase	were	 upregulated	 in	MIBC	 (p	 =	 2.75	 x	 10-15).	 Further	 cell	 cycle	components	 were	 also	 upregulated,	 including	 regulators	 of	 the	 anaphase	promoting	complex	(APC),	including	PLK1	and	CDK1	(p	=	3.47	x	10-12).				
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Figure	 5.7.	 Hierarchical	 clustering	 of	 genes	 and	 tissue	 samples	 displays	
segregation	of	MIBC	and	normal	bladder	 samples	 into	distinct	 clusters.	A	key	is	displayed	at	the	right	of	the	figure;	the	numbers	at	the	bottom	of	the	figure	denote	anonymised	patient	serial	numbers.		
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Figure	5.8.	Pathway	Enrichment:	MIBC	vs	normal	tissue	control	samples.	
	
	
	
	
	
	
	
	
	
	
	
	
	 181	
Table	 5.2.	 Genes	 displaying	 greater	 than	 5-fold	 increased	 expression	 in	
MIBC	when	compared	to	normal	tissue	samples.	
Gene	 Gene	ID	 RefSeq	ID	 p	value	
Fold	 change	
(MIBC	 versus	
control)	
Secreted	
phosphoprotein	 1	
/osteopontin	
SPP1	 NM_001040058	 0.000278942	 10.9828	
Anillin,	 actin	
binding	protein	
ANLN	 NM_018685	 0.000100265	 8.49928	
TPX2,	
microtubule-
associated,	
homolog	
(Xenopus	laevis)	
TPX2	 NM_012112	 0.000281361	 7.51978	
Topoisomerase	
(DNA)	 II	 alpha	
170kDa	
TOP2A	 NM_001067	 0.000327502	 7.07702	
Matrix	
metalloproteinase	
1		
MMP1	 NM_002421	 4.53E-05	 6.48753	
Gasdermin	C		 GSDMC	 NM_031415	 2.47E-06	 6.02525	
N	 serpin	
peptidase	
inhibitor,	 clade	 B,	
member	13	
SERPINB13	 NM_012397	 5.94E-06	 5.98179	
chloride	 channel	
accessory	2	
CLCA2	 NM_006536	 0.00335894	 5.61433	
Antigen	 identified	
by	 monoclonal	
antibody	Ki-67		
MKI67	 NM_002417	 0.000992039	 5.43103	
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Kinesin	 family	
member	23		
KIF23	 NM_138555	 0.000252044	 5.32734	
Serpin	 peptidase	
inhibitor,	 clade	 B	
(ovalbumin),	
member3	
SERPINB3	 NM_006919	 0.00367834	 5.26492	
Centromere	
protein	 F,	
350/400ka	
(mitosin)	
CENPF	 NM_016343	 0.00190184	 5.1824	
Family	 with	
sequence	
similarity	 83,	
member	A	
FAM83A	 NM_032899	 3.54E-06	 5.16728	
cyclin	E2		 CCNE2	 NM_057749	 0.000232145	 5.1512	
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5.2.1.4	A	comparison	of	grade	1	and	grade	3	NMIBC	resulted	in	marked	
segregation	between	each	group		A	 comparison	 between	 the	 expressional	 landscape	 of	 grade	 1	 and	 grade	 3	NMIBCs	revealed	341	genes	to	be	differentially	expressed	at	least	2-fold	(p<0.05	FDR).	 Hierarchical	 clustering	 displayed	 marked	 segregation	 between	 grade	 1	and	 grade	 3	 (Fig	 5.9),	 enriched	 pathways	 are	 presented	 in	 figure	 5.10.	 In	comparison	 to	 grade	 1	 tumours	 multiple	 pathways	 associated	 with	 cell	 cycle	progression	 were	 upregulated	 in	 grade	 3	 NMIBCs.	 Furthermore,	 genes	implicated	in	the	metaphase	checkpoint	were	some	of	the	most	highly	enriched	(p	 =	 3.06	 x	 10-17).	 A	 comparison	 was	 also	 made	 between	 genes	 that	 were	upregulated	 in	both	grade	3	NMIBC	 compared	 to	 grade	1	NMIBC,	 and	 in	MIBC	compared	to	normal	bladder	tissue.		
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Figure	 5.9.	 Hierarchical	 clustering	 displays	 well	 defined	 segregation	
between	grade	1	and	grade	3	NMIBC	samples.	The	key	 is	 to	 the	 right	of	 the	figure;	the	numbers	below	represent	anonymised	patient	serial	numbers.		
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Figure	5.10.	Pathway	enrichment:	Grade	3	NMIBC	vs	grade	1	NMIBC.		
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5.2.1.5	Comparing	grade	3	NMIBC	and	MIBC	resulted	in	clear	segregation	of	
both	groups	
	A	sum	of	292	genes	were	differentially	expressed	greater	than	2-fold	(P<0.05).	Of	this	 group,	 144	 displayed	 increased	 expression	 in	 MIBC,	 whist	 148	 displayed	decreased	 expression	 compared	 to	 grade	 3	 NMIBC.	 Furthermore,	 hierarchal	clustering	displayed	a	clear	disparity	between	the	 two	groups	(Fig	5.11).	Table	5.3	presents	genes	differentially	expressed	greater	than	5-fold	in	grade	3	NMIBC	when	compared	to	MIBC.	The	proteinases	were	amongst	the	most	overexpressed	genes	 in	 MIBC.	 Overexpression	 and	 activation	 of	 proteinases	 is	 key	 in	 the	remodelling	 of	 surrounding	 tumour-associated	 stroma,	 facilitating	 tumour	 cell	invasion.	 The	 most	 proteolytic	 of	 these	 are	 the	 MMPs,	 which	 were	 highly	overexpressed	 in	 MIBC,	 a	 family	 of	 enzymes	 that	 are	 collectively	 capable	 of	degrading	all	components	of	the	ECM.	MMP1	and	MMP16	were	upregulated	4.8	and	 2.6-fold	 respectively	 in	MIBC	 compared	 to	 NMIBC.	 The	 overexpression	 of	this	group	of	proteins	 is	 likely	 imperative	 in	 the	highly	 invasive	and	malignant	MIBCs.													
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Figure	5.11.	Hierarchal	clustering	displays	a	clear	disparity	between	grade	
3	 NMIBC	 and	 MIBC.	 Key	 is	 to	 the	 right	 of	 the	 figure;	 the	 numbers	 below	represent	anonymised	patient	serial	numbers.		
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Table	 5.3.	 Genes	 displaying	 greater	 than	 5-fold	 differential	 expression	
between	grade	3	NMIBC	and	MIBC	samples	(p<0.05	FDR).		
Gene	 ID	 RefSeq	 p	value	 Fold	 change	(MIBC/	
NMIBC)	
family	with	 sequence	 similarity	
83,	member	D	
FAM83D	 NM_030919	5.50E-06	 7.87015	
	retinoic	 acid	 receptor	
responder	(tazarotene	induced)	
1		
RARRES1	NM_206963	0.001291	5.96921	
centromere	protein	I		 CENPI	 NM_006733	1.35E-05	 5.92042	
	fibronectin	1		 FN1	 NM_212482	0.000579	5.86325	
	centromere	 protein	 F,	
350/400KDa	(mitosin)	
CENPF	 NM_016343	0.000505	5.7622	
N	mannosidase,	 alpha,	 class	 1C,	
member	1		
MAN1C1	 NM_020379	0.000401	5.52916	
	topoisomerase	 (DNA)	 II	 alpha	
170kDa		
TOP2A	 NM_001067	0.00091	 5.32363	
	TPX2,	 microtubule-associated,	
homolog	(Xenopus	laevis)		
TPX2	 NM_012112	0.000892	5.27537	
	Ras	 association	 (RalGDS/AF-6)	
domain	family	member	2	
RASSF2	 NM_014737	0.000644	5.04613	
	anillin,	actin	binding	protein		 ANLN	 NM_018685	0.000489	5.01334	
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5.2.2	Further	functional	analysis	employing	Database	for	Annotation,	
Visualization,	and	Integrated	Discovery	(DAVID)			An	additional	analysis	of	143	upregulated	genes	 in	MIBC	 	compared	 to	NMIBC,	was	performed	using	the	DAVID	database.	These	data	are	summarised	in	Table	5.4.																														
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Table	5.4.	Summary	of	DAVID	analysis:	functional	annotation	clusters.	
Annotation	cluster	 Enrichment	score	 Count	 p	value	
Extracellular	glycoproteins	 6.47	 37	 2.7E	-07	
Serine-type	endopeptidase	
inhibitor	activity	 3.29	 7	 7.90E-05	
Negative	regulation	of	immune	
system	processes	 2.21	 6	 4.60E-04	
Zymogen	(proteolytic	enzyme	
precursors)	 1.85	 14	 5.10E	-04	
Cell	migration	 1.33	 9	 1.40E-03	
EGF	 1.18	 5	 1.50E-02	
Response	to	wounding	 0.95	 13	 8.20E-04	
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5.2.3	Meta-analysis	of	publicly	available	datasets		
	To	 validate	 these	 data,	 a	 meta-analysis	 was	 performed	 on	 a	 larger	 90-sample	data	 set,	 produced	 by	 merging	 two	 publicly	 available	 BC	 gene	 expression	datasets	 [280,	 281].	 After	 the	 same	 benchmarks	 as	 used	 in	 our	 study	 were	applied	 for	 classifying	 MIBC	 and	 NMIBC,	 there	 were	 29	 NMIBC	 and	 42	 MIBC	cases,	 14	 cases	 were	 healthy	 bladder	 tissue	 samples,	 whilst	 the	 remainder	represented	Cis	and	were	excluded	from	further	analysis.			
	Meta-analysis	 revealed	 differential	 expression	 of	 4513	 genes	 in	 NMIBC,	compared	to	normal	tissue,	when	a	cut	off	of	FDR	<0.05	and	a	fold-change	of	2.5	were	 applied.	 Upon	 comparison	with	 our	 data,	 there	was	 commonality	 in	 118	genes.	Remarkably,	except	for	pelota	homolog	(PELO),	all	displayed	comparable	expression	patterns.	Including	all	8	genes	upregulated	in	NMIBC,	and	109	genes	downregulated	in	NMIBC,	compared	to	normal	bladder.			Upon	comparison	of	MIBC	 to	healthy	bladder	 tissue,	with	a	 filter	of	FDR	<0.05	and	fold	change	>3,	differential	expression	was	noted	in	3905	genes.	Comparison	with	 our	 data	 revealed	 44	 common	 differentially	 expressed	 genes.	 Except	 for	SERPIN	 B13	 (SERPINEB13)	 and	 CASC5,	 changes	 in	 expression	 shared	commonality	with	our	analyses.		
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5.2.4	Osteopontin	protein	is	overexpressed	in	MIBC	tissue	compared	to	
normal	urothelium	*		To	determine	the	validity	of	microarray	data,	OPN	expression	was	examined	in	MIBC	(n=3),	and	normal	urothelium	(n=3)	using	 immunohistochemistry.	 It	was	hypothesised	that	OPN	would	be	expressed	at	a	higher	level	in	MIBC	compared	to	healthy	tissue.		
	
5.2.4.1	Optimisation	of	OPN	primary	antibody	for	immunohistochemistry	*		Firstly,	 the	 specificity	 of	 a	 candidate	 OPN	 antibody	 for	 IHC	 (AF1433	 R&D	Systems)	was	determined	by	western	blot	utilizing	total	protein	lysates	prepared	from	 253-J	 cells,	 and	 RT112	 cells,	 representing	 MBC,	 and	 papillary	 NMIBC,	respectively.	Full	length	OPN	expression	was	detected	at	the	anticipated	66KDa	in	 253-J	 cells,	 with	 no	 non-specific	 binding.	 Interestingly,	 no	 expression	 was	noted	in	RT112	cells	(Fig	5.12).			The	 anti-OPN	 antibody	 binds	 specifically	 to	 OPN	 by	 western	 blot,	 in	 the	predicted	region	next	it	will	be	tested	for	use	in	IHC	in	tissue.		
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Figure	 5.12.	 OPN	 expression	 in	 253-J	 and	 RT112	 cells.	 Anti-OPN	 displays	specific	 binding,	 and	 expression	 of	 full	 length	 OPN	 (60-65Kda)	 in	 MBC	 253-J	cells,	 but	 no	 expression	 in	 NMIBC	 RT112	 cells.	 Data	 is	 representative	 of	 four	independent	experiments.	Statistical	analysis	unpaired	t-test	p=<0.0001.			
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5.2.4.1.2	Anti-OPN	binds	selectively	to	inflammatory	cells	in	colon	adenocarcinoma,	
although	displays	weak	positivity	in	colon	adenocarcinoma	cells		*	
	To	optimise	the	conditions	for	IHC,	OPN-positive	tissue	 is	required.	OPN	highly	expressed	in	bone,	however	sectioning	bone	tissue	is	technically	challenging,	and	it	 may	 require	 different	 staining	 conditions	 than	 epithelial	 tumours.	 Large	portions	of	advanced	colon	adenocarcinomas	are	reported	to	express	high	levels	of	OPN	[337,	338].	Therefore,	initial	testing	was	performed	in	an	advanced	colon	adenocarcinoma	sample.	Initially,	three	primary	antibody	dilutions	were	tested,	1:100,	 1:500,	 1:1000	 and	 two	 secondary	 antibody	 concentrations,	 1:100	 and	1:200	(Fig	5.13).			No	difference	was	apparent	in	staining	between	the	two	different	concentrations	of	 secondary	 antibody.	 However,	 staining	 with	 1:100	 anti-OPN	 caused	unconvincing	 staining	 of	 adenocarcinoma	 cells,	 consistent	 with	 false	 positive	staining.	 Strong	 positive	 staining	 was	 noted	 in	 areas	 of	 necrosis	 and	 in	 scant	infiltrating	 inflammatory	 cells.	 False	 positive	 staining	 was	 diminished	 at	dilutions	 below	 1:500,	 with	 positive	 staining	 being	 evident	 in	 some	 non-adenocarcinoma	cells	at	1:1000.			The	 lack	of	 positive	 staining	 in	 tumour	 cells	may	be	due	 to	 too	dilute	primary	antibody,	or	lack	of	OPN	in	this	tissue.	With	the	significant	background	staining	in	adenocarcinoma	tissue	evident	at	1:100,	different	tissue	sources	for	OPN	will	be	tested,	before	increasing	the	concentration	of	primary	antibody.												
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Figure	 5.13.	 Osteopontin	 antibody	 optimisation	 in	 advanced	 colon	
adenocarcinoma.	 	 Conditions	were	 as	 follows	A)	OPN	1°:	 1:100,	 anti-Goat	 2°:	1:100,	B)	OPN	1°:	 1:500,	 anti-Goat	2°:	 1:100,	C)	OPN	1°:	 1:1000,	 	 anti-Goat	2°:	1:100,	D)	OPN	1°:	 1:100,	 	 anti-Goat	 2°:	 1:200,	 E)	OPN	1°:	 1:500,	 	 anti-Goat	 2°:	1:200,	 F)	 OPN	 1°:	 1:1000,	 	 anti-Goat	 2°:	 1:200,	 G)	 OPN	 1°:	 N/A,	 anti-Goat	 2°:	1:100,	H)	Isotype:	1:100,	anti-Goat	2°:	1:100.	(n=1).	
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5.2.4.1.3	Anti-OPN	displayed	good	staining	in	tubule	cells	of	normal	kidney,	strong	
staining	in	clear-cell	RCC	cells	*		Anti-OPN	was	 tested	at	 a	dilution	of	1:100	 in	 clear	 cell	 renal	 carcinoma	 tissue,	and	normal	kidney	tissue,	where	OPN	is	reportedly	expressed	in	the	cells	lining	the	 tubules	 (Fig	 5.14).	 Marked	 strong	 positive	 staining	 is	 evident	 in	 clear	 cell	renal	carcinoma	cells.	While	some	kidney	tubules	stain	moderately	for	OPN.	No	staining	was	noted	in	negative	controls.			With	good	staining	being	achieved	in	these	tissues	at	a	primary	antibody	dilution	of	1:100,	 this	concentration	will	now	be	 tested	on	bladder	normal	bladder	and	tumour	samples.																								
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Figure	5.14.	OPN	staining	in	clear	cell	renal	carcinoma	(CCRC)	and	normal	
kidney	 tissue.	 	 A	 dilution	 of	 1:100	primary	 antibody	was	 used,	 and	 1:100	 for	secondary	antibody.	A)	CCRC	stained	for	OPN,	B)	CCRC	secondary	antibody	only,	C)	Normal	kidney	stained	 for	OPN,	D)	Normal	kidney	secondary	antibody	only,	E)	CCRC	Isotype.	(n=1).							
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5.2.4.1.4	Anti-OPN	displays	weak	staining	in	bladder	samples	*		With	good	staining	being	displayed	in	other	tissues,	here	six	bladder	tissue	samples,	consisting	of	normal	bladder	and	MIBC	samples	(n=3),	were	stained	using	a	primary	antibody	dilution	of	1:100	(Fig	5.15).	Strong	staining	was	displayed	in	the	CCRC	positive	control	but	not	in	normal	tissue.	Focal	staining	up-to	moderate	levels	was	apparent	in	MIBC	samples.	However,	staining	appeared	faint	in	the	bladder	tissue.	Therefore,	a	higher	concentration	of	anti-OPN	was	attempted	next.																											
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Figure	 5.15.	 OPN	 staining	 in	 bladder	 using	 1:100	 anti-OPN.	 A)	 Normal	urothelium,	B)	MIBC,	C)	Isotype	control	CCRC,	D)	Positive	control	CCRC.	Images	presented	are	representative	of	the	cohort.	(n=1).								
A B
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5.2.4.2	Osteopontin	is	overexpressed	in	MIBC	samples	*			To	 determine	 whether	 better	 staining	 could	 be	 achieved	 by	 increasing	 the	concentration	 of	 primary	 antibody,	 a	 dilution	 of	 1:50	 was	 used.	 There	 was	 a	marked	 increase	 in	 off	 target	 staining,	 most	 apparent	 when	 comparing	 the	normal	 bladder	 sample	 between	 Fig	 5.15	 and	 Fig	 5.16,	 OPN	 staining	 was	improved.			As	the	paraffin	embedded	CCRC	tissue	block	had	ran	out,	kidney	tissue	was	used	for	positive	and	negative	controls.				A	consultant	pathologist,	Dr	Vijay	Aachi,	scored	slides.	Histopathological	scoring	a	 revealed	 moderate	 (++)	 cell	 membrane	 and	 cytoplasmic	 staining,	 whilst	normal	 urothelium	 was	 typically	 OPN	 negative	 (-)	 (Fig	 5.16).	 Non-specific	background	 staining	 is	 evident	 as	 a	 uniform	 cytoplasmic	 ‘blush’	 in	 normal	urothelial	 tissue	 (Fig5.16A),	 whilst	 positive	 OPN-staining	 in	 MIBC	 samples	 is	focal	and	granular	in	appearance	(Fig5.16B).		There	was	a	significant	difference	(p=0.0286)	in	the	expression	of	OPN	in	normal	bladder	 tissue	 and	 MIBC	 samples,	 with	 expression	 being	 markedly	 higher	 in	MIBC	 tissue	 than	 normal	 urothelium.	 These	 data	 agree	 with	 that	 of	 the	 RNA	microarray	data	in	this	chapter.													
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Figure	 5.16.	 Osteopontin	 is	 overexpressed	 in	 MIBC	 when	 compared	 to	
normal	 bladder	 urothelium.	A)	 Normal	 urothelium	 displaying	 negative	 OPN	immunostaining,	with	 the	presence	of	non-specific	binding	 in	urothelial	 tissue;	B)	MIBC	tissue	exhibiting	moderate	(++)	diffuse	OPN	immunostaining;	C)	Isotype	control,	 OPN	 expressing	 kidney	 tissue	 with	 polyclonal	 goat	 IgG	 antibody;	 D)	Graphical	representation	of	staining	results,	results	IHC	staining	from	3	normal	urothelial	 samples,	 and	 3	 MIBCs,	 statistical	 analysis	 was	 performed	 using	Welch’s	unpaired	t	 test	p	=	0.0286.	All	 images	are	representative	of	the	cohort.	(n=1).				
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5.3	Discussion		Work	 undertaken	 in	 this	 chapter	 supplements	 an	 ever-growing	 body	 of	 work	that	 employs	 microarray	 data	 to	 profile	 BC.	 Allowing	 for	 new	 insights	 into	pathways	 involved	 in	BC	pathogenesis.	The	primary	aim	of	 this	chapter	was	 to	determine	 new	 pathways	 involved	 in	 BC,	 whilst	 secondary	 aims	 include	 the	identification	 of	 drug	 targets	 and	 prognostic	 markers.	 This	 study	 identified	distinctive	patterns	of	 gene	expression	differentiating	between	normal	bladder	tissue,	NMIBC,	and	MIBC,	and	between	high	and	low	grade	BCs.		A	marked	 upregulation	 in	 pathways	 implicated	 in	 cell	 cycle	 management	 was	seen	upon	 comparison	of	MIBC	and	NMIBC,	 and	between	grade	1	 and	 grade	3	NMIBCs.	 Interestingly,	 a	 significant	 overlap	 was	 apparent	 between	 genes	upregulated	in	MIBC	and	in	grade	3	NMIBC,	compared	to	normal	bladder.	These	genes	 were	 primarily	 those	 involved	 in	 cell	 cycle	 management.	 Potentially	reflecting	the	increased	aggressiveness,	and	likelihood	of	progression	of	grade	3	NMIBC,	as	such	this	panel	may	be	useful	in	the	prediction	of	progression	to	MIBC.			The	cell	cycle	gene	ANLN	(upregulated	>8-fold),	a	substrate	of	the	APC	-	involved	in	cytokinesis	[339].	ANLN	is	upregulated	in	a	number	of	cancers	including	those	of	the	pancreas	and	kidney	[255,	256].	Interestingly,	targeting	protein	for	XKLP2	(TPX2),	also	involved	in	spindle	assembly,	was	also	upregulated	[340].		The	upregulation	of	genes	in	involved	in	the	cell	cycle	in	BC	is	not	surprising,	as	similar	findings	have	been	reported	previously	[341].	Several	upregulated	genes	have	been	identified	as	potential	therapeutic	targets	for	BCs.	Inhibitors	of	TOP2A	include	 two	 commonly	 used	 agents	 the	 anthacyclines,	 and	 etopopside.	 An	example	 being	 doxorubicin,	 an	 anthacyclines,	 which	 exhibits	 marked	 anti-BC	effects	and	is	a	component	of	the	commonly	used	MVAC	treatment	combination.		Polo-like	kinase	1	(PLK-1)	inhibitors	such	as	volasertib	have	shown	promise	in	in	
vitro	 models	 of	 BC,	 however	 in	 trials	 despite	 a	 favourable	 safety	 profile,	insufficient	anti-tumour	activity	was	exhibited	as	monotherapy	in	a	phase	II	trial	treating	MIBC	[342-344].	However,	 its	usefulness	in	combination	therapy	is	yet	
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to	be	assessed	 in	BC.	Additionally,	 several	CDK4/6	 inhibitors	are	 in	 trials	 for	a	range	 of	 tumours	 including	 bladder	 one	 example	 is	 recent	 phase	 I	 trial	 (ID:	NCT02897375)	 where	 palbociclib,	 a	 selective	 inhibitor	 of	 CDK4/6,	 is	 being	trailed	in	combination	with	cisplatin	or	carboplatin.			Overexpression	 of	 OPN	 has	 been	 noted	 in	 as	 strong	 tumour	 associated	 factor,	with	upregulation	being	noted	 in	many	tumours	[345].	Furthermore,	 inhibition	of	OPN	using	RNA-silencing	 in	 significantly	 attenuates	BC	 tumour	 cell	 invasion	[260].	 The	 marked	 (greater	 than	 10-fold	 increase	 in	 RNA	 expression)	upregulation	of	OPN	 levels	demonstrated	 in	 this	 study	 is	 concordant	with	past	studies	 demonstrating	 upregulation	 of	OPN	 levels	 in	 BC	 [305,	 306,	 341,	 346].	While	 OPN	 RNA	 expression	 data	 is	 well	 represented	 in	 BC	 tissue,	 protein	expression	data	is	more	limited	[305,	306,	346,	347].	Therefore	OPN	levels	were	investigated	using	IHC,	to	see	if	the	effects	on	OPN	RNA	expression	in	MIBC	were	concordant	with	changes	at	the	protein	level.	OPN	was	significantly	(p=0.0286)	overexpressed	 in	 MIBC	 compared	 to	 normal	 urothelium.	 This	 relationship	 is	concordant	with	 reports	 in	 cervical,	 gastric,	 oesophageal,	 and	prostate	 cancers	[346,	 348-352].	 Though,	 in	 upper	 urinary	 tract	 urothelial	 cell	 carcinoma	significant	 association	 between	 OPN	 overexpression	 and	 poor	 prognosis	 was	reported,	 with	 no	 relationship	 between	 with	 histopathological	 stage	 or	 grade	[306].	 Furthermore,	 it	 was	 interesting	 to	 note	 that	 the	 MBC	 cell	 line,	 253-J,	displayed	OPN	expression	by	western	blot,	whilst	no	OPN	was	detected	in	non-invasive	 RT112	 cells.	 Conversely,	 OPN	 overexpression	 in	 pancreatic	adenocarcinoma	is	linked	with	improved	survival,	highlighting	the	importance	of	cellular	context	on	the	outcome	of	cell	signalling	[353].			Elevated	 OPN	 levels	 have	 been	 detected	 in	 plasma	 of	 patients	 with	 advanced	UCC,	suggesting	promise	as	a	non-invasive	biomarker	of	disease	stage	[261,	354].	However,	 the	usefulness	of	OPN	as	 a	biomarker	 is	 yet	 to	be	proven	 [306,	 346,	355].	 The	 disparity	 between	 OPN	 tissue	 expression,	 and	 expression	 in	 plasma	can	partly	be	explained	by	the	existence	of	OPN	splice	variants,	and	the	cleavage	of	OPN	by	MMPs	[356].	Notably,	OPN	splice	variants,	with	distinct	physiological	functions,	are	differentially	expressed	in	cancers	[357].	Interestingly,	expression	
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of	 CD44,	 a	 key	 OPN	 receptor,	 was	 found	 to	 be	 upregulated	 in	 MIBC	 further	supporting	an	oncogenic	role	of	OPN	in	UCC	[354].		Upon	comparison	of	grade	3	NMIBC	and	MIBC,	overexpression	of	components	in	the	 cell-matrix	 interaction	 network	 was	 observed.	 Notably,	 upregulation	 was	seen	 in	 proteolytic	 enzymes,	 such	 as	 the	MMPs.	 These	 findings	 are	 consistent	with	 the	 increased	 invasive	 ability	 of	MIBC	 [195].	Mechanistically,	 it	would	 be	important	to	determine	whether	overexpression	of	certain	proteolytic	enzymes	can	 cause	 NMIBC	 to	 invade	 muscle.	 Furthermore,	 overexpression	 of	 certain	proteinases	may	predict	progression	of	NMIBC.			Genes	 involved	 in	 EMT	 and	 myogenesis	 were	 downregulated	 in	 BC,	 chiefly	between	NMIBC	 and	 normal	 bladder	 tissue.	 Interestingly,	 this	 could	 represent	BC	 exerting	 an	 inhibitory	 effect	 on	 the	 tumour	 microenvironment.	 EMT	 is	 a	process	where	 epithelial	 cells	 undergo	 transformation	 into	mesenchymal	 cells,	during	 this	 process	 epithelial	 cells	 lose	 their	 apical-basal	 polarity,	 intercellular	junctions,	 epithelial	 markers,	 and	 up-regulate	 the	 expression	 of	 mesenchymal	markers,	 developing	 front-rear	 polarity,	 and	 undergoing	 cytoskeletal	reorganisation	 [358].	 	 In	 cancer,	 EMT	 is	 associated	with	 tumour	 invasion	 and	metastasis,	 indicative	of	a	poor	prognosis	 [359].	 Importantly	 this	study	did	not	use	micro-dissection	during	sample	preparation,	it	is	therefore	possible	that	the	‘admixture’	 may	 have	 confounded	 the	 analysis	 of	 genes	 involved	 in	 EMT	 and	myogenesis.					A	 novel	 discovery	 in	 this	work	 is	 the	 downregulation	 of	 classical	 complement	pathway	 genes	 in	 NMIBC.	 Consistent	 with	 these	 findings,	 the	 upregulation	 of	complement	 inhibitors	 including	 CD46,	 and	 complement	 factor	 H	 (CFH)	 has	previously	 been	 reported	 in	 BC	 [360].	 These	 data	 suggest	 repression	 of	complement	 activity	 is	 potentially	 important	 in	BC	 pathogenesis.	 Interestingly,	CFH	may	alter	OPN	activity	through	masking	of	enzyme	cleavage	sites	[361].			Epithelial	 splicing	 regulatory	 proteins	 1	 and	 2	 (ESRP1	 &	 ESRP2),	 involved	 in	FGFR2	 splicing,	 are	 upregulated	 in	 NMIBC,	 compared	 to	 normal	 tissue	 [362].	
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Interestingly,	 decreased	 variant	 FGFR2b	 expression	 has	 been	 observed	 in	 one	group	of	BCs,	whilst	 upregulation	 of	 FGFR2c	was	 observed	 in	 a	model	 of	MBC	[363,	364].	In	agreement	with	the	notion	that	different	transcriptional	isoforms	are	 expressed	 during	 early	 carcinogenesis,	 this	 data	 supports	 a	 hypothesis	implicating	differential	expression	of	FGFR2	splice	variants	as	a	key	process	 in	bladder	carcinogenesis.			Availability	of	long-term	clinical	outcome	data	would	have	allowed	for	stronger	conclusions	 to	be	drawn	 from	the	small	 cohort.	However,	meta-analysis	of	 two	further	microarray	data	sets,	together	with	the	protein	expression	data	highlight	the	 significance	of	 the	presented	data,	 and	 the	 role	of	OPN	 in	 tumour	 invasion	[260].	 Additionally,	 this	 work	 complements	 an	 increasingly	 rich	 wealth	 of	molecular	data	in	BC,	allowing	further	understanding	of	this	 incredibly	diverse,	multifaceted	disease.			In	 conclusion,	 this	 work	 supplements	 published	 literature	 and	 displays	associations	between	certain	gene	expression	landscapes	with	tumour	stage	and	grade.	 Top	 dysregulated	 genes	 are	 potential	 gene	 signatures,	 which	 may	 be	clinically	useful	when	determining	treatment	options,	where	a	more	aggressive	approach	can	be	taken	in	those	likely	to	progress.	Notably,	several	pathways	and	genes	 were	 identified,	 including	 OPN	 and	 the	 classical	 complement	 pathway,	shows	marked	dysregulation	in	BC,	and	may	serve	as	drug	targets.														
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6.1	Introduction			In	recent	decades	little	progress	has	been	achieved	to	improve	overall	survival	in	BC,	 this	 includes	 the	 usage	 of	 systemic-GC	 in	 place	 of	MVAC,	 allowing	 a	 lower	incidence	of	adverse	events		and	comparable	response	rates	[17].	Furthermore,	the	outcome	of	the	BC2001,	a	multi-centre	phase	3	trial	where	360	patients	with	MIBC	were	randomly	assigned	to	undergo	treatment	with	radiotherapy	with	or	without	 concurrent	 chemotherapy,	 displayed	 a	 significant	 improvement	 in	locoregional	tumour	control	in	patients	treated	with	synchronous	chemotherapy	(5-Flourouracil	 and	 Mitomycin	 C),	 without	 a	 significant	 increase	 in	 adverse	events	[365,	366].	Importantly,	the	implementation	of	bladder-sparing	treatment	resulted	in	a	significant	increase	in	the	quality	of	 life	for	patients	with	BC	[367,	368].	 However,	 despite	 these	 progressions,	 the	 advancement	 of	 care	 in	 BC	 in	terms	 of	 overall	 survival	 is	 severely	 lagging	 when	 compared	 to	 other	 high-incidence	cancers.			This	chapter	will	discuss	how	findings	in	this	thesis	fit-in	with	recent	advances	in	BC,	future	pathways	for	the	development	of	ideas	presented	in	this	thesis	and	the	future	 of	 BC	 treatment,	 both	 in	 terms	 of	 impending	 advances,	 and	 long-term	goals.							
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6.2	The	utility	of	brusatol	in	BC	and	the	future	of	NRF2	inhibition	in	
cancer		Cisplatin	based	chemotherapy	is	often	highly	effective.	However,	a	key	barrier	to	successful	treatment	is	the	high	incidence	of	acquired	chemotherapy	resistance	associated	with	MIBC.	Furthermore,	a	sub-classification	of	BC	has	been	identified	as	 intrinsically	drug	resistant	 [369].	Thus,	attenuation	of	cisplatin	resistance	 in	BC	 would	 have	 significant	 implications	 in	 BC	 outcomes.	 The	 normally	cytoprotective	transcription	factor,	NRF2,	has	been	implicated	in	chemotherapy	resistance,	 as	 well	 as	 displaying	 oncogenic	 traits,	 promoting	 cell	 growth	 and	proliferation	[129].	Notably,	inhibition	of	NRF2	levels	by	siRNA	partially	restores	sensitivity	to	cisplatin	in	UCC	cells	[134].	In	this	work	brusatol	did	increase	the	sensitivity	of	 the	majority	of	UCC	cells	 to	cisplatin	although	published	data	and	that	presented	in	this	thesis	do	not	indicate	this	is	as	a	result	of	NRF2	inhibition.		Future	work	 should	 follow	up	 on	 two	 key	 findings	 of	 chapter	 three.	 Firstly,	 in	most	 cell	 lines,	 the	 combination	 of	 brusatol	 and	 cisplatin	 led	 to	 increased	sensitivity	to	cisplatin,	which	is	in	agreement	with	findings	from	Ren	et	al,	where	they	demonstrate	a	marked	reduction	in	tumour	volume	following	brusatol	and	cisplatin	combination	therapy,	when	compared	to	control	or	either	agent	alone.	Therefore,	 the	 benefit	 of	 combining	 brusatol	 and	 cisplatin	 should	 be	 explored	further,	using	different	dosage	intervals	and	frequencies	to	determine	the	most	effective	regime.	A	key	option	to	explore	is	pulsatile-dosing	of	brusatol	to	evoke	sustained	 protein	 synthesis	 inhibition,	 theoretically	 allowing	 for	 the	 time-dependent	 depletion	 of	 proteins	 involved	 in	 cisplatin	metabolism,	 once	 a	 time	point	 for	 sufficient	 depletion	 of	 these	 genes	 is	 identified	 cisplatin	 may	 elicit	increased	efficacy.	If	further	promise	is	found	in	vitro,	in	vivo	experiments	should	be	employed	in	order	to	evaluate	the	safety	and	efficacy	of	this	combination.			Secondly,	 since	 brusatol	 displayed	marked	 concentration-dependent	 inhibition	of	 UCC	 and	 similar	 compounds	 such	 as	 silvestrol	 have	 displayed	 potential	 as	anti-cancer	 treatments,	 the	utility	of	brusatol	as	a	standalone	setting	should	be	explored	 further	 in	 BC.	 Furthermore,	 Ren	et	al	 reports	 a	 reduction	 in	 tumour	size,	 greater	 than	 that	 of	 cisplatin	 alone,	 when	 brusatol	 was	 used	 alone	 in	 a	
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murine	xenograft	model	using	A549	lung	cancer	cells.	In	vitro	studies	may	begin	by	comparing	the	response	in	normal	urothelial	cell	lines	with	UCC	cells,	whilst	
in	 vivo	 studies	 would	 be	 required	 to	 determine	 the	 systemic	 tolerability	 of	brusatol	 and	 its	 efficacy	 in	 accepted	 murine	 models	 of	 BC	 such	 as	 the	 BBN-induced	model	of	BC.			Brusatol	may	not	be	a	specific	inhibitor	but	the	rationale	behind	NRF2	inhibition	as	 a	 treatment	 for	 cisplatin-resistant	 BC	 is	 robust.	 Aside	 from	 its	 role	 in	chemotherapy	resistance,	this	is	further	exemplified	by	findings	in	recent	years	where	NRF2	 is	described	 in	 an	oncogenic	 context,	 highlighting	 the	potential	 of	NRF2	 inhibition	 as	 a	 mode	 of	 promoting	 tumour	 death.	 Unfortunately,	 whilst	there	are	some	examples	of	NRF2	inducers	such	a	dimethyl	fumarate	approved	for	 clinical	 use,	 and	 a	 number	 in	 under	 investigation,	 including	 bardoxolone	methyl	(CDDO-Me),	there	are	no	approved	inhibitors	of	NRF2,	nor	any	currently	in	clinical	trials.			Encouragingly,	 there	have	been	reports	of	several	potential	 inhibitors	of	NRF2,	(For	 more	 information	 please	 see	 this	 comprehensive	 review	 of	 potential	inhibitors	 of	 NRF2	 [370].	 Briefly,	 In	 A549	 cells	 luteolin,	 a	 flavonoid,	 has	 been	reported	 to	 reduce	 both	 mRNA	 and	 protein	 expression	 of	 NRF2	 and	 increase	sensitivity	 to	 chemotherapy,	 through	 increased	NRF2	mRNA	degradation	 [371,	372].	 Furthermore,	 luteolin	 has	 been	 demonstrated	 to	 display	 selective	cytotoxicity	 to	 cancer	 cells,	 compared	 to	 non-cancer	 cells,	 including	peripheral	blood	monocytes	 [372-374].	 Similar	 effects	 have	 been	 noted	 in	 the	 flavanoids	apigenin,	and	chrysin	[375,	376].		Conversely,	in	rat	cells	luteolin	initiates	NRF2	and	 MAPK	 signalling,	 exerting	 a	 cytoprotective	 role	 [377].	 The	 antitubercular	drug,	 isoniazid,	 has	 been	 demonstrated	 to	 inhibit	 the	 NRF2-pathway,	purportedly	 through	 the	 inhibition	of	NRF2	mRNA	 [378].	 	Other	drugs	used	 in	the	 antitubercular	 class	 including	 ethanbutol,	 dihydrochloride,	 ethionamide,	rifampicin	 and	 sparfloxacin	 have	 also	 been	 demonstrated	 to	 have	 inhibitory	effects	 on	NRF2	 [370].	 Vitamin	 C,	 ascorbic	 acid,	 a	well-recognised	 antioxidant,	has	 been	 shown	 to	 inhibit	 NRF2	 activation	 through	 the	 inhibition	 of	 NRF2	nuclear	 translocation,	 showing	 chemopotentiating	 effects	 in	 cancer	 cell	 lines	
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[379].	 Finally,	 retinoic	 acid	 has	 been	 demonstrated	 as	 an	 inhibitor	 of	 NRF2	activation	 through	 the	 heterodimerisation	 of	 retinoid	 acid	 receptor	 α	 and	retinoid	X	receptor	α,	and	subsequent	inhibitor	binding	of	NRF2	[380].						
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6.3	The	significance	of	CD40-signalling	in	bladder	cancer			CD40	 receptor	 activation	 leads	 to	 a	 plethora	 of	 context-dependent	 changes	 in	cellular	 behaviour.	 CD40	 regulates	 the	 immune	 response	 and	 cell	 defence,	 in	some	cases,	inducing	the	maturation	of	immune	cells	including	peripheral	blood	monocytes.	Although	the	effects	of	CD40-ligation	are	not	confined	to	the	immune	system.	 In	BC	 cell	 lines	CD40-ligation	with	mCD40L	 leads	 to	marked	apoptotic	induction.	This	response	is	the	net	outcome	of	pro-apoptotic,	and	anti-apoptotic	signalling	mediated	by	the	TRAFs.	Furthermore,	CD40	is	highly	expressed	in	BC,	making	 it	 an	 interesting	 putative	 drug	 target.	 Interestingly,	 CD40-ligation	 has	been	 implicated	 in	 direct	 tumour	 cell	 death	 and	 immune-activation	 that	 can	increase	the	anti-tumour	response	to	CD40-directed	therapy,	furthermore	CD40-ligation	 is	 reported	 to	 enhance	 immune	 cell	motility	 and	 infiltration,	 however	little	is	known	about	the	role	of	CD40-ligation	in	tumour	cell	invasion	[323].			Using	 an	 organotypic	 three-dimensional	 model	 of	 BC,	 chapter	 4	 aimed	 to	determine	whether	 CD40-ligation	 induced	 pro-	 or	 anti-	 invasive	 effects.	 A	 key	secondary	aim	was	to	identify	genes	involved	invasive	change.	Notably,	marked	cell	 death,	 and	 attenuation	 of	 invasion	 was	 observed,	 whilst	 CD40-expressing	tumour	 cells	 did	 not	 invade.	 The	 BC	 tissue	 gene	 expression	 microarray	 data	presented	 in	 chapter	 5	 and	 a	microarray	 comparing	 gene	 expression	 between	AdMock	 and	 AdNclCD40L	 treated	 EJ	 cells	 were	 cross-referenced,	MMP1,	 FN1,	
FAM83D	and	ANLN	were	selected	for	further	analysis,	due	to	marked	differential	expression	in	both	datasets,	supported	by	evidence	for	their	 implementation	in	tumour	 invasion,	 growth	 or	 proliferation.	 Expression	 of	 all	 four	 genes	 was	confirmed	by	endpoint	RT-PCR	and	FN1	and	MMP1	expression	was	examined	at	the	protein	level	by	western	blot.	Interestingly,	discordance	was	noted	between	mRNA	and	protein	levels	of	FN1	were	noted	in	EJ	cells.	However,	these	data	did	not	 explain	 the	 marked	 inhibition	 of	 tumour-invasion	 noted	 in	 organotypic	models.			In	order	to	determine	the	mode	of	invasion	inhibition	further	experimentation	is	needed.	 Initially	 the	potential	anti-invasive	effect	of	apoptotic	 induction	should	
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be	 explored,	 using	 current	 knowledge	 of	 CD40-ligation	 mediated	 apoptosis	 to	identify	 targets	 for	commercially	available	 inhibitors	of	apoptosis,	or	siRNAs.	 If	tumour	 invasion	 is	 not	 attenuated	 by	 inhibition	 of	 apoptosis,	 the	 downstream	effects	of	CD40-ligation	should	be	scrutinised	further.	Due	to	the	broad-reaching	effects	of	CD40-ligation,	scrutinisation	of	differentially	expressed	genes	may	be	an	 extensive	 process.	 Therefore,	 a	 similar	 rational	 design	 to	 chapter	 4,	 where	large	datasets	are	used	to	identify	a	small	panel	of	potential	effectors	may	be	the	most-time	 efficient	 method.	 Additionally,	 as	 we	 understand	 more	 about	molecularly	 distinct	 subtypes	 of	 BC,	 candidate	 effectors	 can	 be	 selected	 with	increased	 confidence.	 Exploration	 of	 the	 effects	 of	 on	 tumour	 motility	 and	invasion	 can	 be	 performed	 using	 siRNA	 in	 monolayer	 experiments	 such	 as	scratch-assays.	 Markers	 displaying	 promise	 can	 be	 analysed	 in	 more	 complex	models,	 such	 as	 an	 organotypic	 model	 of	 BC	 where	 lentiviral	 silencing	 and	adenoviral	 infection	 can	 be	 added	 to	 determine	 the	 effects	 of	 up,	 and	 down-regulation	of	specific	genes.			The	immune	activating	and	cell-death	inducing	effects	of	CD40-ligation	have	led	to	 marked	 interest	 as	 a	 drug	 target.	 Agonistic	 antibodies	 have	 shown	encouraging	results	in	pre-clinical	and	phase	I	studies.	A	recent	phase	I	study	in	solid	tumours	has	reported	activation	of	B	and	NK	cells	at	well	tolerated	doses,	indicating	 potential	 in	 combination	 with	 chemotherapy	 [381].	 In	 pancreatic	cancer	 the	usage	of	 a	 CD40	 agonistic	 antibody,	 CP-870,	 893,	 in	 	 a	 phase	 I	 trial	revealed	 promising	 anti-tumour	 activity	 in	 combination	 with	 chemotherapy,	whilst	 a	 phase	 I	 study	 of	 the	 same	 agonistic	 antibody	 with	 carboplatin	 and	paclitaxel,	 for	 advanced	 solid	 tumours,	 produced	promising	 results	warranting	phase	II	studies	[382,	383].	 	Finally,	 in	murine	models	a	 locally	delivered	CD40	agonistic	antibody	leads	to	eradication	of	MBC	[384].			
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6.4	The	importance	gene	expression	analysis	and	biomarker	
identification	in	the	advancement	of	bladder	cancer	care				In	 NMIBC	 20%	 of	 patients	 will	 progress	 to	 MIBC,	 whilst	 under	 half	 of	 MIBC	patients	will	 survive	5	years’	post-diagnosis,	with	survival	down	 to	only	6%	of	patients	with	MBC.	The	current	histological	staging	and	grading	system	does	not	accurately	 determine	 which	 tumours	 are	 most	 likely	 to	 progress	 to	 life	threatening	 disease.	 Thus,	 there	 is	 rationale	 for	 the	 exploration	 of	 alternative	methods	 of	 disease	 stratification	 for	more	 accurate	 diagnosis.	 Gene-expression	analyses	in	cancer	can	allow	for	the	association	of	distinct	expressional	profiles,	with	disease	stage	and	grade.	Additionally,	expressional	profiles	can	be	used	to	determine	traits	involved	in	progression,	useful	in	prognostication.			In	this	study,	distinct	clustering	was	noted	in	a	number	of	different	comparisons	between	 normal	 bladder	 tissue,	 NMIBC	 tissue,	 and	 MIBC	 tissue.	 Furthermore,	expressional	 signatures	 were	 suggested	 that	 might	 be	 predictive	 of	 stage	 and	grade,	also	highlighting	some	genes	that	may	be	involved	in	tumour	progression,	notably	between	grade	3	NMIBC	and	MIBC.			In	 recent	 years,	 there	 has	 been	 an	 extensive	 effort	 to	 define	 the	 expressional,	mutational,	 epigenetic	 and	 proteomic	 landscape	 of	 BCs.	 These	 analyses	 have	resulted	 in	 the	 formation	 of	 molecularly	 distinct	 subsets	 of	 BC,	 some	 with	similarities	 to	 tumours	 at	 different	 anatomical	 sites,	 that	may	 be	 predictive	 of	response	 to	 therapy,	 survival	 and	 disease	 progression	 [369,	 385-387].	 Further	integration	 of	 multiple-‘omics’	 data	 with	 clinicopathological	 features	 and	outcomes	 may	 allow	 the	 development	 of	 diagnostic	 tests	 with	 predictive	 and	prognostic	value.			Overexpressed	 in	 the	 plasma	 of	 patients	 with	 MIBC,	 in	 this	 thesis	 OPN	expression	was	also	upregulated	in	MIBC	tissues,	indicating	prognostic	potential.	However,	 exploration	 of	 OPN	 as	 a	 blood	 biomarker	 of	 BC	 should	 be	 pursued	prior	to	tissue,	as	a	non-invasive	method	of	disease	monitoring	is	direly	needed.			
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In	 order	 to	 determine	 the	 validity	 of	 OPN	 as	 a	 plasma	 available	model	 of	 BC,	blood	 samples	 could	 be	 collected	 from	 groups	 of	 healthy	 volunteers,	 NMIBC	patients,	and	MIBC	patients.	After	plasma	preparation,	detection	of	various	OPN	isoforms	 by	 the	 enzyme-linked	 immunosorbent	 assay	 (ELISA)	 could	 then	 be	correlated	with	clinicopathological	features,	and	outcomes.																													
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6.5	Insight	into	the	near	and	distant	future	of	bladder	cancer	care				One	of	the	key	challenges	in	developing	new	regimens	for	the	treatment	of	BC	is	the	 demographic	 of	 BC	 patients.	 The	 target	 population	 is	 elderly,	 often	harbouring	co-morbidities,	some	smoking	associated	such	as	renal	dysfunction,	and	poor	performance	status.	These	traits	necessitate	the	development	of	well-tolerated	 regimes.	 The	usage	 of	 novel	 targeted-therapies	 in	BC	 aims	 to	 deliver	potent	 tumour	 killing,	 with	 fewer	 systemic	 side	 effects	 than	 conventional	cytotoxic	chemotherapy.	Promising	emerging	treatments	include	inhibitors	of	T-cell	 checkpoint	 molecules,	 programmed	 cell	 death	 protein	 1	 (PD1)	 and	programmed	 death-ligand	 1	 (PD-L1),	 and	 anti-angiogenics.	 Inhibition	 of	 both	PD1	 and	PD-L1	durable	 responses	 in	 patients	with	 advanced	MIBC,	 previously	challenged	with	 platinum-based	 chemotherapy	 [388,	 389].	 Interestingly,	 when	treated	with	the	PD-L1	inhibitor,	atezolizumab,	response-rates	were	increased	in	patients	 with	 higher	 expression	 of	 PD-L1	 in	 immune	 cells	 [388,	 390].	Atezolizumab	and	the	PD1	inhibitor,	pembrolizumab,	are	both	being	investigated	in	 phase	 III	 trials	 as	 second	 line	 treatments,	 in	 comparison	 to	 vinfluinine	 or	taxanes.	 	Additionally,	 several	checkpoint	 inhibitors	are	being	 investigated	as	a	first	 line	 treatment	 in	 platinum-ineligible	 patients,	 one	 example	 being	durvalumab,	 a	 recent	 PD-L1	 inhibitor,	which	 is	 under-investigation	 in	 a	 three-arm	phase	 III	 trial,	where	 it	 is	 being	 tested	 in	 cisplatin-ineligible	 and	 –eligible	patients:	 comparing	GC,	 durvalumab	alone,	 and	durvalumab	plus	 tremeliumab,	an	 inhibitor	 of	 cytotoxic	 T-lymphocyte-associated	 antigen	 4	 (CTLA4).	 With	adjuvant	 atezolizumab,	 nivolumab,	 and	 pembrolizumab	 being	 under	 phase	 III	investigation,	 post-cystectomy,	 in	 patients	 with-	 or	 without	 neoadjuvant	chemotherapy	for	MIBC.			Interestingly,	 cabozatinib,	 responsible	 for	 the	 inhibition	of	vascular	endothelial	growth	 factor	 receptors	 (VEGFRs)	 and	 c-MET,	 displays	 activity	 in	 preliminary	studies	 and	 is	 associated	with	 an	 increase	 in	 PD1	 expression	 in	 regulatory	 T-cells,	suggesting	potential	in	combination	with	PD1	inhibition	[391].	Although	a	number	 of	 VEGFR	 tyrosine	 kinase	 inhibitors	 (TKIs)	 have	 not	 demonstrated	significant	 benefit	 in	 phase	 II	 trains,	 both	 alone	 (pazopanib,	 sunitinib)	 and	 in	
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combination	with	chemotherapy	(sorafenib,	vandetanib)	[392-395].	Conversely,	the	VEGFR-2	 inhibitor,	 ramucirumab,	 extended	progression	 free	 survival	 (PFS)	in	combination	with	docetaxel	in	a	phase	II	trial	and	is	currently	under	phase	III	analysis	[396].	A	multicentre	phase	II	trial,	NEOBLADE,	is	currently	assessing	the	benefit	 of	 the	 triple	 angiokinase	 (VEGFR,	 FGFR,	 platelet	 derived	 growth	 factor	receptor	 (PDGFR))	 inhibitor	 Nintedanib,	 in	 addition	 to	 GC	 in	 the	 neoadjuvant	setting.	 Additionally,	 regorafenib,	 a	 TKI	 that	 inhibits	 VEGFRs,	 FGFR1	 and	 the	angiopoietin-tyrosine	 kinase	 2-axis,	 is	 under	 phase	 II	 evaluation	 in	 the	 second	line	setting	for	advanced	BC.			Several	other	agents	have	performed	well	in	select	groups	of	patients.	Molecular	profiling	 of	 tumour	 tissue	 has	 suggested	 a	 number	 of	 potential	 therapeutic	targets	 including	 constituents	 of	 the	 EGFR	 family,	 mTOR	 pathway,	 MAPK	pathway	 and	 pathways	 controlling	 the	 G1/S	 phase	 checkpoint	 [385,	 397].	Moreover,	 patients	 with	 tumours	 containing	 tuberous	 sclerosis	 1	 (TSC1)	 and	mTOR	mutations	display	marked	response	to	everolimus	[398,	399].	Contrarily,	the	 human	 epidermal	 growth	 factor	 receptor	 (HER)-2	 inhibitors	 trastuzumab	and	 lapatinib	 did	 not	 improve	 outcomes	 in	 HER2	 or	 EGFR-expressing	 MBC	patients	 [400,	 401].	 However,	 afatinib	 demonstrated	 activity	 in	 patients	 with	tumours	containing	HER2,	or	HER3	mutation	or	amplification	[402].	Differences	in	 response	 have	 been	 demonstrated	 between	 TKIs	 of	 divergent	 potency.	 The	use	 of	 FGFR	 inhibitors	 in	 patients	 harbouring	 FGFR2	 and	 FGFR3	 alterations	 is	associated	 with	 durable	 response,	 however,	 the	 usage	 of	 the	 less	 potent	inhibitor,	 dovitinib,	 does	 not	 display	 significant	 activity	 in	 FGFR3-altered	patients.	These	findings	highlight	the	 importance	of	both	target	and	drug	[403-405].	 	 The	 CDK(4/6)	 inhibitor,	 palbociclib,	 approved	 in	 breast	 cancer,	 is	currently	 under	 rational	 evaluation	 in	 a	 population	 of	 patients	with	 functional	retinoblastoma	protein	 (RB)	 and	 either	CDK	 inhibitor	2A-negative	 tumours,	 or	cyclin	 D1	 protein	 overexpression	 by	 IHC.	 Interestingly,	 histone	 deacetylase	inhibitors	are	also	under	investigation	in	BC,	due	to	the	enhanced	expression	of	these	 targets	 in	BC	[385].	 Interestingly,	novel	preparations	of	current	cytotoxic	drugs	are	also	under	investigation	with	encouraging	results,	one	example	being	nanoparticle	albumin-bound-paclitaxel	[406].		
	 217	
The	 identification	 of	 discreet	 molecular	 subtypes	 of	 BC	 by	 gene	 expression	profiling	 may	 have	 consequences	 in	 the	 implementation	 of	 personalised	 care	[369,	 385,	 387,	 407].	 Briefly,	 the	 basal	 subclassification	 is	 proposed	 as	 being	more	chemosensetive,	whilst	the	luminal	subclassification	identifies	FGFR,	HER2	and	 HER3	 as	 targets,	 finally	 the	mesenchymal/claudin-low	 subclassification	 is	rich	in	T-cell	checkpoint	targets	[369,	407].			The	 ever-growing	 number	 of	 clinical	 trials	 in	 BC	 is	 a	 direct	 result	 of	 our-increased	 understanding	 of	 the	 molecular	 underpinnings	 of	 this	 disease.	Translational	 medicine	 allows	 for	 the	 integration	 of	 high-throughput	 target	mining	 techniques	 such	 as	 gene	 expression	 profiling,	 and	 next	 generation	sequencing,	with	pre-clinical	in	vitro	and	in	vivo	analyses,	which	feed	into	clinical	trials.	Work	in	this	thesis	identifies	potential	targets	such	as	OPN,	whilst	recently	published	work	chiefly	 that	by	Choi	et	al,	Damrauer	et	al	and	TGCA	highlights	a	range	 of	 targets	 [369,	 385,	 407].	 With	 further	 integration	 of	 data	 spanning	multiple-‘omics’,	more	targets	will	be	discovered	in	BC,	fuelling	the	generation	of	multimodal	therapies	in	BC.	Excitingly,	the	future	of	BC	care	looks	brighter	with	new	better	tolerated	treatments	in	phase	II	and	III	trials,	offering	advantageous	survival,	treatments	building	upon	recent	findings	may	offer	a	new-generation	in	treatment	 for	 BC,	 where	 the	 implementation	 of	 checkpoint	 inhibitors,	angiokinase	 inhibitors	 and	CD40-agonsits	 in	 the	 clinic	 is	 the	 first	 phase	 in	 this	personalised	 approach.	 Furthermore,	 with	 an	 increased	 number	 of	 putative	targets	and	therapies	the	implementation	of	umbrella	trials	is	an	interesting	trial	design	 for	personalised	 therapy	–	here	patient	 treatment	 is	 stratified	by	 target	expression.	 Finally,	 as	 pan-cancer	 gene-expression	 profiles	 emerge,	 the	 basket	trial	design	is	very	attractive;	in	this	approach	eligibility	is	based	on	the	tumour	expression	profile,	rather	than	location.				
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6.6	Concluding	statements			This	 thesis	 demonstrates	 techniques	 used	 in	 the	 identification	 of	 drug	 targets,	prognostic	markers,	and	pre-clinical	development	of	cancer	therapies.			Here	 the	molecular	 aspects	 of	 BC	 have	 been	 analysed	 in	 BC	 tissue	 using	 gene	expression	profiling	techniques,	allowing	 for	more	 insight	 into	gene	expression	patterns	in	BC	and	their	relation	to	stage	and	grade.	Here	a	number	of	potential	expressional	signatures	were	proposed	and	expression	of	OPN	was	revealed	to	be	associated	with	MIBC.	However,	further	studies	are	required	to	determine	the	clinical	 validity	 of	 the	 proposed	 expressional	 signatures,	 whilst	 mechanistic	investigations	 are	 needed	 to	 determine	 the	 passenger/driver	 status	 of	 the	presented	alterations.				Targeted	 inhibition	of	NRF2	was	evaluated	with	 its	putative	 inhibitor,	brusatol,	whilst	brusatol	inhibited	NRF2	expression,	it	did	not	affect	downstream	protein	expression.	Furthermore,	recently	published	work	by	Vartanian	et	al	questioned	the	specificity	of	brusatol	to	NRF2,	describing	it	as	a	global	 inhibitor	or	protein	synthesis.	 However,	 brusatol	 does	 increase	 the	 sensitivity	 of	 UCC	 cells	 to	cisplatin,	and	as	a	stand-alone	agent	 it	potently	evokes	marked	toxicity	on	UCC	cells,	 warranting	 further	 research	 in	 this	 setting	 –	 especially	 considering	 the	promise	of	similar	molecules	such	as	silvesterol.			The	 implication	 of	 CD40-ligation	 on	 CD40-positive	 UCC	 invasion	 was	investigated	in	an	organotypic	model	of	BC.		Marked	cell	death	was	observed	in	NMIBC	 RT112	 cells	 treated	 with	 AdNclCD40L,	 whilst	 distinct	 attenuation	 of	invasion	was	observed	in	MIBC	EJ	cells,	accompanied	by	marked	cell	death.	IHC	staining	 for	CD40L	revealed	a	 lack	of	CD40	expression	on	 invading	cells.	Gene-expression	analysis	data	comparing	grade	3	NMIBC	and	MIBC	highlighted	genes	potentially	 involved	 in	 invasion,	 this	 data	 was	 cross-referenced	 with	 gene	expression	 data	 comparing	 EJ	 cells	 treated	 with	 AdMock	 or	 AdNclCD40L.	 The	expression	of	four	candidates	were	confirmed	in	EJ	and	RT112	cells	at	the	mRNA	level,	 whilst	 relative	 changes	 in	 FN1	 and	 MMP1	 expression	 in	 response	 to	
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AdNclCD40L-ligation	were	observed,	indicating	increased	expression	of	proteins	involved	in	tumour	invasion,	with	discordance	between	FN1	and	FN1	expression.	These	 data	 highlight	 a	 role	 of	 CD40-ligation	 in	 the	 attenuation	 of	 tumour	 cell	invasion,	 however,	 the	mechanisms	 for	 this	 process	 are	 yet	 to	 be	 determined.	Further	 analysis	 should	determine	whether	 apoptotic-induction	plays	 a	 role	 in	the	 inhibition	of	 tumour-cell	 invasion.	Furthermore,	pharmacological	 inhibition	and	gene	silencing	should	be	employed	in-order	to	determine	the	role	of	altered	downstream	genes	in	invasion.								
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Abstract. Despite advances in management, bladder cancer 
remains a major cause of cancer related complications. 
Characterisation of gene expression patterns in bladder 
FDQFHUDOORZVWKHLGHQWLÀFDWLRQRISDWKZD\VLQYROYHGLQLWV
SDWKRJHQHVLVDQGPD\VWLPXODWHWKHGHYHORSPHQWRIQRYHO
WKHUDSLHVWDUJHWLQJWKHVHSDWKZD\V%HWZHHQDQG
F\VWRVFRSLFEODGGHUELRSVLHVZHUHREWDLQHGIURPSDWLHQWV
DQGFRQWUROV7KHVHZHUHVXEMHFWHGWRZKROHWUDQVFULSW
EDVHG PLFURDUUD\ DQDO\VLV 8QVXSHUYLVHG KLHUDUFKLFDO
FOXVWHULQJZDVXVHGWRLGHQWLI\VDPSOHVZLWKVLPLODUH[SUHV
VLRQSURÀOHV+\SHUJHRPHWULFDQDO\VLVZDVXVHGWRLGHQWLI\
FDQRQLFDOSDWKZD\VDQGFXUDWHGQHWZRUNVKDYLQJVWDWLVWLFDOO\
VLJQLILFDQW HQULFKPHQW RI GLIIHUHQWLDOO\ H[SUHVVHGJHQHV
2VWHRSRQWLQ231H[SUHVVLRQZDVYDOLGDWHGE\LPPXQR
KLVWRFKHPLVWU\+LHUDUFKLFDOFOXVWHULQJGHÀQHGVLJQDWXUHV
ZKLFK GLIIHUHQWLDWHG EHWZHHQ FDQFHU DQG KHDOWK\ WLVVXH
PXVFOHLQYDVLYHRUQRQPXVFOHLQYDVLYHFDQFHUDQGKHDOWK\
WLVVXHJUDGHDQGJUDGH3DWKZD\VDVVRFLDWHGZLWKFHOO
F\FOH DQG SUROLIHUDWLRQ ZHUH PDUNHGO\ XSUHJXODWHG LQ
PXVFOHLQYDVLYHDQGJUDGHFDQFHUV*HQHVDVVRFLDWHGZLWK
WKHFODVVLFDOFRPSOHPHQWSDWKZD\ZHUHGRZQUHJXODWHGLQ
QRQPXVFOHLQYDVLYHFDQFHU2VWHRSRQWLQZDVPDUNHGO\RYHU
H[SUHVVHGLQLQYDVLYHFDQFHUFRPSDUHGWRKHDOWK\WLVVXH7KH
SUHVHQWVWXG\FRQWULEXWHVWRDJURZLQJERG\RIZRUNRQJHQH
expression signatures in bladder cancer. The data support an 
LPSRUWDQWUROHIRURVWHRSRQWLQLQEODGGHUFDQFHUDQGLGHQWLI\
VHYHUDOSDWKZD\VZRUWK\RIIXUWKHULQYHVWLJDWLRQ
Introduction
Carcinoma of the bladder is the most common urothelial 
PDOLJQDQF\DQGLVWKHWKFRPPRQHVWFDQFHULQWKHZRUOGE\
LQFLGHQFH'HVSLWHVLJQLÀFDQWLPSURYHPHQWVLQPDQDJH
ment, bladder cancer remains one of the commonest causes 
RIFDQFHUUHODWHGPRUWDOLW\UDQNHGWKDQGWKLQWKH8.LQ
LQPHQDQGZRPHQUHVSHFWLYHO\$GGLWLRQDOO\FXUD
WLYHVXUJHU\RUUDGLRWKHUDS\FRPPRQO\UHVXOWVLQVLJQLÀFDQW
ORQJWHUPPRUELGLW\
/RFDOLVHG EODGGHU FDQFHUPD\ EH GLYLGHG LQWR HLWKHU
QRQPXVFOHLQYDVLYHEODGGHUFDQFHU10,%&RULQWRPXVFOH
LQYDVLYH EODGGHU FDQFHU 0,%&:KLOH WKH IRUPHUPD\
EHFXUHGE\WUDQVXUHWKUDOUHVHFWLRQWUHDWPHQWRIWKHODWWHU
UHTXLUHVUDGLFDOORFDOPDQDJHPHQWXVLQJHLWKHUF\VWHFWRP\
*HQHH[SUHVVLRQSURÀOLQJLQEODGGHUFDQFHU
LGHQWLÀHVSRWHQWLDOWKHUDSHXWLFWDUJHWV
6<('$+866$,1'$1,(/+3$/0(5:,1*.,16<1-26(3+-6$&&2, 
5,&+$5'0'*5((160,7+7$+$(/0(7:$/,9,-$<$$&+,%5<21<+//2<', 
387+(19-,7+(6+-2+1$55$1''$55(1%$5721-$:$+(5$16$5,, 
'52666,%621  and1,&+2/$6'-$0(6
'HSDUWPHQWRI0ROHFXODUDQG&OLQLFDO&DQFHU0HGLFLQH8QLYHUVLW\RI/LYHUSRRO/LYHUSRRO/*$ 
5HJHQHUDWLRQDQG5HSDLU*URXS7KH,QVWLWXWHRI+HSDWRORJ\)RXQGDWLRQRI/LYHU5HVHDUFK/RQGRQ6(178. 
'HSDUWPHQWRI3K\VLRORJ\8QLYHUVLW\RIWKH%DVTXH&RXQWU\/HLRD6SDLQ7KH5R\DO/LYHUSRRODQG 
%URDGJUHHQ8QLYHUVLW\+RVSLWDO7UXVW/LYHUSRRO/;36FKRRORI&DQFHU6FLHQFHV8QLYHUVLW\RI%LUPLQJKDP 
%LUPLQJKDP%77%HDWVRQ:HVW6FRWODQG&DQFHU&HQWUH*ODVJRZ*<18.
5HFHLYHG1RYHPEHU$FFHSWHG-DQXDU\
'2,LMR
Correspondence to:'U6\HG$+XVVDLQ'HSDUWPHQWRI0ROHFXODU
DQG &OLQLFDO &DQFHU 0HGLFLQH 8QLYHUVLW\ RI /LYHUSRRO 'XQFDQ
%XLOGLQJ'DXOE\6WUHHW/LYHUSRRO/*$8.
(PDLOV\HGKXVVDLQ#OLYHUSRRODFXN
CRQWULEXWHGHTXDOO\
Abbreviations: 10,%& QRQPXVFOH LQYDVLYH EODGGHU
FDQFHU 0,%& PXVFOH LQYDVLYH EODGGHU FDQFHU &'. F\FOLQ
GHSHQGHQW NLQDVH  )2;0 IRUNKHDG ER[ SURWHLQ 0 3/.
SROROLNH NLQDVH  .16/ NLQHVLQ IDPLO\ PHPEHU  0HI
P\RF\WH HQKDQFHU IDFWRU 0\R' P\RJHQLF GLIIHUHQWLDWLRQ 
(07 HSLWKHOLDO WR PHVHQFK\PDO WUDQVLWLRQ 003V PDWUL[
PHWDOORSURWHLQDVHV 003 PDWUL[ PHWDOORSURWHLQDVH  003
PDWUL[ PHWDOORSURWHLQDVH  3(/2 SURWHLQ SHORWD KRPRORJ
6(53,1% 6HUSLQ SHSWLGDVH LQKLELWRU FODGH % RYDOEXPLQ
PHPEHU  &$6& FDQFHU VXVFHSWLLOLW\ FDQGLGDWH  $3&
DQDSKDVH SURPRWLQJ FRPSOH[ 73; WDUJHWLQJ SURWHLQ IRU ;NOS
723$ WRSRLVRPHUDVHDOSKD09$&PHWKRWUH[DWHYLQEODVWLQH
DGULDP\FLQDQGFLVSODWLQ231RVWHRSRQWLQ7&& WUDQVLWLRQDOFHOO
FDUFLQRPD&)+ FRPSOLPHQW IDFWRU+(653 HSLWKHOLDO VSOLFLQJ
UHJXODWRU\SURWHLQ(653HSLWKHOLDOVSOLFLQJUHJXODURW\SURWHLQ
)*)5EF ILEUREODVW JURZWK IDFWRU UHFHSWRU  E LVRIRUP
FLVRIRUP,+&LPPXQRKLVWRFKHPLVWU\
Key words:EODGGHUFDQFHURVWHRSRQWLQJHQHH[SUHVVLRQDQDO\VLV
PROHFXODUFODVVLILFDWLRQPLFURDUUD\PXVFOHLQYDVLYH
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+866$,1et al*(1((;35(66,21352),/,1*,1%/$''(5&$1&(5,'(17,),(6327(17,$/7+(5$3(87,&7$5*(762
RUUDGLFDOUDGLRWKHUDS\ZLWKRUZLWKRXWFRQFXUUHQWFKHPR
WKHUDS\$SSUR[LPDWHO\D WKLUGRI10,%& WXPRXUVZLOO
UHFXUDQGSURJUHVVWRPXVFOHLQYDVLYHRYHUWLPH6HYHUDO
clinicopathological factors including tumour grade, stage, 
size, presence of carcinoma in situSUHYLRXVUHFXUUHQFH
DQGSVWDWXVDUHDVVRFLDWHGZLWKLQFUHDVHGOLNHOLKRRGRI
SURJUHVVLRQ+RZHYHUWKHVHIDFWRUVDUHQRWFXUUHQWO\FOHDUO\
VXIÀFLHQWWRLGHQWLI\SDWLHQWVZKRQHHGPRUHUDGLFDOWKHUDS\
DWWKHRXWVHW6LPLODUO\VWUDWLÀFDWLRQRISDWLHQWVZLWKPXVFOH
LQYDVLYHFDQFHULQWRWKRVHPRVWOLNHO\WRUHFXURUSURJUHVV
IROORZLQJORFDOWKHUDS\ZRXOGHQDEOHDPRUHSHUVRQDOLVHG
approach to treatment.
3UHYLRXVVWXGLHVKDYHHPSOR\HGPLFURDUUD\VWRLQYHVWLJDWH
JHQHH[SUHVVLRQSURÀOHVLQEODGGHUFDQFHU7KHLGHQWL
ÀFDWLRQRIGLIIHUHQWLDOO\UHJXODWHGJHQHVDQGJHQHQHWZRUNV
DOORZV WKH GLVVHFWLRQ RI SDWKZD\V DQG SURFHVVHV WKDW DUH
G\VUHJXODWHGLQEODGGHUFDQFHU7KLVLQWXUQSURYLGHVLQYDOX
DEOHFOXHVUHODWLQJWRSDWKRJHQHVLVDQGPRUHRYHUPD\SURYLGH
novel targets for drug development.
+HUHZH GHVFULEH D VWXG\ LQZKLFKZH SURILOHG JHQH
H[SUHVVLRQLQEODGGHUFDQFHUVDPSOHVDQGFRPSDUHGWKLV
WRKHDOWK\XURWKHOLDOVDPSOHV,QDGGLWLRQWRGHÀQLQJJHQH
H[SUHVVLRQVLJQDWXUHVIRUGLIIHUHQWVXEJURXSVWKHVWXG\LGHQWL
ÀHGVHYHUDOJHQHVDQGJHQHQHWZRUNVZKLFKDUHVLJQLÀFDQWO\
deregulated in bladder cancer. These include osteopontin and 
WKHFODVVLFDOFRPSOHPHQWSDWKZD\,QWKLVVWXG\ZHXVHGWKH
$II\PHWUL[+XPDQ*HQH67DUUD\ZKLFKLVDZKROHWUDQ
VFULSWEDVHGDUUD\FRPSDUHGWRPDQ\RWKHUVWXGLHVZKLFKXVHG
DUUD\VTXHU\LQJRQO\WKH
HQGRIWUDQVFULSWV
0DWHULDOVDQGPHWKRGV
Patients and tumour samples. &\VWRVFRSLF WLVVXHELRSVLHV
ZHUHFROOHFWHGEHWZHHQ0D\DQG1RYHPEHU3ULRU
WRXQGHUJRLQJF\VWRVFRS\SDUWLFLSDQWVJDYHZULWWHQLQIRUPHG
FRQVHQWIRUDGGLWLRQDOELRSVLHVWREHWDNHQIRUWKLVVWXG\GXULQJ
their medical procedure. Patients eligible for inclusion were 
WKRVH DJHG\HDUVZLWK DGLDJQRVLV RI KLVWRORJLFDOO\
FRQÀUPHGVXSHUÀFLDO10,%&RUPXVFOHLQYDVLYH0,%&
WUDQVLWLRQDOFHOOFDUFLQRPDQ DQGQ UHVSHFWLYHO\DQG
ZKRKDGQRWUHFHLYHGDQ\SULRUWKHUDS\&RQWURO&VDPSOHV
were obtained from uninvolved tissues, for which no abnor
PDOLWLHVZHUHREVHUYHGXSRQKLVWRORJLFDOH[DPLQDWLRQQ 
7HQRIWKHVHZHUHSDLUHGZLWKEODGGHUFDQFHUELRSVLHVQRQ
PXVFOHLQYDVLYHDQGPXVFOHLQYDVLYHZKLOHWKHODVWZDVIURP
DSDWLHQWZLWKRXWDGLDJQRVLVRIPDOLJQDQF\'HPRJUDSKLF
characteristics of the patient cohort are presented in Table I. 
0,%&VDPSOHVGLVSOD\HGDEDVDOLPPXQRSKHQRW\SH
7XPRXU VDPSOHV IRU ,+&DQDO\VLVZHUHREWDLQHG IURP
WKH/LYHUSRRO%LRLQQRYDWLRQ+XE%LREDQN/LYHUSRRO8.
3DWKRORJLFDOO\DVVHVVHGVDPSOHVXVHGKHDOWK\EODGGHUWLVVXH
Q DQG0,%&WXPRXUWLVVXHQ 
Ethical considerations. $SSURYDOIRUWKHSUHVHQWVWXG\ZDV
REWDLQHGIURPWKH6RXWK%LUPLQJKDP/RFDO5HVHDUFK(WKLFV
Committee. All participants gave written informed consent for 
WKHLUUHVSHFWLYHELRSVLHVWREHXWLOL]HGLQWKLVVWXG\$SSURYDO
IRUIXUWKHUDQD\OVLVZDVJUDQWHGE\WKH/LYHUSRRO7LVVXH%DQN
(WKLFV&RPPLWWHHDSSOLFDWLRQQR$OOSDUWLFLSDQWV
Table I. Patient demographics.
'HPRJUDSKLFV &RQWUROVQ  10,%&Q  0,%&Q 
$JHLQ\HDUV
  0HGLDQUDQJH   
Gender
0DOH   
)HPDOH   
Grade
* 1$  
* 1$  
* 1$  
T stage
37 1$  
37% 1$  
3WD 1$  
37 1$  
Recurrence
1R 1$  
<HV 1$  
6XUYLYDOLQPRQWKV&, 1$ QRWHVWLPDWDEOH 
1$QRWDSSOLFDEOH
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gave written informed consent for their respective biopsies to 
EHXVHGLQELRPHGLFDODQDO\VLV
Tissue sample preparation. 7LVVXHELRSV\VDPSOHVZHUHVQDS
frozen and stored in liquid nitrogen prior to RNA extraction.
RNA isolation. Total RNA was extracted from each tissue using 
75,]RO,QYLWURJHQSULRUWRSXULÀFDWLRQRQVLOLFD51HDV\
0LQLFROXPQV4LDJHQ+LOGHQ*HUPDQ\DFFRUGLQJWRWKH
PDQXIDFWXUHU
VUHFRPPHQGDWLRQ$Q$JLOHQW%LRDQDO\VHUZDV
XVHGWRFRQÀUP51$LQWHJULW\DQGRQO\VDPSOHVKDYLQJD5,1
RIRUPRUHZHUHXVHG
cDNA probe synthesis. $WRWDORIQJRIWRWDO51$ZDV
converted to cDNA including targeted depletion of rRNA 
WUDQVFULSWVXVLQJD:7([SUHVVLRQNLW$PELRQ&DPEULGJH
0$USA DFFRUGLQJ WR WKH PDQXIDFWXUHU
V SURFHGXUHV
Resultant cDNA was fragmented and biotin end labelled using 
DQ$II\PHWUL[:77HUPLQDO/DEHOOLQJNLW$II\PHWUL[6DQWD
Clara, CA, USA).
Microarray hybridisation analysis. Labelled cDNA was 
K\EULGLVHGWR$II\PHWUL[+XPDQ*HQH67ZKROHWUDQ
VFULSWEDVHGDUUD\VIROORZHGE\ZDVKLQJDQGVWDLQLQJRQDQ
$II\PHWUL[)6ÁXLGLFVVWDWLRQ7KH+XPDQ*HQH67
$UUD\$II\PHWUL[FRPSULVHGGLVWLQFWQWSUREHV
LQWHUURJDWLQJDQQRWDWHGJHQHVEDVHGRQ WKH0DUFK
8&6&KJ1&%,%XLOGKXPDQJHQRPHVHTXHQFH
DVVHPEO\ZLWKFRPSUHKHQVLYHFRYHUDJHRI5HI6HT(QVHPEO
DQGSXWDWLYHFRPSOHWH&'6*HQ%DQNWUDQVFULSWV
Signal collection and analysis. $UUD\VZHUHVFDQQHGXVLQJ
DQ$II\PHWUL[ 6FDQQHU  *$II\PHWUL[ &RPPDQG
Console was used for instrument control and data acquisition. 
All procedures were carried out according to the standard 
$II\PHWUL[SURWRFROV5DZPLFURDUUD\GDWDZHUHVXEPLWWHGWR
$UUD\([SUHVV$FFHVVLRQ(07$%
Statistical analysis of microarray data
Data transformation. 5REXVWPXOWLDUUD\DYHUDJLQJDGMXVWHG
IRUQRQVSHFLÀFELQGLQJ*&50$ZDVXVHGIRUQRUPDOLVD
WLRQDQGVXPPDULVDWLRQRIWKHSUREHLQWHQVLW\VLJQDOV
'DWDZHUHVXEMHFWWR50$EDFNJURXQGFRUUHFWLRQDQGTXDQ
tile normalisation across all chips (to ensure comparable mean 
DQGVWDQGDUGGHYLDWLRQRIWKHSUREHLQWHQVLWLHVSULRUWRORJ
transformation and median polish probe set summarisation.
Array data quality estimation. The normalised unscaled stan
GDUGHUURU186(RIHDFKDUUD\ZDVFDOFXODWHGWRFRPSDUH
GDWDYDULDELOLW\EHWZHHQDQGZLWKLQDUUD\V$186(YDOXH
RIZDVVHWDVWKHXSSHUOLPLWRIDFFHSWDEOHTXDOLW\
Data analysis. 3ULQFLSDO FRPSRQHQWV DQDO\VLV XVLQJ D
covariance dispersion matrix was performed to map high 
GLPHQVLRQDOGDWDRIHDFKVDPSOHWRGLPHQVLRQVIRUHVWLPD
WLRQRIFOXVWHULQJDFFRUGLQJWRFODVVLÀFDWLRQDQGLGHQWLÀFDWLRQ
RIRXWO\LQJVDPSOHV
$PL[HGPRGHODQDO\VLVRIYDULDQFH$129$LQFOXGLQJ
PHWKRGVRIPRPHQWVHVWLPDWLRQZDVXVHGWRLGHQWLI\GLIIHU
HQWLDO H[SUHVVLRQ EHWZHHQQRQLQYDVLYH WXPRXUV LQYDVLYH
WXPRXUVDQGKHDOWK\EODGGHUWLVVXH%DWFKHIIHFWVZHUHWDNHQ
into consideration within the model. ANOVA was conducted 
LQFOXGLQJ ¶SDWLHQW· DV D IDFWRU WDNLQJ WKH SDLUHG VDPSOHV
into consideration. Differences in gene expression between 
tumours of differing grade, and also differential expres
VLRQEHWZHHQWXPRXUVDPSOHVZHUHDVVHVVHGXVLQJWKHWWHVW
To correct for multiple testing, genes were considered to be 
VLJQLÀFDQWO\GLIIHUHQWLDOO\H[SUHVVHGLIDIDOVHGLVFRYHU\UDWH
)'5DGMXVWHG3ZDVREWDLQHG7KH IDOVHGLVFRYHU\
UDWHZDVFDOFXODWHGDVSUHYLRXVO\GHVFULEHG7KRVHJHQHV
ZKRVHIROGFKDQJHH[SUHVVLRQOHYHOZDVIRXQGWRVLJQLÀFDQWO\
GLIIHUE\[RUJUHDWHUZHUHXVHGIRUIXUWKHUDQDO\VLV
Unsupervised hierarchical agglomerative clustering 
(XFOLGHDQGLVWDQFHZLWKDYHUDJHOLQNDJHFOXVWHULQJZDVXVHG
WRLGHQWLI\VDPSOHVZLWKVLPLODUH[SUHVVLRQSURÀOHV
0HWD&RUHYHUVLRQ*HQH*R,QF6W-RVHSK0,86$
,3$,QJHQXLW\S\VWHPV5HGZRRG&LW\&$86$DQG'$9,'
%LRLQIRUPDWLFVUHVRXUFHYZHUHHPSOR\HGWRLGHQWLI\
FDQRQLFDOSDWKZD\VDQGFXUDWHGQHWZRUNVKDYLQJVWDWLVWLFDOO\
VLJQLILFDQW HQULFKPHQW RI GLIIHUHQWLDOO\ H[SUHVVHG JHQHV
3DWKZD\V IURP0HWDCRUH DQDO\VLV ILOWHUHGRQ)'5
are presented in Results, unless otherwise stated. Univariate 
&R[SURSRUWLRQDOKD]DUGVUHJUHVVLRQDQDO\VLVZDVSHUIRUPHG
to evaluate the association between disease progression and 
differential gene expression.
Meta-analysis. 0HWDDQDO\VLVZDVFRQGXFWHGXVLQJSXEOLFO\
available gene expression data from Gene Expression 
2PQLEXV 2XW RI WKH SRVVLEOH  GDWDVHWV LGHQWLILHG
*6(*6(*6(*6(*6(*6(
*6(*6(*6(*6(*6(DQG
*6(ZHVHOHFWHGWZRGDWDVHWVXVLQJWKHVDPHPLFUR
DUUD\SODWIRUP$II\PHWUL[+XPDQ*HQRPH8$DUUD\
ZLWKDODUJHQXPEHURIVDPSOHVIRUIXUWKHUDQDO\VLV5DZ&(/
ÀOHVIURP*6(ZLWKVDPSOHVDQG*6(
ZLWKVDPSOHVZHUHLPSRUWHGLQWR3DUWHN*HQRPLF6XLWH
3DUWHN,QF&KHVWHUÀHOG0286$DQGGDWDZHUHSURFHVVHG
DQGGLIIHUHQWLDOJHQHVLGHQWLÀHGIROORZLQJWKHVDPHSURWRFRO
GHVFULEHGHDUOLHUIRURXURZQGDWD&OLQLFRSDWKRORJLFDOGDWD
IRU WKHGDWDVHWVZHUHNLQGO\SURYLGHGE\ WKHDXWKRUV7KH
*6(GDWDVHWFRQWDLQVVXSHUÀFLDOWUDQVLWLRQDOFHOOFDUFL
QRPD10,%&ZLWKVXUURXQGLQJFDUFLQRPDin situ&,6
SDWLHQWVZLWKRXWVXUURXQGLQJ&,6OHVLRQVSDWLHQWVPXVFOH
LQYDVLYHFDUFLQRPD0,%&SDWLHQWV&,6RQO\Q DQG
KHDOWK\EODGGHU Q 7KH*6(GDWDVHWFRQWDLQV
samples from patients with muscle invasive bladder cancer.
Immunostaining
Western blotting. :HVWHUQEORWWLQJZDVSHUIRUPHGWRYDOLGDWH
WKHVSHFLÀFLW\RIDQWL231DQWLERG\$)5	'6\VWHPV
,QF0LQQHDSROLV0186$IRUVXEVHTXHQW,+&DQDO\VLV
3URWHLQO\VDWHVZHUHSUHSDUHGLQ5,3$EXIIHUIURPD0,%&
FHOOOLQH-DQGD10,%&FHOOOLQH57%UDGIRUGZDV
XVHGIRUSURWHLQTXDQWLÀFDWLRQ3URWHLQVZHUHVHSDUDWHGE\
6'63$*(SULRU WR WUDQVIHUULQJRQWRD3'9)PHPEUDQH
%ORFNLQJZDVSHUIRUPHG IRU  KZLWKPLON SULRU WR
RYHUQLJKWLQFXEDWLRQLQGLOXWLRQRI$)6HFRQGDU\
DQWLERG\ZDVDSSOLHGIRUKEHIRUHYLVXDOLVLQJXVLQJ(&/
ơDFWLQ DE$EFDPZDV XVHG WR GHPRQVWUDWH HTXDO
protein loading.
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Immunohistochemistry. &RQGLWLRQV IRU ,+&ZLWK$)
ZHUHRSWLPLVHGLQFOHDUFHOOUHQDOFDUFLQRPDDQGNLGQH\))3(
VHFWLRQV XVLQJ D QR SULPDU\ DQWLERG\ FRQWURO D JRDW ,J*
LVRW\SHFRQWURO$%&5	'6\VWHPVDQGDQHJDWLYHWLVVXH
FRQWUROEUHDVWVNLQ$QWLJHQUHWUHYDOZDVSHUIRUPHGXVLQJWKH
37OLQNDWS+SULRUWRSHUR[LGDVHEORFN'DNRKSULPDU\
DQWLERG\  $) LQFXEDWLRQ DW 57 K VHFRQGDU\
DQWLERG\LQFXEDWLRQDW57SULRUWRYLVXDOLVDWLRQZLWK
'$%&KURPDJHQ'DNR6WDLQLQJLQWHQVLW\ZDVVFRUHGE\D
FRQVXOWDQWSDWKRORJLVW%ULHÁ\VWDLQLQJLQWHQVLW\ZDVJUDGHGDV
QHJDWLYHZHDNPRGHUDWHDQGVWURQJ
5HVXOWV
%ODGGHUFDQFHUWLVVXHVH[KLELWVSHFLÀFJHQHVLJQDWXUHVA 
WRWDO RI  JHQHVZHUH GLIIHUHQWLDOO\ H[SUHVVHG EHWZHHQ
)LJXUH&HOOSUROLIHUDWLRQJHQHVDUHXSUHJXODWHGLQEODGGHUFDQFHU$3ULQFLSDOFRPSRQHQWVDQDO\VLV6HJUHJDWLRQLQWRJURXSVE\WLVVXHW\SHDQGWXPRXU
JUDGHZDVDVVHVVHG%+LHUDUFKLFDOFOXVWHULQJVHJUHJDWHVWXPRXUVDPSOHVIURPKHDOWK\WLVVXH.H\VKRZQRQWKHULJKW7KHQXPEHUVDWWKHERWWRPRIHDFK
FROXPQFRUUHVSRQGWRSDWLHQWVHULDOQXPEHUV6WDQGDUGLVHGLQWHQVLW\UDQJHJUHHQWRUHGEODFNIROGFKDQJH&*HQHVLQYROYHGLQWKHLQLWLDWLRQRI
PLWRVLVDUHXSUHJXODWHGLQEODGGHUFDQFHU3 [*HQHVFLUFOHGLQUHGDQGEOXHZHUHUHVSHFWLYHO\XSUHJXODWHGRUGRZQUHJXODWHGLQFDQFHUVDPSOHV7KH
length of the bar is proportional to the degree of change in expression.
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FDQFHUDQGFRQWUROVDPSOHVXVLQJDIROGFKDQJHRIDWOHDVW
DQGDIDOVHGLVFRYHU\UDWH)'5RI2IWKHVHJHQHV
VKRZHGUHGXFHGH[SUHVVLRQLQWXPRXUVZKLOHJHQHVVKRZHG
increased expression in tumours. Principal components 
DQDO\VLVGHPRQVWUDWHGVHJUHJDWLRQRIVDPSOHVE\WLVVXHW\SH
and tumour grade (FLJ$6LPLODUO\KLHUDUFKLFDOFOXVWHULQJ
)LJXUH*HQHVLQYROYHGLQP\RJHQHVLVDQG(07DUHG\VUHJXODWHGLQEODGGHUFDQFHU$*HQHVLQYROYHGLQP\RJHQHVLVZHUHGRZQUHJXODWHGLQFDQFHU
VDPSOHV3 [7KHUHODWLYHH[SUHVVLRQIRUHDFKJHQHLVGHSLFWHGE\WKHFRORXUDQGLQWHQVLW\RIWKHFLUFOHEOXHGRZQUHJXODWLRQUHGXSUHJXODWLRQ
%'RZQUHJXODWLRQRIJHQHVLQYROYHGLQ(07LQFDQFHUVDPSOHV3 [). Genes circled in blue exhibited reduced expression within the tumour samples 
UHODWLYHWRKHDOWK\EODGGHUWLVVXH7KHOHQJWKRIWKHEOXHEDULVSURSRUWLRQDOWRWKHH[WHQWRIGRZQUHJXODWLRQ
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VHJUHJDWHGKHDOWK\EODGGHUWLVVXHDQGEODGGHUFDQFHULQWRWZR
groups (FLJ%
0XOWLSOHJHQHVLQYROYHGLQSUROLIHUDWLRQZHUHXSUHJXODWHG
LQEODGGHUFDQFHUVDPSOHVDVFRPSDUHGWRKHDOWK\VDPSOHV
3 [) (FLJ&7KHVHLQFOXGHGFRPSRQHQWVRIWKH
F\FOLQGHSHQGHQWNLQDVH&'.F\FOLQ%FRPSOH[DFWLYD
WLRQRIZKLFKLVUHTXLUHGWRGULYHSURJUHVVLRQIURP*WR
0SKDVH,QLWLDWLRQRIF\FOLQ%WUDQVFULSWLRQLVFDUULHGRXWE\
)2;00RUHRYHUWKHHTXLOLEULXPEHWZHHQQXFOHDULPSRUW
DQGH[SRUWRIF\FOLQ%LVLQÁXHQFHGE\LWVSKRVSKRU\ODWLRQ
)LJXUH&ODVVLFDOFRPSOHPHQWJHQHVDUHGRZQUHJXODWHGLQ10,%&$+LHUDUFKLFDOFOXVWHULQJVKRZLQJFOXVWHULQJRI10,%&DQGKHDOWK\WLVVXHVDPSOHV
WKRXJKFRPSOHWHVHSDUDWLRQLVQRWHVWDEOLVKHG$NH\LVJLYHQRQWKHULJKWRIWKHÀJXUH7KHQXPEHUVDWWKHERWWRPRIHDFKFROXPQFRUUHVSRQGWRSDWLHQW
VHULDOQXPEHUV6WDQGDUGLVHGLQWHQVLW\UDQJHJUHHQWRUHGEODFNIROGFKDQJH%*HQHVDVVRFLDWHGZLWKWKHFODVVLFDOFRPSOHPHQWSDWKZD\DUH
GRZQUHJXODWHGLQ10,%&3 [).
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VWDWXVE\3/.ZKLFKZDVDOVRXSUHJXODWHG7KHVXEVWUDWHVRI
&'.F\FOLQ%LQFOXGH/DPLQ%OHDGLQJWRGHSRO\PHUL]DWLRQ
RIWKHODPLQQXFOHDUF\WRVNHOHWRQDQG.LQHVLQUHODWHGPRWRU
SURWHLQ(J.16/ZKLFKDVVRFLDWHVZLWKFHQWURVRPHVDQG
spindle apparatus.
Genes involved in myogenesis and epithelial-to-mesenchymal 
transition (EMT) are downregulated in cancer samples. Genes 
GRZQUHJXODWHGLQFDQFHUFRPSDUHGWRKHDOWK\WLVVXHLQFOXGHG
VHYHUDOZKLFK DUH LQYROYHG LQP\RJHQHVLV 3 [) 
(FLJ$7KHVHLQFOXGHGWKHP\RF\WHHQKDQFHUIDFWRU0HI
ZKLFK LV H[SUHVVHG GXULQJP\RJHQHVLV0HI DQG0\R'
LQWHUDFWOHDGLQJWR0\R'DFWLYDWLRQDQGKHQFHWKHH[SUHVVLRQ
RIP\RVLQKHDY\DQGOLJKWFKDLQV,QDGGLWLRQJHQHVLQYROYHG
LQ(07ZHUHDOVRGRZQUHJXODWHG 3 [) (FLJ%
(07LVFULWLFDOGXULQJP\RJHQHVLVSDUWLFXODUO\DVWKHPXVFOH
SUHFXUVRUFHOOVGHODPLQDWHIURPWKHGHUPRP\RWRPH0XVFOH
precursors invade the developing tissue and differentiate into 
mature muscle cells.
Comparison of NMIBC and healthy bladder tissue. $VSHFLÀF
FRPSDULVRQZDV DOVRPDGHEHWZHHQ10,%&DQGKHDOWK\
WLVVXH7KLVLGHQWLÀHGJHQHVZKLFKZHUHGLIIHUHQWLDOO\
H[SUHVVHGE\IROG3IDOVHGLVFRYHU\UDWH2IWKHVH
ZHUHGRZQUHJXODWHGLQFDQFHUZKLOHLQFUHDVHGH[SUHVVLRQ
ZDVREVHUYHGLQGDWDQRWVKRZQ+LHUDUFKLFDOFOXVWHULQJ
JHQHUDOO\ VHJUHJDWHG LQWR WZRJURXSV EXWZLWK DGGLWLRQDO
branching in one cluster as shown in FLJ$
6LPLODU WR WKH DQDO\VLV FRPSDULQJ DOO EODGGHU FDQFHU
VDPSOHVWRKHDOWK\VDPSOHVJHQHVLQYROYHGLQVPRRWKPXVFOH
)LJXUH'\VUHJXODWLRQRISDWKZD\VLQ0,%&$+LHUDUFKLFDOFOXVWHULQJRIJHQHVDQGVDPSOHVVKRZLQJVHJUHJDWLRQRIPXVFOHLQYDVLYHWXPRXUVDPSOHV
DQGFRQWUROVDPSOHVLQWRGLIIHUHQWFOXVWHUV$NH\LVVKRZQRQWKHULJKWRIWKHÀJXUH7KHQXPEHUVDWWKHERWWRPRIHDFKFROXPQFRUUHVSRQGWRSDWLHQWVHULDO
QXPEHUV6WDQGDUGLVHGLQWHQVLW\UDQJHJUHHQWRUHGEODFNIROGFKDQJH%3DWKZD\HQULFKPHQW0,%&YVFRQWUROVDPSOHV
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GHYHORSPHQWDQG(07ZHUHGRZQUHJXODWHG 3 [). 
1RWDEO\ JHQHV DVVRFLDWHGZLWK WKH FODVVLFDO FRPSOHPHQW
SDWKZD\ZHUHVWURQJO\GRZQUHJXODWHGLQ10,%&VDPSOHV
ZKLFK PD\ LQGLFDWH D PHFKDQLVP IRU LPPXQH HYDVLRQ
3 [) (FLJ%
MIBC vs. healthy tissue +LHUDUFKLFDO FOXVWHULQJ VKRZHG
VHJUHJDWLRQRI0,%&DQGKHDOWK\VDPSOHVLQWRWZRJURXSV
(FLJ $ 7KHUHZHUH  JHQHV WKDWZHUH DOWHUHG E\ DW
OHDVWIROG3IDOVHGLVFRYHU\UDWH2XWRIWKHVH
showed increased expression between invasive tumours and 
KHDOWK\VDPSOHVZKLOHZHUHGHFUHDVHG LQH[SUHVVLRQ
3DWKZD\VHQULFKHGIRUWKHVHGLIIHUHQWLDOO\UHJXODWHGJHQHVDUH
shown in FLJ%*HQHVLQYROYHGLQFKURPRVRPHFRQGHQVD
tion in prometaphase were upregulated in invasive bladder 
FDQFHU 3 [ 6LPLODUO\ VHYHUDO UHJXODWRUV RI WKH
anaphase promoting complex (APC) were also upregulated 
3 [7KHVHLQFOXGHGWKHNLQDVHV3/.DQG&'.
Comparison of grade 1 and 3 NMIBC. A further comparison 
ZDVPDGHEHWZHHQJHQHH[SUHVVLRQSURÀOHVLQJUDGHDQG
EODGGHU FDQFHUVZKLFK LGHQWLILHGJHQHV WKDWZHUH
GLIIHUHQWLDOO\ UHJXODWHGE\DW OHDVWIROG )'53
+LHUDUFKLFDOFOXVWHULQJFOHDUO\VHJUHJDWHVEHWZHHQJUDGH
DQGFLJ$(QULFKHGSDWKZD\VDUHVKRZQLQFLJ%
1RWDEO\PXOWLSOHSDWKZD\VDVVRFLDWHGZLWKFHOOF\FOHSURJUHV
VLRQZHUH XSUHJXODWHG LQ JUDGH  WXPRXUV DQGPXOWLSOH
FRUH FHOO F\FOH FRPSRQHQWVZHUHXSUHJXODWHG LQJUDGH
WXPRXUV*HQHVLQYROYHGLQWKHPHWDSKDVHFKHFNSRLQWZHUH
SDUWLFXODUO\XSUHJXODWHG3 [). A comparison was 
DOVRPDGHRIJHQHVWKDWZHUHXSUHJXODWHGERWKLQJUDGH
FRPSDUHG WRJUDGH10,%&DQG LQ0,%&FRPSDUHG WR
KHDOWK\VDPSOHV
Comparing grade 3 NMIBC and MIBC. $WRWDORIJHQHV
ZHUHGLIIHUHQWLDOO\H[SUHVVHGRUPRUH IROG 32I
WKHVHVKRZHGLQFUHDVHGH[SUHVVLRQLQ0,%&ZKLOHWKH
UHPDLQLQJ  H[KLELWHG GHFUHDVHG H[SUHVVLRQ LQ0,%&
+LHUDUFKLFDOFOXVWHULQJUHVXOWHGLQFOHDUVHJUHJDWLRQEHWZHHQ
WKHWZRJURXSV7DEOH,,OLVWVJHQHVWKDWZHUHGLIIHUHQWLDOO\
H[SUHVVHGE\!IROGLQJUDGH10,%&FRPSDUHGWR0,%&
$PRQJ WKH JHQHV PRVW XSUHJXODWHG LQ 0,%& ZHUH WKH
proteinases. Overexpression and activation of proteinases, that 
GHVWUR\WKHFRQQHFWLYHWLVVXHDUHLQYROYHGLQYDULRXVSDWKR
logical processes including tumour progression. The most 
SURWHRO\WLFRIHQ]\PHVDUHWKHPHWDOORSURWHLQDVHV7KHPDWUL[
PHWDOORSURWHLQDVHV003VFRPSULVHDIDPLO\RIHQ]\PHV
WKDWFROOHFWLYHO\FDQGHJUDGHDOOFRPSRQHQWVRIWKHH[WUDFHO
OXODUPDWUL[(&0WKHVHZHUHXSUHJXODWHGLQWKLVVWXG\)RU
H[DPSOHWKHPDWUL[PHWDOORSURWHLQDVHV003DQG003
ZHUHXSUHJXODWHGDQGIROG UHVSHFWLYHO\ LQ0,%&
FRPSDUHGWR10,%&
Further functional analysis using Database for Annotation, 
Visualization and Integrated Discovery (DAVID). A further 
DQDO\VLV RI  JHQHVZKLFKZHUH XSUHJXODWHG LQ0,%&
7DEOH,,*HQHVH[KLELWLQJ!IROGGLIIHUHQWLDOH[SUHVVLRQEHWZHHQJUDGHDQG0,%&)'5P
    Fold change
Gene ID RefSeq PYDOXH 0,%&10,%&
FaPLO\ZLWKVHTXHQFHVLPLODULW\PHPEHU' )$0' 10B ( 
RHWLQRLFDFLGUHFHSWRUUHVSRQGHUWD]DURWHQHLQGXFHG 5$55(6 10B  
CHQWURPHUHSURWHLQ, &(13, 10B ( 
FLEURQHFWLQ )1 10B  
CHQWURPHUHSURWHLQ)NDPLWRVLQ &(13) 10B  
N mannosidase, ƠFODVV&PHPEHU 0$1& 10B  
Topoisomerase (DNA) II ƠN'D 723$ 10B  
73;PLFURWXEXOHDVVRFLDWHGKRPRORJXenopus laevis 73; 10B  
5DVDVVRFLDWLRQ5DO*'6$)GRPDLQIDPLO\PHPEHU 5$66) 10B  
AQLOOLQDFWLQELQGLQJSURWHLQ $1/1 10B  
Table III. DAVID functional annotation clusters.
Annotation cluster Enrichment score Count PYDOXH
([WUDFHOOXODUJO\FRSURWHLQV   (
6HULQHW\SHHQGRSHSWLGDVHLQKLELWRUDFWLYLW\   (
1HJDWLYHUHJXODWLRQRILPPXQHV\VWHPSURFHVVHV   (
=\PRJHQSURWHRO\WLFHQ]\PHSUHFXUVRUV   (
&HOOPLJUDWLRQ   (
(*)   (
5HVSRQVHWRZRXQGLQJ   (
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FRPSDUHGWR10,%&ZDVSHUIRUPHGXVLQJWKH'$9,'GDWD
EDVH$VXPPDU\RIDQQRWDWLRQFOXVWHUVLVJLYHQLQTable III.
Meta-analysis of gene expression data. In order to validate our 
UHVXOWVZHXVHGDPHWDDQDO\VLVRIDODUJHUGDWDVHWFRQVLVWLQJ
RIVDPSOHVJHQHUDWHGE\WKHFRPELQDWLRQRIWZRSXEOLFO\
DYDLODEOHEODGGHU FDQFHUJHQHH[SUHVVLRQGDWDVHWV 
:KHQZHIROORZHGWKHVDPHFULWHULDXVHGZLWKRXUGDWDVHW
IRUFODVVLI\LQJ0,%&DQG10,%&WKHUHZHUH10,%&
VDPSOHVDQG0,%&VDPSOHVLQWKHPHWDDQDO\VLVGDWDVHW
7KHUHZHUH DOVRKHDOWK\EODGGHU WLVVXH VDPSOHVZKLOH
the rest of the samples (carcinoma in situ) were not used in 
DQDO\VLV
$ WRWDORIJHQHVZHUHGLIIHUHQWLDOO\ H[SUHVVHG LQ
10,%&FRPSDUHGWRKHDOWK\WLVVXHZKHQDFXWRIIRI)'5
DQGIROGFKDQJH!ZHUHDSSOLHG:KHQFRPSDUHG
ZLWKGLIIHUHQWLDOJHQHVIURPRXUGDWDWKHUHZHUHJHQHV
FRPPRQLQERWKDQDO\VHV6XUSULVLQJO\H[FHSWIRURQHJHQH
PELO, all the other genes showed concordant expression. This 
LQFOXGHGDOOWKHJHQHVXSUHJXODWHGLQ10,%&DQGJHQHV
GRZQUHJXODWHGLQ10,%&FRPSDUHGWRKHDOWK\EODGGHUWLVVXH
(data not shown).
:KHQ0,%&VDPSOHVZHUHFRPSDUHGZLWKKHDOWK\EODGGHU
VDPSOHVZLWKDÀOWHURI)'5DQGIROGFKDQJH!
JHQHVZHUH GLIIHUHQWLDOO\ H[SUHVVHG LQ WKHPHWDDQDO\VLV
A comparison with differential genes from our data under 
VLPLODUFRQGLWLRQVDQGÀOWUDWLRQVUHYHDOHGFRPPRQJHQHV
6LPLODUO\WKHH[SUHVVLRQVRIDOOH[FHSWJHQHV6(53,1(%
DQG&$6&ZHUHFRQFRUGDQWLQERWKWKHDQDO\VHV$OOWKH
JHQHVGRZQUHJXODWHGLQ0,%&FRPSDUHGWRKHDOWK\WLVVXH
VKRZHGFRQFRUGDQWH[SUHVVLRQZKLOHRXWRIJHQHVKLJKO\
H[SUHVVHGLQ0,%&LQWKLVVWXG\VKRZHGVLPLODUH[SUHVVLRQLQ
WKHPHWDDQDO\VLVGDWDQRWVKRZQ
Osteopontin protein is overexpressed in MIBC compared to 
healthy urothelium. ,QRUGHUWRGHWHUPLQHWKHYDOLGLW\RIWKH
)LJXUH&RPSDULQJJUDGHDQG10,%&$+LHUDUFKLFDOFOXVWHULQJVHJUHJDWHVJUDGHDQG10,%&VDPSOHV7KHQXPEHUVDWWKHERWWRPRIHDFKFROXPQ
FRUUHVSRQGWRSDWLHQWVHULDOQXPEHUV6WDQGDUGLVHGLQWHQVLW\UDQJHJUHHQWRUHGEODFNIROGFKDQJH%3DWKZD\HQULFKPHQWJUDGHYVJUDGH
10,%&
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+866$,1et al*(1((;35(66,21352),/,1*,1%/$''(5&$1&(5,'(17,),(6327(17,$/7+(5$3(87,&7$5*(7610
PLFURDUUD\GDWD231H[SUHVVLRQZDVH[DPLQHG LQ0,%&
Q  DQG KHDOWK\ XURWKHOLDO WLVVXH Q  XVLQJ WKH ,+&
WHFKQLTXH6WDWLVWLFDODQDO\VLVXVLQJ:HOFK
VXQSDLUHGWWHVW
UHYHDOHGDVLJQLÀFDQWGLIIHUHQFH3 EHWZHHQ0,%&
DQGKHDOWK\WLVVXHZLWK0,%&GLVSOD\LQJGLIIXVHF\WRSODVPLF
231 VWDLQLQJ RIPRGHUDWH  LQWHQVLW\ ZKLOVW KHDOWK\
XURWKHOLXPZDVW\SLFDOO\231QHJDWLYH)LJ
Discussion
7KHSUHVHQWVWXG\FRQWULEXWHV WRDERG\RIZRUN WKDWXVHV
PLFURDUUD\GDWDWRSURÀOHEODGGHUFDQFHUDQGSURYLGHVIUHVK
LQVLJKWVLQWRSDWKZD\VLQYROYHGLQLWVSDWKRJHQHVLV'LVWLQFWLYH
SDWWHUQVRIJHQHH[SUHVVLRQGLIIHUHQWLDWLQJEHWZHHQ10,%&
DQG0,%&DQGEHWZHHQKLJKDQGORZJUDGHFDQFHUVZHUH
LGHQWLÀHG
$VWULNLQJXSUHJXODWLRQLQSDWKZD\VLQYROYHGLQFHOOF\FOH
FRQWUROZDVREVHUYHGLQFRPSDULVRQVRI0,%&DQG10,%&
DQG EHWZHHQ JUDGH  DQG JUDGH  10,%& WXPRXUV $
VLJQLÀFDQWRYHUODSZDVREVHUYHGEHWZHHQJHQHVXSUHJXODWHG
LQJUDGH10,%&WXPRXUVDQGWKRVHXSUHJXODWHGLQ0,%&
FRPSDUHGWRKHDOWK\WLVVXHDQGWKHVHJHQHVZHUHSUHGRPL
QDQWO\PDSSHGWRFHOOF\FOHFRQWUROSDWKZD\V7KLVLVOLNHO\WR
UHÁHFWWKHLQFUHDVHGDJJUHVVLYHQHVVDQGOLNHOLKRRGRISURJUHV
VLRQRIJUDGH10,%&7KLVSDQHORIJHQHVPD\WKHUHIRUHEH
XVHIXOLQSUHGLFWLQJSURJUHVVLRQRI10,%&
&HOOF\FOHJHQHVZKLFKZHUHXSUHJXODWHGLQFOXGHGDQLOOLQ
!IROGXSUHJXODWLRQDVXEVWUDWHRI$3&ZKLFKLVLQYROYHG
LQF\WRNLQHVLV$QLOOLQLVXSUHJXODWHGLQYDULRXVFDQFHUV
LQFOXGLQJSDQFUHDWLFDQGUHQDOFDUFLQRPD73;
ZKLFKLVLQYROYHGLQVSLQGOHDVVHPEO\ZDVDOVRXSUHJX
lated.
7KLVXSUHJXODWLRQRIFHOOF\FOHUHODWHGJHQHVLQEODGGHU
FDQFHULVQRWXQH[SHFWHGDQGZDVVLPLODUO\VKRZQLQDVWXG\
E\=DUDYLQRV et al 1RWDEO\VHYHUDORIWKHXSUHJXODWHG
JHQHVKDYHEHHQLGHQWLÀHGDVSRWHQWLDOWKHUDSHXWLFWDUJHWVIRU
EODGGHUFDQFHUV,QKLELWRUVRI723$LQFOXGHDQWKUDF\FOLQHV
DQGHWRSRVLGHWZRZHOOHVWDEOLVKHGFKHPRWKHUDS\DJHQWV
7KHDQWKUDF\FOLQHGR[RUXELFLQIRUH[DPSOHH[KLELWVDQWL
EODGGHUFDQFHUHIIHFWVDQGLVDFRPSRQHQWRIWKHFRPPRQO\
HPSOR\HG09$&UHJLPHQ3/. LQKLELWRUVDUHFXUUHQWO\
LQ SKDVH  DQG  WULDOV DQG SUHOLPLQDU\ VWXGLHV VXJJHVW
WKDW3/. LQKLELWRUVPD\UHGXFHSUROLIHUDWLRQRIEODGGHU
FDQFHU FHOO OLQHV +RZHYHU UHVXOWV REWDLQHG IURP D
UHFHQWSKDVHVWXG\HYDOXDWLQJ WKHHIÀFDF\RI WKH3/.
LQKELWRUYRODVHUWLEDVDVHFRQGOLQHWUHDWPHQWLQSDWLHQWVZLWK
ORFDOO\DGYDQFHGRUPHWDVWDWLFXURWKHOLDOFDQFHUVXJJHVWV
WKDWDOWKRXJKYRODVHUWLEZDVZHOOWROHUDWHGZLWKDQDFFHSW
DEOHVDIHW\SURÀOHWKHDQWLWXPRXUDFWLYLW\RIYRODVHUWLEZDV
QRWVXIIHFLHQWIRUIXUWKHUHYDOXDWLRQDVDPRQRWKHUDS\
6HYHUDO&'.LQKLELWRUVDUHDOVRFXUUHQWO\LQSKDVHDQG
clinical trials.
The expression of osteopontin (OPN) ‘secreted phos
SKRSURWHLQ·DPDWULFHOOXODUSURWHLQLVVWURQJO\DVVRFLDWHG
ZLWKPDOLJQDQFLHVUHYLHZHGLQUHI)XUWKHUPRUH231
51$VLOHQFLQJ LQ%&VLJQLILFDQWO\DWWHQXDWHV WXPRXUFHOO
)LJXUH&RPSDULQJ231SURWHLQH[SUHVVLRQLQ0,%&DQGKHDOWK\XURWKHOLDOWLVVXH$+HDOWK\XURWKHOLXPGLVSOD\LQJQHJDWLYH231LPPXQRVWDLQLQJZLWK
WKHSUHVHQFHRIQRQVSHFLÀFELQGLQJLQXURWKHOLDOWLVVXH%0,%&WLVVXHH[KLELWLQJPRGHUDWHGLIIXVH231LPPXQRVWDLQLQJ&,VRW\SHFRQWURO231
H[SUHVVLQJNLGQH\WLVVXHZLWKSRO\FORQDOJRDW,J*DQWLERG\'JUDSKLFDOUHSUHVHQWDWLRQRIVWDLQLQJUHVXOWVUHVXOWVDUHDYHUDJHRIVWDLQLQJIURPKHDOWK\
XURWKHOLDOVDPSOHVDQG0,%&VVWDWLVWLFDODQDO\VLVZDVSHUIRUPHGXVLQJ:HOFK
VXQSDLUHGWWHVW3 $OOLPDJHVDUHUHSUHVHQWDWLYHRIWKHFRKRUW
6FRULQJZDVSHUIRUPHGE\DSDWKRORJLVW
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LQYDVLRQ7KHILQGLQJ WKDW231H[SUHVVLRQZDVVWULN
LQJO\ XSUHJXODWHG !IROG LQ LQYDVLYH EODGGHU FDQFHUV
FRPSDUHGZLWKWKHKHDOWK\WLVVXHLVFRQVLVWHQWZLWKSUHYLRXV
studies demonstrating upregulation of OPN in urothelial 
PDOLJQDQF\:KLOVW23151$H[SUHVVLRQGDWDLV
ZHOOUHSUHVHQWHGLQ%&WLVVXHSURWHLQH[SUHVVLRQGDWD
DUHOLPLWHG7KHUHIRUH231H[SUHVVLRQZDVH[DP
LQHGEHWZHHQ0,%&DQGKHDOWK\XURWKHOLXP WRGHWHUPLQH
ZKHWKHUFRPPRQDOLW\EHWZHHQ51$DQGSURWHLQH[SUHVVLRQ
H[LVWVLQ%&231ZDVIRXQGWREHVLJQLIFDQWO\P 
RYHUH[SUHVVHG LQ0,%&FRPSDUHG WR KHDOWK\ XURWKHOLXP
7KHVHGDWDDUHFRQVLVWHQWZLWKREHVHUYDWLRQVLQJDVWULF
RHVRSKDJHDO  FHUYLFDO  DQG SURVWDWH  FDQFHUV
:KLOVWDVLJQLÀFDQWUHODWLRQVKLSEHWZHHQ231DQG
SRRUSURJQRVLVZDVQRWHGLQXSSHUXULQDU\WUDFWXURWKHOLDO
cell carcinoma no correlation between stage and grades was 
IRXQG&RQYHUVHO\231H[SUHVVLRQLVDVVRFLDWHGZLWK
LPSURYHGVXUYLYDOLQSDQFUHDWLFDGHQRFDUFLQRPD
Elevated levels of osteopontin have also been detected in 
the plasma of patients with advanced transitional cell carci
QRPD7&&VXJJHVWLQJWKDW231FRXOGEHDQRYHOELRPDUNHU
RIGLVHDVHVWDJH7KHXWLOLW\RI231H[SUHVVLRQDVD
SURJQRVWLFPDUNHUDQGRUSUHGLFWRURIWUHDWPHQWUHVSRQVH
KRZHYHUUHPDLQVXQSURYHQ7KHGLIIHUHQFHVLQ231
expression (in blood and tissue) observed in studies could be 
H[SODLQHGDWOHDVWLQSDUWE\WKHH[SUHVVLRQRI231LVRIRUPV
6SHFLILFDOO\231VSOLFHYDULDQWVZKLFK H[KLELW GLYHUJHQW
ELRORJLFDOIXQFWLRQVDUHGLIIHUHQWLDOO\H[SUHVVHGLQFDQFHUV
,QWULJXLQJO\&'WKHK\DOXURQLFDFLGUHFHSWRUIRUZKLFK
RVWHRSRQWLQLVDNH\OLJDQGZDVIRXQGWREHXSUHJXODWHG
among invasive bladder cancers, further supporting a potential 
role for OPN in pathogenesis of TCC.
:KHQ FRPSDULQJ JUDGH  10,%& ZLWK 0,%& ZH
REVHUYHG DQRYHUH[SUHVVLRQRI WKH FHOOPDWUL[ LQWHUDFWLRQ
QHWZRUN,QSDUWLFXODUWKHUHZDVXSUHJXODWLRQLQSURWHRO\WLF
HQ]\PHVVXFKDVWKHPDWUL[PHWDOORSURWHDVHV003V7KLVLV
FRQVLVWHQWZLWKWKHLQFUHDVHGDELOLW\RI0,%&WRLQYDGHORFDO
tissues. It would be important to evaluate if overexpression of 
003VSUHGLFWV10,%&SURJUHVVLRQ
*HQHVLQYROYHGLQP\RJHQHVLVDQGHSLWKHOLDOWRPHVHQ
FK\PDOWUDQVLWLRQ(07ZHUHGRZQUHJXODWHGLQWXPRXUVDQG
WKLVZDVSDUWLFXODUO\QRWHGLQ10,%&VDPSOHVFRPSDUHGZLWK
WKHKHDOWK\WLVVXH7KLVLVLQWULJXLQJDQGFRXOGUHSUHVHQWDQ
LQKLELWRU\HIIHFWRIEODGGHUFDQFHURQQRUPDOEODGGHUPXVFOH
JURZWK(07GHVFULEHVDSURFHVVE\ZKLFKHSLWKHOLDOFHOOVORVH
WKHLUFKDUDFWHULVWLFDSLFDOEDVDOSRODULW\LQWHUFHOOXODUMXQF
WLRQVDQGHSLWKHOLDOPDUNHUVZKLOHXSUHJXODWLQJPHVHQFK\PDO
PDUNHUVDFTXLULQJIURQWUHDUSRODULW\DQGXQGHUJRLQJF\WR
VNHOHWRQUHRUJDQL]DWLRQLQWRPHVHQFK\PDOFHOOV(07
is associated with invasive cancers and metastases, portends 
DSRRUSURJQRVLVLQSDWLHQWVZLWKEODGGHUFDQFHU,QWKH
SUHVHQWVWXG\WXPRXUVDPSOHVZHUHQRWPLFURGLVVHFWHGDQG
the possible ‘admixture’ with normal muscle tissue within 
VDPSOHVFRXOGKDYHFRQIRXQGHGWKHDQDO\VLVRIP\RJHQHVLV
DQG(07JHQHV
2QHQRYHOÀQGLQJLQWKLVVWXG\LVWKHGRZQUHJXODWLRQRI
JHQHVLQYROYHGLQWKHFODVVLFDOFRPSOHPHQWSDWKZD\ZLWKLQWKH
10,%&JURXS3UHYLRXVO\RWKHUVKDYHVKRZQWKDWFRPSOH
PHQW LQKLELWRUV VXFK DV &' DQG FRPSOHPHQW IDFWRU+
&)+DUHXSUHJXODWHGLQEODGGHUFDQFHUV7KHDJJUHJDWH
GDWD VXJJHVW WKDW UHSUHVVLRQRI FRPSOHPHQW DFWLYLW\ LV DQ
important pathogenic mechanism in bladder cancer develop
PHQW,QWULJXLQJO\&)+ELQGVWRWKH231SURWHLQDQGPDVNV
SXWDWLYHHQ]\PDWLFFOHDYDJHVLWHVDQGFRXOG WKHUHE\DOWHU
231DFWLYLW\8ULQDU\OHYHOVRI&)+ZHUHDOVRLQYHVWLJDWHG
DVPDUNHUVRIEODGGHUPDOLJQDQF\EXWZHUHIRXQGWR
H[KLELWORZVHQVLWLYLW\DQGVSHFLÀFLW\7KLVFRXOGEHH[SODLQHG
E\FKDQJHV LQ&)+OHYHOVGXULQJGLVHDVHSURJUHVVLRQDQG
supports our findings that downregulation of complement 
JHQHVRFFXUUHGLQ10,%&UDWKHUWKDQ0,%&VDPSOHV
(653DQG(653DUHXSUHJXODWHGLQ10,%&FRPSDUHG
WRKHDOWK\WLVVXHDQGDUHLQYROYHGLQWKHUHJXODWLRQRI)*)5
VSOLFLQJ:KLOHGHFUHDVHGH[SUHVVLRQRI)*)5ERQHRI
WKH)*)5VSOLFHYDULDQWVZDVREVHUYHGLQDVXEVHWRIEODGGHU
FDQFHUVXSUHJXODWLRQRI)*)5FDQRWKHUVSOLFHYDULDQW
ZDV GHWHFWHG LQ D EODGGHU FDQFHUPHWDVWDVLVPRGHO 
Consistent with reports on differential protein isoforms during 
FDQFHUGHYHORSPHQWRXUÀQGLQJVVXSSRUWWKHK\SRWKHVLVWKDW
GLIIHUHQWLDOH[SUHVVLRQRI)*)5VSOLFHYDULDQWVLVDQLPSRU
tant pathogenic mechanism in bladder cancer. In agreement 
with data published from the Cancer Genome Atlas Reseach 
1HWZRUNLQZKLFKFRPSUHKHQVLYHO\HYDOXDWHGWKH
PROHFXODUVLJQDWXUHRIXURWKHOLDOFDUFLQRPDVDQGUHYHDOHG
WKDWPXWDWLRQDOVSHFWUXPZDVLQYROYHGLQFHOOF\FOHUHJXODWLRQ
FKURPDWLQUHJXODWLRQDQGNLQDVHVLJQDOOLQJSDWKZD\VZLWK
SRWHQWLDOWKHUDSHXWLFDSSOLFDWLRQWKHSUHVHQWVWXG\KLJKOLJKWV
VHYHUDOG\VUHJXODWHGWUDQVFULSWVLQ%&WKDWSRWHQWLDOO\FRXOG
EHWDUJHWHGLQ%&WUHDWPHQW
:KLOVW WKHORQJWHUPFOLQLFDORXWFRPHGDWDZRXOGKDYH
allowed more robust conclusions to be drawn from the small 
FRKRUWPHWDDQDO\VLVRI WKHPLFURDUUD\GDWDWRJHWKHUZLWK
the protein expression experiment highlight the importance 
of the presented data, in addition to the role of OPN in inva
VLRQ)XUWKHUPRUHWKLVVWXG\VXSSOHPHQWVDJURZLQJERG\
of molecular data in bladder cancer allowing further under
standing of this complex and heterogeneous disease.
,QFRQFOXVLRQWKLVVWXG\FRPSOHPHQWVWKHSXEOLVKHGOLWHUD
ture, and gives credence to observed associations between 
patterns of gene signatures with the stage and grade of bladder 
FDQFHUV8OWLPDWHO\VXFKVLJQDWXUHVZRXOGEHPRVWFOLQLFDOO\
XVHIXO LI WKH\ LPSURYHSURJQRVWLFDWLRQRIGLVHDVHSDUWLFX
ODUO\DPRQJ10,%&ZKHUHDPRUHDJJUHVVLYHWKHUDSHXWLF
DSSURDFKFRXOGEHHPSOR\HGLQFDQFHUVWKDWZHUHPRUHOLNHO\
WRSURJUHVV7KHSUHVHQWVWXG\LGHQWLÀHGH[SUHVVLRQSDWWHUQV
ZKLFKPD\KHOSWKLVSUHGLFWLRQVXFKDVSURWHRO\WLFHQ]\PHV
DQGWKHVHPD\EHLQFRUSRUDWHGLQWRIXWXUHSURVSHFWLYHVWXGLHV
6LJQLÀFDQWO\ZHDOVRLGHQWLÀHGVHYHUDOJHQHVDQGSDWKZD\V
VXFKDV231DQGWKHFODVVLFDOFRPSOHPHQWSDWKZD\ZKLFK
ZHUHVWULNLQJO\GHUHJXODWHGLQEODGGHUFDQFHUDQGZKLFKPD\
be valuable drug targets.
$FNQRZOHGJHPHQWV
:HWKDQN6LP6LKRWDIRUKHUVNLOOHGWHFKQLFDODVVLVWDQFHLQWKH
H[WUDFWLRQDQGPLFURDUUD\DQDO\VLVRI51$
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molecular characterization of urothelial bladder carcinoma. 
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